Fan1 targeting agents

Fan1 targeting agents, designed to relieve miRNA repression of FAN1 mRNA, enhance protein expression and serve as disease-modifying agents for triplet repeat disorders, addressing the lack of therapeutic interventions for Huntington's disease and similar conditions.

WO2026234385A1PCT designated stage Publication Date: 2026-11-12HARNESS THERAPEUTICS LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/GB2026/050782
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a lack of effective therapeutic interventions for triplet repeat disorders, particularly Huntington's disease, due to the paucity of disease-modifying agents that can modulate the expression of the FAN1 protein, which is implicated in the progression and onset of these diseases.

Method used

Development of Fan1 targeting agents comprising two or more oligonucleotide moieties that specifically bind to the 3'UTR of FAN1 mRNA to relieve microRNA-mediated repression, thereby increasing FAN1 protein expression and acting as disease-modifying agents for triplet repeat disorders.

Benefits of technology

The Fan1 targeting agents effectively increase FAN1 protein expression, potentially delaying the onset and progression of triplet repeat disorders by blocking miRNA repression, providing a novel therapeutic approach for diseases like Huntington's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000015_0001
    Figure IMGF000015_0001
  • Figure IMGF000054_0001_TABLE
    Figure IMGF000054_0001_TABLE
  • Figure IMGF000055_0001_TABLE
    Figure IMGF000055_0001_TABLE
Patent Text Reader

Abstract

The present invention relates to Fan1 targeting agents comprising two or more oligonucleotide moieties that each target t, or miRNAs that bind to the, and thereby relieve microRNA mediated repression of FAN1. The invention also encompasses methods of enhancing FAN1 protein expression, and methods of treating or ameliorating diseases or disorders associated with FAN1, such as triplet expansion disorders, including those of the polyglutamine family of disorders, using the Fan1 targeting agents of the invention.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] FAN1 TARGETING AGENTS

[0002] FIELD OF THE INVENTION

[0003] The present invention relates to Fan1 targeting agents that target FAN1 mRNA, or miRNAs that bind to FAN1 mRNAs, and thereby relieve microRNA-mediated repression of FAN1. The invention also encompasses methods of enhancing FAN1 protein expression, and methods of treating or ameliorating diseases or disorders associated with FAN1, such as triplet expansion disorders, using the Fan1 targeting agents of the invention.

[0004] BACKGROUND OF THE INVENTION

[0005] Triplet, or trinucleotide, repeat disorders are a large group of human diseases that result from the expansion of repetitive trinucleotide sequences within the genome, which gives rise to a disease-specific tandem repeat tract. These diseases are typically neurological and vary in terms of the genomic location of the repeat tract, symptomology, and stage of development in which they occur.

[0006] Expansion of these triplet repeats ultimately gives rise to aberrant proteins, which can result in either gain- or loss of function mutations. The number of triplet repeats is typically associated with the age at onset (AAO) of disease, with a greater expansion of the repeat sequences generally corresponding to an earlier AAO.

[0007] One family of triplet repeat disorders is the polyglutamine (polyQ) disease family, which consists of a group of hereditary neurological diseases that are linked to the expansion of a triplet ‘CAG’ repeat. Further disorders are associated with: the expansion of ‘OGG’ repeats, such as fragile X-related disorders (FXDs); ‘CTG’ repeats, such as myotonic dystrophy type 1; ‘GAA’ repeats, such as Friedreich ataxia; ‘GCC’ repeats, such as FRAXE mental retardation; and ‘GOG’ repeats, such as oculopharyngeal muscular dystrophy.

[0008] The polyglutamine group comprises disorders that are amongst the most common inherited neurological diseases and includes a number of Spinocerebellar Ataxias (e.g., Type 1 (SCA1), Type 2 (SCA2), Type 3 (SCA3), 6 (SCA6), Type 7 (SCA7), and Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), spinal and bulbar muscular atrophy X-linked 1 (SMAX1 / SBMA), and Huntington’s disease (HD).Huntington's disease (HD) is an autosomal dominant, inherited, degenerative neurological disease caused by an expanded CAG trinucleotide repeat in the huntingtin gene. HD causes a spectrum of cognitive, movement and psychiatric disorders, which are associated with a variety of symptoms.

[0009] The onset of symptoms of HD often varies greatly between individuals. Both the CAG repeat length and genetic variation at other locations within the genome are known to affect age of disease onset. Indeed, genome-wide association studies (GWAS) have identified a number of single nucleotide polymorphisms (SNPs) that are associated with modulating the age of onset of HD symptoms.

[0010] Several of the identified SNPs map to chromosome 15 and are linked to the Fan1 gene. Fan1 encodes the protein FAN1 (FANCD2 / FANCI-associated nuclease 1), an enzyme possessing both endo- and exo-nuclease activity that is important in DNA interstrand cross-link repair.

[0011] Increased FAN1 expression has been shown in model systems to limit somatic CAG repeat expansion and is associated with delayed HD onset and progression, whilst Fan1 knockdown increases CAG repeat expansion (Goold R, et al., FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat. Hum Mol Genet. 2019 Feb 15;28(4):650-661. doi: 10.1093 / hmg / ddy375. PMID: 30358836; PMCID: PMC6360275). FAN1 is thus implicated in modulating HD onset and progression; McAllister B, et al.,. Exome sequencing of individuals with Huntington's disease implicates FAN1 nuclease activity in slowing CAG expansion and disease onset. Nat Neurosci. 2022 Apr;25(4):446-457. doi: 10.1038 / s41593-022-01033-5. Epub 2022 Apr 4. PMID: 35379994; PMCID: PMC8986535).

[0012] A SNP that has been identified that is associated with delayed onset of HD motor dysfunction is rs3512. rs3512 maps to the 3’-UTR (exon 15) of the Fan1 gene, which is also within an intron of the MTMR10 gene encoded on the antisense strand. Expression quantitative trait loci (eQTL) transcriptomic analyses have revealed that rs3512 is associated with increased expression of the Fan1 gene (Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell. 2015 Jul 30;162(3):516-26. doi: 10.1016 / j.cell.2015.07.003. PMID: 26232222; PMCID: PMC4524551), suggesting that rs3512 delays HD onset by impacting a regulatory mechanism inhibiting Fan1 expression.Gene regulatory mechanisms are diverse and complex. One group of regulatory mechanisms is mediated by microRNAs (miRNAs). miRNAs are short non-coding RNAs that are expressed within a cell that are able to negatively regulate target gene expression through their ability to bind to the 3’-UTR of specific target mRNAs and thereby either repress translation initiation / elongation or trigger mRNA decay.

[0013] HD is associated with debilitating symptoms that worsen over an individual’s lifetime until their premature death. Despite being a well-known disease, a paucity of therapeutic interventions exist for the control of disease onset and progression. Further, there is a general lack of any disease-modifying interventions for both HD and triplet repeat diseases more widely.

[0014] The aim of the invention is to provide target specific Fan1 targeting agents that can function as disease-modifying agents in the treatment and prevention of triplet repeat diseases, especially HD.

[0015] SUMMARY OF THE INVENTION

[0016] The present inventors sought to develop Fan1 targeting agents that may function as diseasemodifying agents for triplet repeat diseases. In particular, HD.

[0017] Fan1 is implicated both in HD, in the wider polyQ family of diseases, and further in triplet repeat disorders associated with the expansion of other motifs.

[0018] In a first aspect, provided herein is a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’UTR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0019] The present inventors conducted a literature and database search in order to identify regulatory pathways involved in the control of Fan1.

[0020] The present inventors have identified a microRNA, miR-124-3p, which targets Fan1. Interestingly, the binding site of miR-124-3p, which is located in the Fan1 3’-UTR is altered in rs3512-bearing HD patients, who exhibit delayed onset of HD motor dysfunction.Together, these observations suggest that increased expression of Fan1 in rs3512-bearing HD patients is linked to loss of miR-124-3p-mediated Fan1 repression. As such, the present inventors sought to replicate the naturally observed repressive effect of the rs3512 SNP by designing Fan1 targeting agents that are able to relieve the repressive effect of miR-124-3p upon Fan1 and thereby act as disease-modulators in the triplet expansion disorders with which Fan1 is associated. The present inventors further extended this rationale to design Fan1 targeting agents that are able to relieve the repressive effect of other miRNAs that bind Fan1 and which can therefore also act as disease-modulators in the triplet expansion disorders with which Fan1 is associated. Without wishing to be bound by theory, the Fan1 targeting agents of the invention may therefore function by relieving the repressive effect of miR-124-3p and other miRNAs upon Fan1

[0021] In an aspect, provided herein is a conjugate comprising the Fan1 targeting agent of the invention and one or more moieties covalently bound to said agent.

[0022] In an aspect, provided herein is a pharmaceutically acceptable salt of the Fan1 targeting agent or conjugate of the invention.

[0023] In an aspect, there is provided a composition comprising the Fan1 targeting agent, the conjugate or the pharmaceutically acceptable salt of the invention and a diluent, solvent, carrier, salt and / or adjuvant.

[0024] In an aspect, there is provided a pharmaceutical composition comprising the Fan1 targeting agent, the conjugate or the pharmaceutically acceptable salt of the invention and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0025] In an aspect, there is provided an in vivo or in vitro method for modulating FAN1 protein expression in a target cell in which Fan1 and a microRNA targeting Fan1 are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition or the pharmaceutical composition of the present invention.

[0026] In an aspect, there is provided a method of treating, preventing, or delaying the onset of a disease associated with FAN1 protein in a subject, comprising administering to the subject a therapeutically or prophylactically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt or the pharmaceutical composition of the present invention.In an aspect, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the present invention for use in medicine.

[0027] In an aspect, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the present invention for use in treating, preventing, or delaying the onset of a disease.

[0028] In an aspect there is provided use of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the present invention for the preparation of a medicament for the treatment, prevention, or delay of a disease.

[0029] In some embodiments of the invention according to the foregoing methods and uses the disease is a triplet repeat disorder.

[0030] In some embodiments of the invention according to the foregoing methods and uses the disease is a disease associated with or caused by CAG triplet repeat expansion, CGG triplet repeat expansion, CTG triplet repeat expansion, GAA triplet repeat expansion, GCC triplet repeat expansion, or GCG triplet repeat expansion.

[0031] In some embodiments of the invention according to the foregoing methods and uses the disease is selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7), Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0032] In some embodiments of the invention according to the foregoing methods and uses the disease is Huntington’s disease (HD).

[0033] In an aspect there is provided a method of stoichiometrically delivering two or more oligonucleotide moieties to a cell wherein the method comprises administering the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the present invention.BRIEF DESCRIPTION OF THE FIGURES

[0034] Figure 1 - Schematic representation of bispecific ASOs targeting Fan1 3’-UTR at multiple miRNA binding sites. Bispecific miRNA steric blocking ASO arms were designed against the 3’-UTR region of human Fan1, where multiple miRNAs are predicted to bind (A). Bispecific ASOs were designed carrying arms of varying lengths (12, 14, 18 or 20 nt) united by a linker, some bispecific ASOs contained LNA-modified positions and some did not (B).

[0035] Figure 2 - Bispecific miRNA steric blocking ASOs induce increased FAN1 upregulation compared to a monospecific miRNA steric blocking ASO. Transfection of 25 nM bispecific ASOs targeting miR-197-3p and miR-145-3p or miR-197-3p and miR-181-3p with 12 nt (A), 14 nt (B), 18 nt (C) or 20 nt (D) long arms results in increased FAN1 upregulation relative to transfection of a monospecific miR-197-3p steric blocking ASO at the same concentration. Non-targeting ASO, CTRL (non-targeting) and FAN1 gapmer serve as negative and positive controls, respectively. Data represent the mean and SD within one representative experiment (n=2).

[0036] Figure 3 - Bispecific miRNA steric blocking ASOs induce increased FAN1 upregulation compared to monospecific miRNA steric blocking ASO. Transfection of 25 nM bispecific ASOs result in increased upregulation when compared to transfection of monospecific miRNA steric blocking ASOs at the same concentration. CTRL (non-targeting) and FAN1 gapmers serve as negative and positive controls, respectively. Data represent the mean and SD within one representative experiment (n=2).

[0037] Figure 4 - Bispecific miRNA steric blocking ASOs induce dose-dependent Fan1 upregulation at RNA and protein level. Transfection of bispecific ASOs in concentrations ranging from 1.25 to 100 nM result in dose-dependent FAN1 upregulation at the protein (A) and RNA (B) level, when compared to a non-targeting control ASO transfected under the same conditions. Data represent the mean and SD within one representative experiment (n=2).

[0038] Figure 5 - Therapeutically-optimised bispecific miRNA steric blocking ASOs retain additive upregulation activity. Transfection of 25 nM bispecific ASO iterations carrying shortened arms, varying numbers of PO backbones or missing a TrEG linker induce increased upregulation activity relative to a monospecific miRNA steric blocking ASO. Data represent the mean and SD within one representative experiment (n=2).Figure 6 - Bispecific miRNA steric blocking ASOs targeting the different miRNA seed regions in the 3’-UTR of Fan1 increase FAN1 protein expression in HD patient -derived striatal neurons. The Fan1 upregulating activity of monospecific and bispecific miRNA steric blocking ASOs is replicated in a HD relevant cell model, wherein bispecific ASOs are able to more potently upregulate FAN1 in a disease-related cell type. Observed (A-B) and quantified (C) FAN1 band intensity following normalisation with TUBB3 after 5 weeks of weekly dosing at 5 pM. Fold change was calculated relative to untreated samples. Data represent the mean and SD of within one representative experiment.

[0039] Figure 7 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation over 5 weeks of dosing in HD patient-derived medium spiny neurons. / 7TT-CAG109 striatal neurons were treated weekly with non-targeting gapmer, FAN1 gapmer, compound 12 (‘miR-124-3p_miR-181-5p’) or compound 10 (‘miR-145-5p_miR-197-3p’) for 5 weeks. FAN1 was quantified by western blot analysis.

[0040] Figure 8 - Bispecific miRNA steric blocking ASO-induced FAN1 upregulation follows a dose response in HD patient-derived medium spiny neurons. / 7TT-CAG109 striatal neurons were treated weekly with non-targeting gapmer, FAN1 gapmer, compound 12 (‘miR-124-3p_miR-181-5p (Parental)’) or compound 125 (‘miR-124-3p_miR-181-5p, no LNAs, 4 PO’) for 5 weeks at varying doses. FAN1 was quantified by ELISA.

[0041] Figure 9 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation and reduce H7T-CAG tract expansion in HD patient-derived medium spiny neurons. (A-B) / 7TT-CAG109 striatal neurons were treated with non-targeting control gapmer, FAN1 gapmer, or bispecific ASO (compound 10 referred to as ‘miR-145-5p_miR-197-3p’ in the figure) for up to 100 days. FAN1 protein was quantified by western blotting after 5 weeks of dosing (A). DNA was extracted, the HTT locus was amplified by PCR and sequenced by Nanopore. Mean somatic CAG length gain was calculated (B).

[0042] Figure 10 - Bispecific miRNA steric blocking ASOs upregulate FAN1 and reduce HTT-CAG tract expansion in HD patient iPSC-derived cerebral organoids. / 7TT-CAG127 iPSCs were used to generate mature, CAG-expanding cerebral organoids in culture. (A-B) Organoids were treated with non-targeting control gapmer, FAN1 gapmer, or bispecific ASO (compound 12 referred to as ‘miR-124-3p_miR-181-5p’) for up to 112 days. FAN1 mRNA and protein levels were quantified by RT-qPCR (A) and western blotting (B), respectively, after 140 days in culture. DNA was extracted, the HTT locus was amplified by PCR and sequenced by Nanopore. Mean somatic CAG length gain was calculated (C).Figure 11 - Bispecific miRNA steric blocking ASOs outcompete miRNAs for binding to FAN1 3’-UTR. (A) Schematic representation of a FRET assay designed to interrogate interactions between synthetic fluorophore-conjugated miRNAs, FAN1 3’-UTR fragments and bispecific ASO (compound 10 referred to as ‘miR-145-5p_miR-197-3p’ in the figure). (B-C) At equimolar quantities, the same bispecific ASO outcompetes miR-145-5p (B) and miR-197-3p (C) for binding to different FAN1 3’-UTR fragments.

[0043] DETAILED DESCRIPTION OF THE INVENTION

[0044] It is an object of the present invention to provide a Fan1 targeting agent that acts to relieve post-transcriptional repression of Fan1 mRNA.

[0045] To this end, the inventors have devised Fan1 targeting agents, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’UTR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0046] Complementarity of the Fan1 targeting agents of the present invention to the 3’ UTR of an RNA encoding FAN1 allow them to prevent post-transcriptional repression of Fan1, effectively increasing expression of Fan1.

[0047] Targeting the RNA encoding FAN1 may block one or more miRNAs, for example miR-124-3p, binding to RNA encoding FAN1 and thereby prevent it’s repressive effect upon Fan1 expression.

[0048] The Fan1 targeting agent of the invention may therefore be utilised for targeted modulation of Fan1 expression, e.g., in diseases or disorders wherein Fan1 modulates disease. Fan1 is implicated in modulating triplet expansion diseases of the polyglutamine family. Hence, the Fan1 targeting agents of the invention may be utilised as disease-modifying agents in polyglutamine disorders such as Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7),Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0049] The Fan1 targeting agent of the present invention comprises two or more oligonucleotide moieties capable of targeting the RNA encoding FAN 1. Without wishing to be bound by theory, including two or more oligonucleotide moieties within a single agent may be beneficial for the treatment of diseases or disorders wherein Fan1 modulates disease due to the inclusion of two or more moieties that prevent post-transcriptional modification in a single agent. This may make it more straightforward to deliver the single agent to a cell.

[0050] Without wishing to be bound by theory, it may be beneficial to combine two or more oligonucleotide moieties within a single agent due to a decrease in the number of oligonucleotide moieties which need to be delivered to a cell. This may increase the number of copies of each oligonucleotide moiety which may be able to be delivered to a cell.

[0051] Without wishing to be bound by theory, it may be beneficial to combine two or more oligonucleotide moieties within a single agent due to reduced toxicity when the agent is administered in vivo.

[0052] Without wishing to be bound by theory, it may be beneficial to combine two or more oligonucleotide moieties within a single agent due to increased potency of the agent.

[0053] Without wishing to be bound by theory, in some cases it may be beneficial to combine two or more oligonucleotide moieties within a single agent to increase the number of targets within the 3’IITR, which consequently increases number of cells said agent will be effective in. This could be due to the fact that different cells or cell types may express different isoforms of FAN 1 which have different 3’llTRs. In such cases certain target sequences may be present in some cells / cell type but not others. This could also be due to the fact different cells or cell types have differing miRNA profiles. In such cases certain miRNAs may be more highly expressed in some cells / cell types than others.

[0054] Without wishing to be bound by theory, it may be beneficial to combine two or more oligonucleotide moieties within a single agent due to improved pharmacokintetics of the agent.Fan1 Targeting Agent

[0055] Provided herein is a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0056] A Fan1 targeting agent according to the invention may also be referred to using other terms in the art, depending upon structural and functional features of the specific Fan1 targeting agent. For example, the Fan1 targeting agent may be considered to be an antisense oligonucleotide (ASO), long non-coding RNA (IncRNA), a steric-blocking oligonucleotide (SBO), or an anti-miRNA oligonucleotide (AMO).

[0057] In one embodiment, the Fan1 targeting agent is an antisense oligonucleotide (ASO).

[0058] In one embodiment, the Fan1 targeting agent is an anti-miRNA oligonucleotide (AMO).

[0059] In one embodiment, the Fan1 targeting agent is a steric-blocking oligonucleotide (SBO).

[0060] By way of further example, the Fan1 targeting agent may be a small activating RNA (saRNA), a small interfering RNA (siRNA), or a heteroduplex oligonucleotide (HDO).

[0061] In one embodiment, the Fan1 targeting agent is a small activating RNA (saRNA).

[0062] In one embodiment, the Fan1 targeting agent is a small interfering RNA (siRNA).

[0063] In one embodiment, the Fan1 targeting agent is a heteroduplex oligonucleotide (HDO).

[0064] A Fan1 targeting agent according to the invention may be considered to be a multispecific or bispecific antisense oligonucleotide (ASO), long non-coding RNA (IncRNA), steric-blocking oligonucleotide (SBO), or anti-miRNA oligonucleotide (AMO).

[0065] In one embodiment, the Fan1 targeting agent is a multispecific antisense oligonucleotide (ASO), preferably a bispecific antisense oligonucleotide (ASO).In one embodiment, the Fan1 targeting agent is a multispecifc anti-miRNA oligonucleotide (AMO), preferably a bispecific anti-miRNA oligonucleotide (AMO).

[0066] In one embodiment, the Fan1 targeting agent is a multispecific steric-blocking oligonucleotide (SBO), preferably a bispecific steric-blocking oligonucleotide (SBO).

[0067] By way of further example, the Fan1 targeting agent may be a multispecific small activating RNA (saRNA), a small interfering RNA (siRNA), or a heteroduplex oligonucleotide (HDO), preferably a bispecific small activating RNA (saRNA), a small interfering RNA (siRNA), or a heteroduplex oligonucleotide (HDO).

[0068] In one embodiment, the Fan1 targeting agent is a multispecific small activating RNA (saRNA), preferably a bispecific small activating RNA (saRNA).

[0069] In one embodiment, the Fan1 targeting agent is a multispecific small interfering RNA (siRNA), preferably a bispecific small interfering RNA (siRNA).

[0070] In one embodiment, the Fan1 targeting agent is a multispecific heteroduplex oligonucleotide (HDO), preferably a bispecific heteroduplex oligonucleotide (HDO).

[0071] The term “multispecific” as used herein refers to a Fan1 targeting agent with multiple oligonucleotide moieties wherein each moiety is capable of binding to a target sequence within the 3’IITR of an RNA encoding FAN1. In some embodiments two or more of the oligonucleotide moieties may target the same target sequence, and the Fan1 targeting agent may still be referred to as “multispecific”.

[0072] The term “bispecific” as used herein refers to a Fan1 targeting agent with two oligonucleotide moieties, wherein each moiety is capable of binding to a target sequence within the 3’IITR of an RNA encoding FANI. In some embodiments both of the oligonucleotide moieties may target the same target sequence, and the Fan1 targeting agent may still be referred to as “bispecific”.

[0073] The term “monospecific” as used herein refers to a Fan1 targeting agent with one oligonucleotide moiety. The oligonucleotide moiety will generally be capable of binding to a single target sequence within the 3’IITR of an RNA encoding FAN1.The “Fan1 targeting agent” referred to herein is a synthetic molecule of the invention. In particular, the term “Fan1 targeting agent” describes an agent comprising nucleic acid molecules (e.g. DNA, RNA, or a mixture, or synthetic analogue thereof) that is capable of relieving post-translational repression of Fan1.

[0074] It will be understood that terms such as “relieving post-translational repression of Fan1" may also be expressed in relation to other functional effects that are linked with this effect. For example, it could equally be said that the Fan1 targeting agent of the invention increases the expression of Fan1 (i.e., by relieving said repression).

[0075] The term “Fan1 targeting agent” refers equally to instances wherein the Fan1 targeting agent comprises any combination of RNA and modified versions thereof; of DNA and modified versions thereof; of a mixture of RNA and DNA, and modified versions thereof; and of chemical analogues of nucleotides.

[0076] The term “Fan1 targeting agent” refers equally to instances wherein the Fan1 targeting agent consists of any combination of RNA and modified versions thereof; of DNA and modified versions thereof; of a mixture of RNA and DNA, and modified versions thereof; and of chemical analogues of nucleotides.

[0077] A Fan1 targeting agent of the invention may be a DNA molecule that is transcribed into a Fan1 targeting agent RNA molecule according to the invention.

[0078] A Fan1 targeting agent of the invention may be a DNA molecule that is transcribed into a functional RNA molecule according to the invention that is then further modified by chemical or enzymatic modification.

[0079] In one embodiment, the Fan1 targeting agent is a single-stranded molecule.

[0080] In one embodiment, the Fan1 targeting agent is a double stranded molecule.

[0081] In one embodiment, the Fan1 targeting agent comprises regions of single stranded and double stranded oligonucleotides and / or analogues thereof.

[0082] In relation to the foregoing, it will be understood that “double stranded” refers to complementary base pairing between two or more distinct molecules (or strands). Hence, a single stranded molecule (i.e., single molecule) will be considered single stranded accordingto the foregoing even if said molecule forms double stranded secondary structures (e.g., stem loops). Similarly, a double stranded molecule (i.e., containing two distinct strands) will be considered double stranded according to the foregoing even if the two strands are not 100% complementary (i.e., the two strands may be 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more complementary).

[0083] In one embodiment, the Fan1 targeting agent consists of DNA.

[0084] In one embodiment, the Fan1 targeting agent comprises DNA.

[0085] A DNA molecule may not be a targeting agent in the same way that an RNA molecule is a targeting agent. For example, a DNA molecule may be a targeting agent in that it encodes an RNA molecule, wherein the RNA molecule is a Fan1 targeting agent according to the invention.

[0086] In one embodiment, the Fan1 targeting agent consists of RNA.

[0087] In one embodiment, the Fan1 targeting agent comprises RNA.

[0088] In one embodiment, the Fan1 targeting agent consists of modified RNA nucleotides.

[0089] In one embodiment, the Fan1 targeting agent comprises modified RNA nucleotides.

[0090] In one embodiment, the Fan1 targeting agent consists of synthetic nucleotide analogues.

[0091] In one embodiment, the Fan1 targeting agent comprises synthetic nucleotide analogues.

[0092] In one embodiment, the Fan1 targeting agent comprises or consists of morpholino nucleotides.

[0093] In one embodiment, the Fan1 targeting agent comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 oligonucleotide moieties.

[0094] In one embodiment, the Fan1 targeting agent comprises 2 oligonucleotide moieties.

[0095] In one embodiment, the Fan1 targeting agent comprises 3 oligonucleotide moieties.

[0096] In one embodiment, the Fan1 targeting agent comprises 4 oligonucleotide moieties.In one embodiment, the Fan1 targeting agent comprises 5 oligonucleotide moieties.

[0097] Linker

[0098] In one embodiment, two or more of the oligonucleotide moieties within a Fan1 targeting agent of the invention are separated by an independently selected linker.

[0099] A linker may be any moiety that serves to link, such as covalently link, two or more distinct moieties (e.g., oligonucleotide moieties of the Fan1 targeting agent).

[0100] In one embodiment, two or more of the oligonucleotide moieties are not separated by a linker.

[0101] In one embodiment each of the oligonucleotide moieties are separated by an independently selected linker.

[0102] In certain embodiments one linker may be used to separate more than 2 oligonucleotide moieties. For example a branched linker may be used to separate 3 or more oligonucleotide moieties.

[0103] In one embodiment, none of the oligonucleotide moieties are separated by a linker. In other words, the oligonucleotide moieties are continuous with one another.

[0104] In certain embodiments the independently selected linker is a non-oligonucleotide linker.

[0105] In certain embodiments, the independently selected linker is selected from an ethylene glycol chain of 2 to 10 subunits (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 subunits), an alkyl chain, a carbohydrate chain, a block copolymer, or a peptide.

[0106] In certain embodiments, the independently selected linker is selected from triethyleneglycol (TrEG), tetraethyleneglycol (TEG), hexa-ethyleneglycol (HEG), polyethylene glycol (PEG), cathepsin B-sensitive dipeptide, phosphodiester bridge (abasic) or a disulfide bond

[0107] . In some embodiments the independently selected linker is preferably a triethyleneglycol (TrEG) linker.

[0108] In certain embodiments, the TrEG linker has the following structure:

[0109]

[0110] In certain embodiments the linker may be a PEG linker.

[0111] In certain embodiments, the PEG linker may be linear.

[0112] In certain embodiments, the PEG linker may be non-linear. For example the PEG linker may be a branched PEG, a linear forked PEG or a branched fork PEG.

[0113] In certain embodiments, the independently selected linker is an oligonucleotide linker.

[0114] In certain embodiments, the independently selected linker is a RNA linker.

[0115] In certain embodiments, the independently selected linker is a DNA linker.

[0116] In certain embodiments, the independently selected linker is a single / multiple non-templated nucleotide linker. It will be understand that “non-templated” nucleotide linker as used herein means that the nucleotide(s) linking two oligonucleotide moieties does not take part in complementary base pairing with the 3’IITR of an RNA encoding FAN1 when one or more of the oligonucleotide moieties binds a target sequence.

[0117] In certain embodiments, the independently selected linker is a single guanine nucleotide.

[0118] In certain embodiments, the independently selected linker is a single adenine nucleotide.

[0119] In certain embodiments, the independently selected linker is a single cytosine nucleotide.

[0120] In certain embodiments, the independently selected linked is a single thymine nucleotide.

[0121] In certain embodiments, the independently selected linker is a single uracil nucleotide.In certain embodiments, the independently selected linker comprises or consists of a repeated sequence of 2-5 identical nucleotides with a PO backbone.

[0122] In certain embodiments, the independently selected linker is a self cleaving RNA.

[0123] In certain embodiments, the independently selected linker is a self cleaving ribozyme.

[0124] In certain embodiments, the independently selected liner is a substrate for a nuclease. In certain embodiments, the nuclease is selected from RNase H or RNase P.

[0125] Advantageously, linkers may be cleavable, such as by enzymes, in order to facilitate temporal and / or spatial control of release of oligonucleotide moieties. For example, a Fan1 targeting agent may comprise a cleavable linker, which, upon contact with a cellular protease may be cleaved to liberate one or more oligonucleotide moieties.

[0126] In certain embodiments, the independently selected linker is a cleavable linker, preferably a bio-cleavable linker.

[0127] In certain embodiments, the independently selected linker is more susceptible to cleavage by a protease or nuclease than the oligonucleotide moieties of the Fan1 targeting agent.

[0128] In certain embodiments, the independently selected linker is a non-cleavable linker.

[0129] In one embodiment the Fan1 targeting agent comprises 2 oligonucleotide moieties and the oligonucleotide moieties are separated by a linker, preferably an oligonucleotide linker.

[0130] In one embodiment the Fan1 targeting agent comprises 2 oligonucleotide moieties and the oligonucleotide moieties are not separated by a linker.

[0131] Target sequence

[0132] In one embodiment there is provided a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.In one embodiment there is provided a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’UTR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0133] The phrase “wherein no two target sequences are within five nucleotides of each other” as used herein refers to the case when the 3’ end of one target sequence is not within 5 nucleotides of the 5’ end of another target sequence. It will be understood that this is necessarily the case when two or more target sequences are identical i.e. not distinct. In other words, when two or more target sequences are identical they are not considered to be within five nucleotides of each another.

[0134] The two or more oligonucleotide moieties may be selected independently from one another. Features (e.g., length, composition, contiguous nucleotide sequence and % complementarity of the contiguous nucleotide sequence to the target sequence) of any one oligonucleotide moiety can be selected entirely independently of any other one (i.e., all of the other) oligonucleotide moieties within the same Fan1 targeting agent. As a result of the foregoing, there is no limitation imposed on any one oligonucleotide moiety by any other oligonucleotide moiety within the Fan1 targeting agent.

[0135] Two or more of the oligonucleotide moieties may target different sequences within the 3’IITR of an RNA encoding FANI. In other words, two or more of the oligonucleotide moieties may compete with miRNAs for binding to different target sequences within the 3’UTR of an RNA encoding FAN1.

[0136] In certain embodiments, each of the two or more oligonucleotide moieties may target a different sequence within the 3’UTR of an RNA encoding FAN1.

[0137] Two or more of the oligonucleotide moieties may target the same sequence within the 3’UTR of an RNA encoding FANI. In other words, two or more of the oligonucleotide moieties may compete with an miRNA for binding to an identical target sequence within the 3’UTR of an RNA encoding FAN1.In certain embodiments, each of the two or more oligonucleotide moieties may target an identical sequence within the 3’IITR of an RNA encoding FAN1.

[0138] The phrase “target sequence” as used herein refers to a sequence within the 3’IITR of an RNA encoding FAN1. In certain embodiments miRNAs target this target sequence. The oligonucleotide moieties comprised in the Fan1 targeting agent of the present invention comprise a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to one of these target sequences. It will be understood that the target sequences targeted by the contiguous nucleotide sequences within a Fan1 targeting agent could be present on the same RNA molecule or on different RNA molecules. For instance a Fan1 targeting agent of the present invention may simultaneously bind two or more separate RNA molecules. When simultaneously binding two or more separate RNA molecules, the Fan1 targeting agent may be binding identical or distinct target sequences.

[0139] In certain embodiments, the Fan1 targeting agent does not bind two or more target sequences (be they identical or distinct) simultaneously.

[0140] In certain embodiments the target sequence may overlap with a sequence selected from any one of the seed target sequences listed in table 1.

[0141] Oligonucleotide moieties

[0142] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence which is 10 to 40 nucleotides in length, such as 10 to 35, 10 to 30, 10 to 25, 10 to 20, or 10 to 15 nucleotides in length.

[0143] The oligonucleotide moieties of the Fan1 targeting agent of the present invention may also be referred to as “arms” or “binding arms". For instance the present invention may be described as a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more arms, and each arm independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0144] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence whichis more than 10 nucleotides in length, such as more than 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or more than 39 nucleotides in length.

[0145] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and one oligonucleotide moiety independently comprises an oligonucleotide sequence which is 12 nucleotides in length. The other oligonucleotide moiety may comprise an oligonucleotide sequence which is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0146] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and one oligonucleotide moiety independently comprises an oligonucleotide sequence which is 14 nucleotides in length. The other oligonucleotide moiety may comprise an oligonucleotide sequence which is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0147] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and one oligonucleotide moiety independently comprises an oligonucleotide sequence which is 18 nucleotides in length. The other oligonucleotide moiety may comprise an oligonucleotide sequence which is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0148] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and one oligonucleotide moiety independently comprises an oligonucleotide sequence which is 20 nucleotides in length. The other oligonucleotide moiety may comprise an oligonucleotide sequence which is 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0149] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence which is 12 nucleotides in length.

[0150] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence which is 14 nucleotides in length.In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence which is 18 nucleotides in length.

[0151] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties and each oligonucleotide moiety independently comprises an oligonucleotide sequence which is 20 nucleotides in length.

[0152] In one embodiment, the one or more contiguous nucleotide sequences are independently 5 to 40 nucleotides in length, such as 10 to 35, 10 to 30, 10 to 25, 10 to 20, or 10 to 15 nucleotides in length.

[0153] In one embodiment, the contiguous nucleotide sequences are independently more than 5 nucleotides in length, such as more than 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, or more than 39 nucleotides in length.

[0154] In one embodiment, the contiguous nucleotide sequences are independently 5 nucleotides in length. In other embodiments, the contiguous nucleotide sequences are independently 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length.

[0155] In some embodiments one or more of the oligonucleotide moieties within the Fan1 targeting agent of the invention independently consists of a contiguous nucleotide sequence, such that the oligonucleotide moiety and the contiguous nucleotide sequence are the same length.

[0156] In some embodiments each of the oligonucleotide moieties within the Fan1 targeting agent of the invention consists of a contiguous nucleotide sequence, such that the oligonucleotide moiety and the contiguous nucleotide sequence are the same length.

[0157] In one embodiment, the contiguous nucleotide sequences are independently at least 80% complementary to a target sequence within the 3’ UTR of an RNA encoding FAN1.

[0158] In one embodiment, the contiguous nucleotide sequences are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a target sequence within the 3’ UTR of an RNA encoding FANI.In one embodiment, the contiguous nucleotide sequences are independently at least 85% complementary to a target sequence within the 3’ UTR of an RNA encoding FAN1.

[0159] In one embodiment, the contiguous nucleotide sequences are independently at least 90% complementary to a target sequence within the 3’ UTR of an RNA encoding FAN1.

[0160] In one embodiment, the contiguous nucleotide sequences are independently at least 95% complementary to a target sequence within the 3’ UTR of an RNA encoding FAN1.

[0161] In one embodiment, the contiguous nucleotide sequences are 100% complementary to a target sequence within the 3’ UTR of an RNA encoding FAN1.

[0162] It will be understood that by 3’ UTR of an RNA encoding Fan1 it is meant the complete 3’ UTR sequence as present on both the coding and non-coding strand of the DNA. Thus, each contiguous nucleotide sequence may or may not be complementary to the RNA and may or may not be complementary to a miRNA (which is itself complementary to the 3’ UTR of an RNA encoding Fan1).

[0163] It will be understood that RNA encoding FAN1 refers to either a pre-mRNA or a mature mRNA. As such the term “RNA encoding FAN1” as used herein could be replaced with either pre-mRNA or mRNA. Therefore, it will be understood that by 3’ UTR of an RNA encoding FAN1 it is meant the complete 3’ UTR sequence of either the pre-mRNA or mRNA.

[0164] It will be understood that the Fan1 targeting agent of the present invention may be a DNA or an RNA molecule, as such, sequences that are represented herein as being implicitly DNA (i.e., by containing T rather than U) are to be understood as also representing a corresponding RNA molecule in which each T nucleotide in the sequence is replaced with a U nucleotide. Hence, sequences according to the invention may be either DNA sequences or RNA sequences. The representation of a sequence as either one or the other herein is enacted solely for simplicity and does not imply a sequence is restricted to being a DNA or RNA sequence, unless expressly indicated in the text.

[0165] Reference to nucleotides or nucleosides herein may equally refer to ribo- or deoxyribo-nucleotides / nucleosides, and modified versions thereof.With reference to target sequences, it will be readily understood by those skilled in the art what the substituent parts of such a molecule are. For example, in instances where the target molecule is an mRNA said nucleotides / nucleosides will be ribo-nucleotides / nucleosides, etc.

[0166] Herein, polypeptide or polynucleotide sequences are said to be the same as or “identical” to other polypeptide or polynucleotide sequences, if they share 100% sequence identity. Residues in sequences are numbered from left to right, i.e. from N- to C- terminus for polypeptides; from 5’ to 3’ terminus for polynucleotides. If closely related sequences are not identical they may be similar, i.e., they may possess a certain, quantifiable, degree of sequence identity, e.g., a sequence may have 50%, 60%, 70%, 80%, 90%, 95% or 99% sequence identity to another sequence. Unless a specific reference range is given, e.g., with respect to the nucleotide positions, any quoted sequence identity will be understood as being calculated across the residue range over which the two sequences are aligned. The aligned residue range may represent the entirety of one or more of the input sequences or a contiguous section of sequence of one or more of the input sequences, and is typically determined by standard tools known in the art, e.g., NCBI BLAST.

[0167] For the purposes of comparing two closely-related polynucleotide sequences, the “% sequence identity” between a first nucleotide sequence and a second nucleotide sequence may be calculated using NCBI BLAST, using standard settings for nucleotide sequences (BLASTN). For the purposes of comparing two closely-related polypeptide sequences, the “% sequence identity” between a first polypeptide sequence and a second polypeptide sequence may be calculated using NCBI BLAST, using standard settings for polypeptide sequences (BLASTP). A “difference” between sequences refers to an insertion, deletion or substitution of a single nucleotide in a position of the second sequence, compared to the first sequence. Insertions, deletions or substitutions in a second sequence which is otherwise identical (100% sequence identity) to a first sequence result in reduced % sequence identity.

[0168] “Complementarity” relates to the Watson-Crick base pairing principle that ‘A’ nucleotides will hydrogen bond with T (or ‘U’) nucleotides, and ‘G’ nucleotides will hydrogen bond with ‘C’ nucleotides to form double stranded structures that associate via said “complementary” nucleotides. Herein, a “complementary” sequence is a sequence closely related to another sequence such that such base pairing can occur. Complementary sequences may be 100% complementary such that they may base pair across their entire length, or they may be e.g., 99%, 90%, 80%, 70%, or 60% complementary etc., such that they base pair across portions of their sequence. Here, as is common in the art, a complementary sequence may also be called a “reverse complementary” sequence.The Fan1 targeting agent comprises two or more sequences, which are sufficient in length to bind to a target (e.g., RNA or miRNA).

[0169] Contiguous nucleotide sequences

[0170] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0171] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of the sequences of ASOs 1 to 212, or ASOs 213 to 306 as shown in Table 9.

[0172] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985.

[0173] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 986 to 1010.

[0174] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1011 to 1076.

[0175] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1077 to 1142.

[0176] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1144.

[0177] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1595 to 1688.

[0178] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1689 to 1782.

[0179] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1145 to 1150 and 1152 to 1154.

[0180] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1282 to 1294.

[0181] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1295 to 1307.

[0182] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising orconsisting of a sequence selected from the group consisting of: SEQ ID NOs: 1308 to 1343, preferably selected from the group consisting of SEQ ID NOs 1308 to 1315 and SEQ ID NOs 1326 to 1333.

[0183] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence with 80% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0184] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence with 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0185] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence comprising or consisting of a sequence with 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0186] Oligonucleotide moieties

[0187] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of the sequences of ASOs 1 to 212, or ASOs 213 to 306 as shown in Table 9.

[0188] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985.

[0189] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 986 to 1010.

[0190] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1011 to 1076.

[0191] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1077 to 1142.

[0192] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1144.

[0193] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1145 to 1150 and 1152 to 1154.

[0194] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1282 to 1294.

[0195] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1295 to 1307.

[0196] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1308 to 1343, preferably selected from the group consisting of SEQ ID NOs 1308 to 1315 and SEQ ID NOs 1326 to 1333.

[0197] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1595 to 1688.

[0198] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 1689 to 1782.

[0199] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence with 80% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0200] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence with 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence with 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0201] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length comprising or consisting of a sequence selected from the group consisting of: SEQ ID NOs: 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

[0202] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties.

[0203] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties independently selected from the group consisting of: SEQ ID NOs: 1285, 1286, 1287, 1633, and 1634.

[0204] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties independently selected from the group consisting of: SEQ ID NOs: 1391, 1381, 1421, 1727, and 1728.

[0205] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties, wherein the respective oligonucleotide moieties comprise or consist of:

[0206] a) SEQ ID NO: 1285 and SEQ ID NO: 1286;

[0207] b) SEQ ID NO: 1391 and SEQ ID NO: 1381;

[0208] c) SEQ ID NO: 1385 and SEQ ID NO: 1387;

[0209] d) SEQ ID NO: 1391 and SEQ ID NO: 1421;

[0210] e) SEQ ID NO: 1633 and SEQ ID NO: 1634; or

[0211] f) SEQ ID NO: 1727 and SEQ ID NO: 1728.

[0212] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties, wherein the respective oligonucleotide moieties comprise or consist of SEQ ID NO: 1391 and 1381.In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties, wherein the respective oligonucleotide moieties comprise or consist of SEQ ID NO: 1391 and 1421.

[0213] In one embodiment, the Fan1 targeting agent comprises two oligonucleotide moieties, wherein the respective oligonucleotide moieties comprise or consist of SEQ ID NO: 1727 and 1728.

[0214] Fan1 targeting agent sequences

[0215] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281,1344 to 1355 and 1425 to 1499.

[0216] A sequence selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594.

[0217] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of the sequences of compounds 1 to 99 as shown in Table 10.

[0218] In one embodiment, the Fan1 targeting agent is compound 10.

[0219] In one embodiment, the Fan1 targeting agent is compound 12.

[0220] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of the sequences of compounds 100 to 171 as shown in Table 10.

[0221] In one embodiment, the Fan1 targeting agent is compound 125.

[0222] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1155 to 1166 and 1356, preferably the group consisting of SEQ ID NOs 1158, 1159, 1160, 1356, 1170, 1171, 1172, 1185, and 1186.

[0223] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1208 to 1232, preferably the group consisting of SEQ ID NOs 1217 to 1219, 1232, 1234, 1240, 1244, 1245, 1246, 1259 and 1260.

[0224] In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1158.In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1217.

[0225] In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1160.

[0226] In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1219.

[0227] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1233 to 1240.

[0228] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1167 to 1207.

[0229] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1241 to 1281.

[0230] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1344 to 1355.

[0231] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1451 to 1522.

[0232] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 1523 to 1594.

[0233] In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1476.

[0234] In one embodiment, the Fan1 targeting agent comprises or consists of SEQ ID NO: 1548.

[0235] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence with 80% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594.

[0236] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence with 90% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 1155 to1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594.

[0237] In one embodiment, the Fan1 targeting agent comprises or consists of a sequence with 95% sequence identity to a sequence selected from the group consisting of: SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594.

[0238] In one embodiment, the Fan1 targeting agent is selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594.

[0239] In one embodiment the Fan1 targeting agent comprises a 5’-cap. A “5’-cap” refers to an altered nucleotide at the 5’-end of the transcript which provides stability to the molecule, particularly from degradation from exonucleases, and can promote translation. Most commonly, the 5’-cap may be a 7-methylguanylate cap (m7G), i.e. a guanine nucleotide connected to the RNA via a 5' to 5' triphosphate linkage and methylated on the 7 position.

[0240] FAN1

[0241] Fan1 encodes the protein FAN1 (FANCD2 / FANCI-associated nuclease 1), an enzyme possessing both endo- and exo-nuclease activity that is important in DNA interstrand crosslink repair.

[0242] Herein, Fan1 is used to refer to the gene (i.e., DNA) and any other sequences encoding the sequence thereof (e.g., mRNAs). The protein is referred to as FAN1. Nevertheless, the context of reference to Fan1 will readily be understood by the skilled protein in order to determine the type of molecule being referred to. The aforementioned naming convention is thus not intended to be in any way limiting.

[0243] The 3’-UTR sequences of 9 human Fan1 variants are set out below.

[0244] FAN1-201; ensembl_transcript_id: ENST00000362065 (SEQ ID NO: 1) AAGAUUCCCUACAGGAGAAAAUGGAAAUGAGGAGGAGAGAAACUCCGGUGUCCCCGA GGUGUCGGUGUGGUGAGGGCCGCUGGCGUUGAAGUACAUCCUGCUCUGGCCCAGC UCCCCAUAGCAGGCCUCCAGGGGGCCACUGCGCUGUUGCCGCAGCAUCCUGCUCAG UACGUCGACUUCAUCAGCCAGGAGGGAGAGCUUGUGAAAGGCUGUGAUGGAGCCACCCAGGCUGAUCUGGGCCUCGGGAACCCAGCGGAAGUAGCACAGUUUCCACAGUUUU AUGUGUGUUCCAGAGACACGUGGCAGAAUAACACCGUGCAGGUUGGCGGGUUUGGA AAACCAUUCUCUAAAAUACUGCUCCGUAUCACUGUUCUGGCUGUCGGUUUGCUGAG CUGGAUCUGGCUUUGGUUUUAAUAUCAAUGAAUUUCUCCUUGGAAGUAAUUCUUGG UCACUGAUGAUUCCAUUCUUUAAGGCAGACGGCAUUCCUCUUAGUGUGGAGCUGUA GCUUUUCUAUACAGAAGAGAUUUUAUUAUGUUCCGGGGAUUCCCUUUUUAGAAAGAU UGAAGGAUGCAAUGGCAAAUAUAAACUCAAUACUAUGAAAAAUUAAUGGAAUUUCAGC CUCAAAGAACAUUUUCCUCCCUUCCUUUGUGUCCUUAUUCUAAUCCUCCUCCCCUGG AAUUACACUUUUUUAUGUGUUGACUCUACCUAGGCUGUUACUAUCAGCCUGAAUGG GGGCGGGAUGAGAGUACCUCCUAUCCACUAAUUUGCUUAAGGAUAAGUUCUAAGAC GGGCUAGAAAAAACACUAGACCUGGCCGAUUCUAUCAAGAACAAUGGCAAACUGAAC AGAGGCAGUCAGGAGGCCAAAUGUCUGAUUCUUUGUUCUGUACCUUUCAGUAGUCU GCAAAUUUUCUACCAAAAAAAAUCCCAAGAAUUUAUUUGGGAAUUAUUAAAAAGGCAA ACAAUGAAUGUUAUUAGGACAAGAAUAUAGCAGUCAGGAGGCCAUGACUACAUCACA GCCAGGCGGCAUUCCCUGCCACAGUGGCGGCUUGAAUCAUCAAGAAAUGGAUAAAU GGGGCUUUAGUAAAUCAGGCUUGCAGGCUCAAAGCUGCAAUCUGCCCACUCUCAGG UACUGAGACUUUGUGGGCCUCAGACACCAGGAAGAAAGCUGGGAUACAGUCAUUUG AGUUAAAAAGGGAAUGACCCCUCAGAAACCCGCAUUAGCAGUGUUACUCUUGGAAGU GCCUUUACUUUUAACGCUCUCUGUUCUGAAAAAGAGGUGUUUGGUUACGUGUGAGC CAACAUCACGUUUUGUUAGCUGUGAUUUACCUUUGUCCGUUUAAAAGACUUCACGGA GCCAUUCUGUAUACAAGGUGUGCUCUUUCCAAUGUAGAAGGGGUUAUGGAAAAGGG UGCGAUCCUUUGCUGUAAACUGGAGAGACCAGUCCCAAACAGAGGGGAAUUUUAAG CCCUUCUCAUCACCCAAUUGGAUGUUUUUGCUUAUAGCAAAUUCCUGCAAAAUAAAU AAAUAAAUAUUUGCAAAACUAAA

[0245] FAN1-215; ensembl_transcript_id: ENST00000656435 (SEQ ID NO: 2) AAGAUUCCCUACAGGAGAAAAUGGAAAUGAGGAGGAGAGAAACUCCGGUGUCCCCGA GGUGUCGGUGUGGUGAGGGCCGCUGGCGUUGAAGUACAUCCUGCUCUGGCCCAGC UCCCCAUAGCAGGCCUCCAGGGGGCCACUGCGCUGUUGCCGCAGCAUCCUGCUCAG UACGUCGACUUCAUCAGCCAGGAGGGAGAGCUUGUGAAAGGCUGUGAUGGAGCCAC CCAGGCUGAUCUGGGCCUCGGGAACCCAGCGGAAGUAGCACAGUUUCCACAGUUUU AUGUGUGUUCCAGAGACACGUGGCAGAAUAACACCGUGCAGGUUGGCGGGUUUGGA AAACCAUUCUCUAAAAUACUGCUCCGUAUCACUGUUCUGGCUGUCGGUUUGCUGAG CUGGAUCUGGCUUUGGUUUUAAUAUCAAUGAAUUUCUCCUUGGAAGUAAUUCUUGG UCACUGAUGAUUCCAUUCUUUAAGGCAGACGGCAUUCCUCUUAGUGUGGAGCUGUA GCUUUUCUAUACAGAAGAGAUUUUAUUAUGUUCCGGGGAUUCCCUUUUUAGAAAGAU UGAAGGAUGCAAUGGCAAAUAUAAACUCAAUACUAUGAAAAAUUAAUGGAAUUUCAGCCUCAAAGAACAUUUUCCUCCCUUCCUUUGUGUCCUUAUUCUAAUCCUCCUCCCCUGG AAUUACACUUUUUUAUGUGUUGACUCUACCUAGGCUGUUACUAUCAGCCUGAAUGG GGGCGGGAUGAGAGUACCUCCUAUCCACUAAUUUGCUUAAGGAUAAGUUCUAAGAC GGGCUAGAAAAAACACUAGACCUGGCCGAUUCUAUCAAGAACAAUGGCAAACUGAAC AGAGGCAGUCAGGAGGCCAAAUGUCUGAUUCUUUGUUCUGUACCUUUCAGUAGUCU GCAAAUUUUCUACCAAAAAAAAUCCCAAGAAUUUAUUUGGGAAUUAUUAAAAAGGCAA ACAAUGAAUGUUAUUAGGACAAGAAUAUAGCAGUCAGGAGGCCAUGACUACAUCACA GCCAGGCGGCAUUCCCUGCCACAGUGGCGGCUUGAAUCAUCAAGAAAUGGAUAAAU GGGGCUUUAGUAAAUCAGGCUUGCAGGCUCAAAGCUGCAAUCUGCCCACUCUCAGG UACUGAGACUUUGUGGGCCUCAGACACCAGGAAGAAAGCUGGGAUACAGUCAUUUG AGUUAAAAAGGGAAUGACCCCUCAGAAACCCGCAUUAGCAGUGUUACUCUUGGAAGU GCCUUUACUUUUAACGCUCUCUGUUCUGAAAAAGAGGUGUUUGGUUACGUGUGAGC CAACAUCACGUUUUGUUAGCUGUGAUUUACCUUUGUCCGUUUAAAAGACUUCACGGA GCCAUUCUGUAUACAAGGUGUGCUCUUUCCAAUGUAGAAGGGGUUAUGGAAAAGGG UGCGAUCCUUUGCUGUAAACUGGAGAGACCAGUCCCAAACAGAGGGGAAUUUUAAG CCCUUCUCAUCACCCAAUUGGAUGUUUUUGCUUAUAGCAAAUUCCUGCAAAAUAAAU

[0246] FAN1-221; ensembl_transcript_id: ENST00000664837 (SEQ ID NO: 3) AAGAUUCCCUACAGGAGAAAAUGGAAAUGAGGAGGAGAGAAACUCCGGUGUCCCCGA GGUGUCGGUGUGGUGAGGGCCGCUGGCGUUGAAGUACAUCCUGCUCUGGCCCAGC UCCCCAUAGCAGGCCUCCAGGGGGCCACUGCGCUGUUGCCGCAGCAUCCUGCUCAG UACGUCGACUUCAUCAGCCAGGAGGGAGAGCUUGUGAAAGGCUGUGAUGGAGCCAC CCAGGCUGAUCUGGGCCUCGGGAACCCAGCGGAAGUAGCACAGUUUCCACAGUUUU AUGUGUGUUCCAGAGACACGUGGCAGAAUAACACCGUGCAGGUUGGCGGGUUUGGA AAACCAUUCUCUAAAAUACUGCUCCGUAUCACUGUUCUGGCUGUCGGUUUGCUGAG CUGGAUCUGGCUUUGGUUUUAAUAUCAAUGAAUUUCUCCUUGGAAGUAAUUCUUGG UCACUGAUGAUUCCAUUCUUUAAGGCAGACGGCAUUCCUCUUAGUGUGGAGCUGUA GCUUUUCUAUACAGAAGAGAUUUUAUUAUGUUCCGGGGAUUCCCUUUUUAGAAAGAU UGAAGGAUGCAAUGGCAAAUAUAAACUCAAUACUAUGAAAAAUUAAUGGAAUUUCAGC CUCAAAGAACAUUUUCCUCCCUUCCUUUGUGUCCUUAUUCUAAUCCUCCUCCCCUGG AAUUACACUUUUUUAUGUGUUGACUCUACCUAGGCUGUUACUAUCAGCCUGAAUGG GGGCGGGAUGAGAGUACCUCCUAUCCACUAAUUUGCUUAAGGAUAAGUUCUAAGAC GGGCUAGAAAAAACACUAGACCUGGCCGAUUCUAUCAAGAACAAUGGCAAACUGAAC AGAGGCAGUCAGGAGGCCAAAUGUCUGAUUCUUUGUUCUGUACCUUUCAGUAGUCU GCAAAUUUUCUACCAAAAAAAAUCCCAAGAAUUUAUUUGGGAAUUAUUAAAAAGGCAA ACAAUGAAUGUUAUUAGGACAAGAAUAUAGCAGUCAGGAGGCCAUGACUACAUCACA GCCAGGCGGCAUUCCCUGCCACAGUGGCGGCUUGAAUCAUCAAGAAAUGGAUAAAUGGGGCUUUAGUAAAUCAGGCUUGCAGGCUCAAAGCUGCAAUCUGCCCACUCUCAGG UACUGAGACUUUGUGGGCCUCAGACACCAGGAAGAAAGCUGGGAUACAGUCAUUUG AGUUAAAAAGGGAAUGACCCCUCAGAAACCCGCAUUAGCAGUGUUACUCUUGGAAGU GCCUUUACUUUUAACGCUCUCUGUUCUGAAAAAGAGGUGUUUGGUUACGUGUGAGC CAACAUCACGUUUUGUUAGCUGUGAUUUACCUUUGUCCGUUUAAAAGACUUCACGGA GCCAUUCUGUAUACAAGGUGUGCUCUUUCCAAUGUAGAAGGGGUUAUGGAAAAGGG UGCGAUCCUUUGCUGUAAACUGGAGAGACCAGUCCCAAACAGAGGGGAAUUUUAAG CCCUUCUCAUCACCCAAUUGGAUGUUUUUGCUUAUAGCAAAUUCCUGCAAAAUAAA

[0247] FAN1-228; ensembl_transcript_id: ENST00000670849.1 (SEQ ID NO: 4) AAGATTCCCTACAGGAGAAAATGGAAATGAGGAGGAGAGAAACTCCGGTGTCCCCGAG GTGTCGGTGTGGTGAGGGCCGCTGGCGTTGAAGTACATCCTGCTCTGGCCCAGCTCC CCATAGCAGGCCTCCAGGGGGCCACTGCGCTGTTGCCGCAGCATCCTGCTCAGTACG TCGACTTCATCAGCCAGGAGGGAGAGCTTGTGAAAGGCTGTGATGGAGCCACCCAGG CTGATCTGGGCCTCGGGAACCCAGCGGAAGTAGCACAGTTTCCACAGTTTTATGTGTG TTCCAGAGACACGTGGCAGAATAACACCGTGCAGGTTGGCGGGTTTGGAAAACCATTC TCTAAAATACTGCTCCGTATCACTGTTCTGGCTGTCGGTTTGCTGAGCTGGATCTGGCT TTGGTTTTAATATCAATGAATTTCTCCTTGGAAGTAATTCTTGGTCACTGATGATTCCATT CTTTAAGGCAGACGGCATTCCTCTTAGTGTGGAGCTGTAGCTTTTCTATACAGAAGAGA TTTTATTATGTTCCGGGGATTCCCTTTTTAGAAAGATTGAAGGATGCAATGGCAAATATA AACTCAATACTATGAAAAATTAATGGAATTTCAGCCTCAAAGAACATTTTCCTCCCTTCCT TTGTGTCCTTATTCTAATCCTCCTCCCCTGGAATTACACTTTTTTATGTGTTGACTCTACC TAGGCTGTTACTATCAGCCTGAATGGGGGCGGGATGAGAGTACCTCCTATCCACTAATT TGCTTAAGGATAAGTTCTAAGACGGGCTAGAAAAAACACTAGACCTGGCCGATTCTATC AAGAACAATGGCAAACTGAACAGAGGCAGTCAGGAGGCCAAATGTCTGATTCTTTGTTC TGTACCTTTCAGTAGTCTGCAAATTTTCTACCAAAAAAAATCCCAAGAATTTATTTGGGA ATTATTAAAAAGGCAAACAATGAATGTTATTAGGACAAGAATATAGCAGTCAGGAGGCC ATGACTACATCACAGCCAGGCGGCATTCCCTGCCACAGTGGCGGCTTGAATCATCAAG AAATGGATAAATGGGGCTTTAGTAAATCAGGCTTGCAGGCTCAAAGCTGCAATCTGCCC ACTCTCAGGTACTGAGACTTTGTGGGCCTCAGACACCAGGAAGAAAGCTGGGATACAG TCATTTGAGTTAAAAAGGGAATGACCCCTCAGAAACCCGCATTAGCAGTGTTACTCTTG GAAGTGCCTTTACTTTTAACGCTCTCTGTTCTGAAAAAGAGGTGTTTGGTTACGTGTGA GCCAACATCACGTTTTGTTAGCTGTGATTTACCTTTGTCCGTTTAAAAGACTTCACGGAG CCATTCTGTATACAFAN1-202; ensembl_transcript_id: ENST00000561594.5 (SEQ ID NO: 5) AAACATTTAAAATGTTGATAGCACATATTAACTTACAGTAGATTGTATACTTGATTGAACT GTAATTGTTTATTTCAGTTGTAGTTAGATTGAGAAGGCTGGAAAAGCCTTAATTGCAATA GCCTGGATTCTTTCTTGGGTTATTATTCAAAATTTTTGTCGTAATACCGTACTAATTTCCA GGACCAAGAAAAATCGGAAGGCAATAGGCCTTTGGTAAATTGTAGTATTTTATTTTCCGA GAAAAATACAGTTTTAAGTGATTCTTATGGGATTTTAAGGTAAACTATTTAGTCAAATTTT TATTTTAGTTTTTGTTTACTAAACAAAGTATAATCAGGCAGTCTTAATGTGCAAGTTTTCC TGAGTTTAAACGTAACAATTTACCAAAAACTGTGAGTGGCTTCTTTTGTCCTTGAGAAGC CCTTGACCTGTTTCAGTTGAAAATTACAAAAACTTTTAGAATTGATTTCTTTTGCCCATGT TATTTATATAATCAAACTATATCAACTCTAGCCTGGGAATTCACTACTGTGGAGTCGAGG ATGAAATGAGAGGATGCTTTTGAAAACACTTTAACATGATGTTGTTATTTATTTTATATAT TTGTTTTGTATATTTCAGTTGTTATGAGCCCATCCTTGTTGGGGAGGTGCTATAAATACT AATCTTTAATGAAACATAGGTGTAATAAGGCAGACATTAAGAAAAATATAAATACCAACA CTTGAAAAAAGCTCGTGTTATAGATTTTTAAAAAGTACTTCAATAAATTACATACTTGTAA TTAATTGACTTGAGAAGTATAGAATCCTCATCTGTGTGGTATGTTAAATGTCTTCTAAGT CCTTTCTTTATCTAATTGTATTTCTTAAGTATTTGATGTTAACCTTATATGTAACATTTTAT AAGCAAGTAAACATTAAATTTAGCCACCCTCTGGCTGGG

[0248] FAN1-203; ensembl_transcript_id: ENST00000561607.6 (SEQ ID NO: 6) AAACATTTAAAATGTTGATAGCACATATTAACTTACAGTAGATTGTATACTTGATTGAACT GTAATTGTTTATTTCAGTTGTAGTTAGATTGAGAAGGCTGGAAAAGCCTTAATTGCAATA GCCTGGATTCTTTCTTGGGTTATTATTCAAAATTTTTGTCGTAATACCGTACTAATTTCCA GGACCAAGAAAAATCGGAAGGCAATAGGCCTTTGGTAAATTGTAGTATTTTATTTTCCGA GAAAAATACAGTTTTAAGTGATTCTTATGGGATTTTAAGGTAAACTATTTAGTCAAATTTT TATTTTAGTTTTTGTTTACTAAACAAAGTATAATCAGGCAGTCTTAATGTGCAAGTTTTCC TGAGTTTAAACGTAACAATTTACCAAAAACTGTGAGTGGCTTCTTTTGTCCTTGAGAAGC CCTTGACCTGTTTCAGTTGAAAATTACAAAAACTTTTAGAATTGATTTCTTTTGCCCATGT TATTTATATAATCAAACTATATCAACTCTAGCCTGGGAATTCACTACTGTGGAGTCGAGG ATGAAATGAGAGGATGCTTTTGAAAACACTTTAACATGATGTTGTTATTTATTTTATATAT TTGTTTTGTATATTTCAGTTGTTATGAGCCCATCCTTGTTGGGGAGGTGCTATAAATACT AATCTTTAATGAAACATAGGTGTAATAAGGCAGACATTAAGAAAAATATAAATACCAACA CTTGAAAAAAGCTCGTGTTATAGATTTTTAAAAAGTACTTCAATAAATTACATACTTGTAA TTAATTGACTTGA

[0249] FAN1-207; ensembl_transcript_id: ENST00000565466.5 (SEQ ID NO: 7) AAACATTTAAAATGTTGATAGCACATATTAACTTACAGTAGATTGTATACTTGATTGAACT GTAATTGTTTATTTCAGTTGTAGTTAGATTGAGAAGGCTGGAAAAGCCTTAATTGCAATAGCCTGGATTCTTTCTTGGGTTATTATTCAAAATTTTTGTCGTAATACCGTACTAATTTCCA GGACCAAGAAAAATCGGAAGGCAATAGGCCTTTGGTAAATTGTAGTATTTTATTTTCCGA GAAAAATACAGTTTTAAGTGATTCTTATGGGATTTTAAGGTAAACTATTTAGTCAAATTTT TATTTTAGTTTTTGTTTACTAAACAAAGTATAATCAGGCAGTCTTAATGTGCAAGTTTTCC TGAGTTTAAACGTAACAATTTACCAAAAACTGTGAGTGGCTTCTTTTGTCCTTGAGAAGC CCTTGAC

[0250] FAN1-216; ensembl_transcript_id: ENST00000657391.1 (SEQ ID NO: 8) AAGATTCCCTACAGGAGAAAATGGAAATGAGGAGGAGAGAAACTCCGGTGTCCCCGAG GTGTCGGTGTGGTGAGGGCCGCTGGCGTTGAAGTACATCCTGCTCTGGCCCAGCTCC CCATAGCAGGCCTCCAGGGGGCCACTGCGCTGTTGCCGCAGCATCCTGCTCAGTACG TCGACTTCATCAGCCAGGAGGGAGAGCTTGTGAAAGGCTGTGATGGAGCCACCCAGG CTGATCTGGGCCTCGGGAACCCAGCGGAAGTAGCACAGTTTCCACAGTTTTATGTGTG TTCCAGAGACACGTGGCAGAATAACACCGTGCAGGTTGGCGGGTTTGGAAAACCATTC TCTAAAATACTGCTCCGTATCACTGTTCTGGCTGTCGGTTTGCTGAGCTGGATCTGGCT TTGGTTTTAATATCAATGAATTTCTCCTTGGAAGTAATTCTTGGTCACTGATGATTCCATT CTTTAAGGCAGACGGCATTCCTCTTAGTGTGGAGCTGTAGCTTTTCTATACAGAAGAGA TTTTATTATGTTCCGGGGATTCCCTTTTTAGAAAGATTGAAGGATGCAATGGCAAATATA AACTCAATACTATGAAAAATTAATGGAATTTCAGCCTCAAAGAACATTTTCCTCCCTTCCT TTGTGTCCTTATTCTAATCCTCCTCCCCTGGAATTACACTTTTTTATGTGTTGACTCTACC TAGGCTGTTACTATCAGCCTGAATGGGGGCGGGATGAGAGTACCTCCTATCCACTAATT TGCTTAAGGATAAGTTCTAAGACGGGCTAGAAAAAACACTAGACCTGGCCGATTCTATC AAGAACAATGGCAAACTGAACAGAGGCAGTCAGGAGGCCAAATGTCTGATTCTTTGTTC TGTACCTTTCAGTAGTCTGCAAATTTTCTACCAAAAAAAATCCCAAGAATTTATTTGGGA ATTATTAAAAAGGCAAACAATGAATGTTATTAGGACAAGAATATAGCAGTCAGGAGGCC ATGACTACATCACAGCCAGGCGGCATTCCCTGCCACAGTGGCGGCTTGAATCATCAAG AAATGGATAAATGGGGCTTTAGTAAATCAGGCTTGCAGGCTCAAAGCTGCAATCTGCCC ACTCTCAGGTACTGAGACTTTGTGGGCCTCAGACACCAGGAAGAAAGCTGGGATACAG TCATTTGAGTTAAAAAGGGAATGACCCC

[0251] FAN1-217; ensembl_transcript_id: ENST00000658773.1 (SEQ ID NO: 9) AAACATTTAAAATGTTGATAGCACATATTAACTTACAGTAGATTGTATACTTGATTGAACT GTAATTGTTTATTTCAGTTGTAGTTAGATTGAGAAGGCTGGAAAAGCCTTAATTGCAATA GCCTGGATTCTTTCTTGGGTTATTATTCAAAATTTTTGTCGTAATACCGTACTAATTTCCA GGACCAAGAAAAATCGGAAGGCAATAGGCCTTTGGTAAATTGTAGTATTTTATTTTCCGA GAAAAATACAGTTTTAAGTGATTCTTATGGGATTTTAAGGTAAACTATTTAGTCAAATTTTTATTTTAGTTTTTGTTTACTAAACAAAGTATAATCAGGCAGTCTTAATGTGCAAGTTTTCC TGAGTTTA

[0252] In one embodiment, the sequence from the 3’ UTR of an RNA encoding Fan1 is a sequence from the coding strand of Fan1.

[0253] In one embodiment, the 3’ UTR of an RNA encoding Fan1 is as set forth in SEQ ID NOs:1 to 9.

[0254] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to any one or more of SEQ ID NOs: 1 to 9.

[0255] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 85% complementary to a target sequence within any one or more of SEQ ID NOs: 1 to 9.

[0256] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 90% complementary to a target sequence within any one or more of SEQ ID NOs: 1 to 9.

[0257] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 95% complementary to a target sequence within any one or more of SEQ ID NOs: 1 to 9.

[0258] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or morenucleotides in length that is 100% complementary to a target sequence within any one or more of SEQ ID NOs: 1 to 9.

[0259] A further 9 sequences of the human Fan13’-UTR are set out below. Each of these sequences represents the reverse complement of SEQ ID NOs: 1 to 9, as set out above. Thus, SEQ ID NOs 1 to 9 and 10 to 18 are 100% complementary to one another.

[0260] FAN1-201_reverse complement (SEQ ID NO: 10) UUUAGUUUUGCAAAUAUUUAUUUAUUUAUUUUGCAGGAAUUUGCUAUAAGCAAAAAC AUCCAAUUGGGUGAUGAGAAGGGCUUAAAAUUCCCCUCUGUUUGGGACUGGUCUCU CCAGUUUACAGCAAAGGAUCGCACCCUUUUCCAUAACCCCUUCUACAUUGGAAAGAG CACACCUUGUAUACAGAAUGGCUCCGUGAAGUCUUUUAAACGGACAAAGGUAAAUCA CAGCUAACAAAACGUGAUGUUGGCUCACACGUAACCAAACACCUCUUUUUCAGAACA GAGAGCGUUAAAAGUAAAGGCACUUCCAAGAGUAACACUGCUAAUGCGGGUUUCUGA GGGGUCAUUCCCUUUUUAACUCAAAUGACUGUAUCCCAGCUUUCUUCCUGGUGUCU GAGGCCCACAAAGUCUCAGUACCUGAGAGUGGGCAGAUUGCAGCUUUGAGCCUGCA AGCCUGAUUUACUAAAGCCCCAUUUAUCCAUUUCUUGAUGAUUCAAGCCGCCACUGU GGCAGGGAAUGCCGCCUGGCUGUGAUGUAGUCAUGGCCUCCUGACUGCUAUAUUCU UGUCCUAAUAACAUUCAUUGUUUGCCUUUUUAAUAAUUCCCAAAUAAAUUCUUGGGA UUUUUUUUGGUAGAAAAUUUGCAGACUACUGAAAGGUACAGAACAAAGAAUCAGACA UUUGGCCUCCUGACUGCCUCUGUUCAGUUUGCCAUUGUUCUUGAUAGAAUCGGCCA GGUCUAGUGUUUUUUCUAGCCCGUCUUAGAACUUAUCCUUAAGCAAAUUAGUGGAUA GGAGGUACUCUCAUCCCGCCCCCAUUCAGGCUGAUAGUAACAGCCUAGGUAGAGUC AACACAUAAAAAAGUGUAAUUCCAGGGGAGGAGGAUUAGAAUAAGGACACAAAGGAA GGGAGGAAAAUGUUCUUUGAGGCUGAAAUUCCAUUAAUUUUUCAUAGUAUUGAGUUU AUAUUUGCCAUUGCAUCCUUCAAUCUUUCUAAAAAGGGAAUCCCCGGAACAUAAUAA AAUCUCUUCUGUAUAGAAAAGCUACAGCUCCACACUAAGAGGAAUGCCGUCUGCCUU AAAGAAUGGAAUCAUCAGUGACCAAGAAUUACUUCCAAGGAGAAAUUCAUUGAUAUU AAAACCAAAGCCAGAUCCAGCUCAGCAAACCGACAGCCAGAACAGUGAUACGGAGCA GUAUUUUAGAGAAUGGUUUUCCAAACCCGCCAACCUGCACGGUGUUAUUCUGCCAC GUGUCUCUGGAACACACAUAAAACUGUGGAAACUGUGCUACUUCCGCUGGGUUCCC GAGGCCCAGAUCAGCCUGGGUGGCUCCAUCACAGCCUUUCACAAGCUCUCCCUCCU GGCUGAUGAAGUCGACGUACUGAGCAGGAUGCUGCGGCAACAGCGCAGUGGCCCCC UGGAGGCCUGCUAUGGGGAGCUGGGCCAGAGCAGGAUGUACUUCAACGCCAGCGG CCCUCACCACACCGACACCUCGGGGACACCGGAGUUUCUCUCCUCCUCAUUUCCAU UUUCUCCUGUAGGGAAUCUUFAN1-215_reverse complement (SEQ ID NO: 11) AUUUAUUUUGCAGGAAUUUGCUAUAAGCAAAAACAUCCAAUUGGGUGAUGAGAAGGG CUUAAAAUUCCCCUCUGUUUGGGACUGGUCUCUCCAGUUUACAGCAAAGGAUCGCA CCCUUUUCCAUAACCCCUUCUACAUUGGAAAGAGCACACCUUGUAUACAGAAUGGCU CCGUGAAGUCUUUUAAACGGACAAAGGUAAAUCACAGCUAACAAAACGUGAUGUUGG CUCACACGUAACCAAACACCUCUUUUUCAGAACAGAGAGCGUUAAAAGUAAAGGCAC UUCCAAGAGUAACACUGCUAAUGCGGGUUUCUGAGGGGUCAUUCCCUUUUUAACUC AAAUGACUGUAUCCCAGCUUUCUUCCUGGUGUCUGAGGCCCACAAAGUCUCAGUAC CUGAGAGUGGGCAGAUUGCAGCUUUGAGCCUGCAAGCCUGAUUUACUAAAGCCCCA UUUAUCCAUUUCUUGAUGAUUCAAGCCGCCACUGUGGCAGGGAAUGCCGCCUGGCU GUGAUGUAGUCAUGGCCUCCUGACUGCUAUAUUCUUGUCCUAAUAACAUUCAUUGU UUGCCUUUUUAAUAAUUCCCAAAUAAAUUCUUGGGAUUUUUUUUGGUAGAAAAUUUG CAGACUACUGAAAGGUACAGAACAAAGAAUCAGACAUUUGGCCUCCUGACUGCCUCU GUUCAGUUUGCCAUUGUUCUUGAUAGAAUCGGCCAGGUCUAGUGUUUUUUCUAGCC CGUCUUAGAACUUAUCCUUAAGCAAAUUAGUGGAUAGGAGGUACUCUCAUCCCGCCC CCAUUCAGGCUGAUAGUAACAGCCUAGGUAGAGUCAACACAUAAAAAAGUGUAAUUC CAGGGGAGGAGGAUUAGAAUAAGGACACAAAGGAAGGGAGGAAAAUGUUCUUUGAG GCUGAAAUUCCAUUAAUUUUUCAUAGUAUUGAGUUUAUAUUUGCCAUUGCAUCCUUC AAUCUUUCUAAAAAGGGAAUCCCCGGAACAUAAUAAAAUCUCUUCUGUAUAGAAAAGC UACAGCUCCACACUAAGAGGAAUGCCGUCUGCCUUAAAGAAUGGAAUCAUCAGUGAC CAAGAAUUACUUCCAAGGAGAAAUUCAUUGAUAUUAAAACCAAAGCCAGAUCCAGCUC AGCAAACCGACAGCCAGAACAGUGAUACGGAGCAGUAUUUUAGAGAAUGGUUUUCCAAACCCGCCAACCUGCACGGUGUUAUUCUGCCACGUGUCUCUGGAACACACAUAAAAC UGUGGAAACUGUGCUACUUCCGCUGGGUUCCCGAGGCCCAGAUCAGCCUGGGUGG CUCCAUCACAGCCUUUCACAAGCUCUCCCUCCUGGCUGAUGAAGUCGACGUACUGA GCAGGAUGCUGCGGCAACAGCGCAGUGGCCCCCUGGAGGCCUGCUAUGGGGAGCU GGGCCAGAGCAGGAUGUACUUCAACGCCAGCGGCCCUCACCACACCGACACCUCGG GGACACCGGAGUUUCUCUCCUCCUCAUUUCCAUUUUCUCCUGUAGGGAAUCUU

[0261] FAN1-221_reverse complement (SEQ ID NO: 12) UUUAUUUUGCAGGAAUUUGCUAUAAGCAAAAACAUCCAAUUGGGUGAUGAGAAGGGC UUAAAAUUCCCCUCUGUUUGGGACUGGUCUCUCCAGUUUACAGCAAAGGAUCGCAC CCUUUUCCAUAACCCCUUCUACAUUGGAAAGAGCACACCUUGUAUACAGAAUGGCUC CGUGAAGUCUUUUAAACGGACAAAGGUAAAUCACAGCUAACAAAACGUGAUGUUGGC UCACACGUAACCAAACACCUCUUUUUCAGAACAGAGAGCGUUAAAAGUAAAGGCACU UCCAAGAGUAACACUGCUAAUGCGGGUUUCUGAGGGGUCAUUCCCUUUUUAACUCA AAUGACUGUAUCCCAGCUUUCUUCCUGGUGUCUGAGGCCCACAAAGUCUCAGUACCUGAGAGUGGGCAGAUUGCAGCUUUGAGCCUGCAAGCCUGAUUUACUAAAGCCCCAU UUAUCCAUUUCUUGAUGAUUCAAGCCGCCACUGUGGCAGGGAAUGCCGCCUGGCUG UGAUGUAGUCAUGGCCUCCUGACUGCUAUAUUCUUGUCCUAAUAACAUUCAUUGUUU GCCUUUUUAAUAAUUCCCAAAUAAAUUCUUGGGAUUUUUUUUGGUAGAAAAUUUGCA GACUACUGAAAGGUACAGAACAAAGAAUCAGACAUUUGGCCUCCUGACUGCCUCUGU UCAGUUUGCCAUUGUUCUUGAUAGAAUCGGCCAGGUCUAGUGUUUUUUCUAGCCCG UCUUAGAACUUAUCCUUAAGCAAAUUAGUGGAUAGGAGGUACUCUCAUCCCGCCCCC AUUCAGGCUGAUAGUAACAGCCUAGGUAGAGUCAACACAUAAAAAAGUGUAAUUCCA GGGGAGGAGGAUUAGAAUAAGGACACAAAGGAAGGGAGGAAAAUGUUCUUUGAGGC UGAAAUUCCAUUAAUUUUUCAUAGUAUUGAGUUUAUAUUUGCCAUUGCAUCCUUCAA UCUUUCUAAAAAGGGAAUCCCCGGAACAUAAUAAAAUCUCUUCUGUAUAGAAAAGCU ACAGCUCCACACUAAGAGGAAUGCCGUCUGCCUUAAAGAAUGGAAUCAUCAGUGACC AAGAAUUACUUCCAAGGAGAAAUUCAUUGAUAUUAAAACCAAAGCCAGAUCCAGCUCA GCAAACCGACAGCCAGAACAGUGAUACGGAGCAGUAUUUUAGAGAAUGGUUUUCCAA ACCCGCCAACCUGCACGGUGUUAUUCUGCCACGUGUCUCUGGAACACACAUAAAACU GUGGAAACUGUGCUACUUCCGCUGGGUUCCCGAGGCCCAGAUCAGCCUGGGUGGC UCCAUCACAGCCUUUCACAAGCUCUCCCUCCUGGCUGAUGAAGUCGACGUACUGAG CAGGAUGCUGCGGCAACAGCGCAGUGGCCCCCUGGAGGCCUGCUAUGGGGAGCUG GGCCAGAGCAGGAUGUACUUCAACGCCAGCGGCCCUCACCACACCGACACCUCGGG GACACCGGAGUUUCUCUCCUCCUCAUUUCCAUUUUCUCCUGUAGGGAAUCUU

[0262] FAN1-228_reverse complement (SEQ ID NO: 13) UGUAUACAGAAUGGCUCCGUGAAGUCUUUUAAACGGACAAAGGUAAAUCACAGCUAA CAAAACGUGAUGUUGGCUCACACGUAACCAAACACCUCUUUUUCAGAACAGAGAGCG UUAAAAGUAAAGGCACUUCCAAGAGUAACACUGCUAAUGCGGGUUUCUGAGGGGUCA UUCCCUUUUUAACUCAAAUGACUGUAUCCCAGCUUUCUUCCUGGUGUCUGAGGCCC ACAAAGUCUCAGUACCUGAGAGUGGGCAGAUUGCAGCUUUGAGCCUGCAAGCCUGA UUUACUAAAGCCCCAUUUAUCCAUUUCUUGAUGAUUCAAGCCGCCACUGUGGCAGG GAAUGCCGCCUGGCUGUGAUGUAGUCAUGGCCUCCUGACUGCUAUAUUCUUGUCCU AAUAACAUUCAUUGUUUGCCUUUUUAAUAAUUCCCAAAUAAAUUCUUGGGAUUUUUU UUGGUAGAAAAUUUGCAGACUACUGAAAGGUACAGAACAAAGAAUCAGACAUUUGGC CUCCUGACUGCCUCUGUUCAGUUUGCCAUUGUUCUUGAUAGAAUCGGCCAGGUCUA GUGUUUUUUCUAGCCCGUCUUAGAACUUAUCCUUAAGCAAAUUAGUGGAUAGGAGG UACUCUCAUCCCGCCCCCAUUCAGGCUGAUAGUAACAGCCUAGGUAGAGUCAACACA UAAAAAAGUGUAAUUCCAGGGGAGGAGGAUUAGAAUAAGGACACAAAGGAAGGGAGG AAAAUGUUCUUUGAGGCUGAAAUUCCAUUAAUUUUUCAUAGUAUUGAGUUUAUAUUU GCCAUUGCAUCCUUCAAUCUUUCUAAAAAGGGAAUCCCCGGAACAUAAUAAAAUCUCUUCUGUAUAGAAAAGCUACAGCUCCACACUAAGAGGAAUGCCGUCUGCCUUAAAGAA UGGAAUCAUCAGUGACCAAGAAUUACUUCCAAGGAGAAAUUCAUUGAUAUUAAAACC AAAGCCAGAUCCAGCUCAGCAAACCGACAGCCAGAACAGUGAUACGGAGCAGUAUUUUAGAGAAUGGUUUUCCAAACCCGCCAACCUGCACGGUGUUAUUCUGCCACGUGUCU CUGGAACACACAUAAAACUGUGGAAACUGUGCUACUUCCGCUGGGUUCCCGAGGCC CAGAUCAGCCUGGGUGGCUCCAUCACAGCCUUUCACAAGCUCUCCCUCCUGGCUGA UGAAGUCGACGUACUGAGCAGGAUGCUGCGGCAACAGCGCAGUGGCCCCCUGGAGG CCUGCUAUGGGGAGCUGGGCCAGAGCAGGAUGUACUUCAACGCCAGCGGCCCUCAC CACACCGACACCUCGGGGACACCGGAGUUUCUCUCCUCCUCAUUUCCAUUUUCUCC UGUAGGGAAUCUU

[0263] FAN1-202_reverse complement (SEQ ID NO: 14) CCCAGCCAGAGGGTGGCTAAATTTAATGTTTACTTGCTTATAAAATGTTACATATAAGGT TAACATCAAATACTTAAGAAATACAATTAGATAAAGAAAGGACTTAGAAGACATTTAACAT ACCACACAGATGAGGATTCTATACTTCTCAAGTCAATTAATTACAAGTATGTAATTTATTG AAGTACTTTTTAAAAATCTATAACACGAGCTTTTTTCAAGTGTTGGTATTTATATTTTTCTT AATGTCTGCCTTATTACACCTATGTTTCATTAAAGATTAGTATTTATAGCACCTCCCCAAC AAGGATGGGCTCATAACAACTGAAATATACAAAACAAATATATAAAATAAATAACAACAT CATGTTAAAGTGTTTTCAAAAGCATCCTCTCATTTCATCCTCGACTCCACAGTAGTGAAT TCCCAGGCTAGAGTTGATATAGTTTGATTATATAAATAACATGGGCAAAAGAAATCAATT CTAAAAGTTTTTGTAATTTTCAACTGAAACAGGTCAAGGGCTTCTCAAGGACAAAAGAAG CCACTCACAGTTTTTGGTAAATTGTTACGTTTAAACTCAGGAAAACTTGCACATTAAGAC TGCCTGATTATACTTTGTTTAGTAAACAAAAACTAAAATAAAAATTTGACTAAATAGTTTA CCTTAAAATCCCATAAGAATCACTTAAAACTGTATTTTTCTCGGAAAATAAAATACTACAA TTTACCAAAGGCCTATTGCCTTCCGATTTTTCTTGGTCCTGGAAATTAGTACGGTATTAC GACAAAAATTTTGAATAATAACCCAAGAAAGAATCCAGGCTATTGCAATTAAGGCTTTTC CAGCCTTCTCAATCTAACTACAACTGAAATAAACAATTACAGTTCAATCAAGTATACAAT CTACTGTAAGTTAATATGTGCTATCAACATTTTAAATGTTT

[0264] FAN1-203_reverse complement (SEQ ID NO: 15) TCAAGTCAATTAATTACAAGTATGTAATTTATTGAAGTACTTTTTAAAAATCTATAACACG AGCTTTTTTCAAGTGTTGGTATTTATATTTTTCTTAATGTCTGCCTTATTACACCTATGTTT CATTAAAGATTAGTATTTATAGCACCTCCCCAACAAGGATGGGCTCATAACAACTGAAAT ATACAAAACAAATATATAAAATAAATAACAACATCATGTTAAAGTGTTTTCAAAAGCATCC TCTCATTTCATCCTCGACTCCACAGTAGTGAATTCCCAGGCTAGAGTTGATATAGTTTGA TTATATAAATAACATGGGCAAAAGAAATCAATTCTAAAAGTTTTTGTAATTTTCAACTGAA ACAGGTCAAGGGCTTCTCAAGGACAAAAGAAGCCACTCACAGTTTTTGGTAAATTGTTACGTTTAAACTCAGGAAAACTTGCACATTAAGACTGCCTGATTATACTTTGTTTAGTAAAC AAAAACTAAAATAAAAATTTGACTAAATAGTTTACCTTAAAATCCCATAAGAATCACTTAA AACTGTATTTTTCTCGGAAAATAAAATACTACAATTTACCAAAGGCCTATTGCCTTCCGA TTTTTCTTGGTCCTGGAAATTAGTACGGTATTACGACAAAAATTTTGAATAATAACCCAA GAAAGAATCCAGGCTATTGCAATTAAGGCTTTTCCAGCCTTCTCAATCTAACTACAACTG AAATAAACAATTACAGTTCAATCAAGTATACAATCTACTGTAAGTTAATATGTGCTATCAA CATTTTAAATGTTT

[0265] FAN1-207_reverse complement (SEQ ID NO: 16) GTCAAGGGCTTCTCAAGGACAAAAGAAGCCACTCACAGTTTTTGGTAAATTGTTACGTT TAAACTCAGGAAAACTTGCACATTAAGACTGCCTGATTATACTTTGTTTAGTAAACAAAA ACTAAAATAAAAATTTGACTAAATAGTTTACCTTAAAATCCCATAAGAATCACTTAAAACT GTATTTTTCTCGGAAAATAAAATACTACAATTTACCAAAGGCCTATTGCCTTCCGATTTTT CTTGGTCCTGGAAATTAGTACGGTATTACGACAAAAATTTTGAATAATAACCCAAGAAAG AATCCAGGCTATTGCAATTAAGGCTTTTCCAGCCTTCTCAATCTAACTACAACTGAAATA AACAATTACAGTTCAATCAAGTATACAATCTACTGTAAGTTAATATGTGCTATCAACATTT TAAATGTTT

[0266] FAN1-216_reverse complement (SEQ ID NO: 17) GGGGTCATTCCCTTTTTAACTCAAATGACTGTATCCCAGCTTTCTTCCTGGTGTCTGAG GCCCACAAAGTCTCAGTACCTGAGAGTGGGCAGATTGCAGCTTTGAGCCTGCAAGCCT GATTTACTAAAGCCCCATTTATCCATTTCTTGATGATTCAAGCCGCCACTGTGGCAGGG AATGCCGCCTGGCTGTGATGTAGTCATGGCCTCCTGACTGCTATATTCTTGTCCTAATA ACATTCATTGTTTGCCTTTTTAATAATTCCCAAATAAATTCTTGGGATTTTTTTTGGTAGA AAATTTGCAGACTACTGAAAGGTACAGAACAAAGAATCAGACATTTGGCCTCCTGACTG CCTCTGTTCAGTTTGCCATTGTTCTTGATAGAATCGGCCAGGTCTAGTGTTTTTTCTAGC CCGTCTTAGAACTTATCCTTAAGCAAATTAGTGGATAGGAGGTACTCTCATCCCGCCCC CATTCAGGCTGATAGTAACAGCCTAGGTAGAGTCAACACATAAAAAAGTGTAATTCCAG GGGAGGAGGATTAGAATAAGGACACAAAGGAAGGGAGGAAAATGTTCTTTGAGGCTGA AATTCCATTAATTTTTCATAGTATTGAGTTTATATTTGCCATTGCATCCTTCAATCTTTCTA AAAAGGGAATCCCCGGAACATAATAAAATCTCTTCTGTATAGAAAAGCTACAGCTCCAC ACTAAGAGGAATGCCGTCTGCCTTAAAGAATGGAATCATCAGTGACCAAGAATTACTTC CAAGGAGAAATTCATTGATATTAAAACCAAAGCCAGATCCAGCTCAGCAAACCGACAGC CAGAACAGTGATACGGAGCAGTATTTTAGAGAATGGTTTTCCAAACCCGCCAACCTGCA CGGTGTTATTCTGCCACGTGTCTCTGGAACACACATAAAACTGTGGAAACTGTGCTACT TCCGCTGGGTTCCCGAGGCCCAGATCAGCCTGGGTGGCTCCATCACAGCCTTTCACAA GCTCTCCCTCCTGGCTGATGAAGTCGACGTACTGAGCAGGATGCTGCGGCAACAGCGCAGTGGCCCCCTGGAGGCCTGCTATGGGGAGCTGGGCCAGAGCAGGATGTACTTCAA CGCCAGCGGCCCTCACCACACCGACACCTCGGGGACACCGGAGTTTCTCTCCTCCTCA TTTCCATTTTCTCCTGTAGGGAATCTT

[0267] FAN1-217_reverse complement (SEQ ID NO: 18) TAAACTCAGGAAAACTTGCACATTAAGACTGCCTGATTATACTTTGTTTAGTAAACAAAA ACTAAAATAAAAATTTGACTAAATAGTTTACCTTAAAATCCCATAAGAATCACTTAAAACT GTATTTTTCTCGGAAAATAAAATACTACAATTTACCAAAGGCCTATTGCCTTCCGATTTTT CTTGGTCCTGGAAATTAGTACGGTATTACGACAAAAATTTTGAATAATAACCCAAGAAAG AATCCAGGCTATTGCAATTAAGGCTTTTCCAGCCTTCTCAATCTAACTACAACTGAAATA AACAATTACAGTTCAATCAAGTATACAATCTACTGTAAGTTAATATGTGCTATCAACATTT TAAATGTTT

[0268] In one embodiment, the sequence from the 3’ UTR of an RNA encoding Fan1 is a sequence from the non-coding strand of Fan1.

[0269] In one embodiment, the 3’ UTR of Fan1 is as set forth in SEQ ID NOs: 10 to 18.

[0270] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to any one or more of SEQ ID NOs: 10 to 18.

[0271] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 85% complementary to a target sequence within any one or more of SEQ ID NOs: 10 to 18.

[0272] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 90% complementary to a target sequence within any one or more of SEQ ID NOs: 10 to 18.In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that are independently at least 95% complementary to a target sequence within any one or more of SEQ ID NOs: 10 to 18.

[0273] In one embodiment, the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length that is 100% complementary to a target sequence within any one or more of SEQ ID NOs: 10 to 18.

[0274] The sequence from the 3’ UTR of Fan1 may be derived from either the coding or non-coding strand of Fan1.

[0275] MicroRNAs

[0276] MicroRNAs (miRNAs) are short non-coding RNAs that act to post-transcriptionally regulate target gene expression by their ability to bind to the 3’-UTR of target mRNAs and thereby either repress translation initiation / elongation or trigger mRNA decay.

[0277] miRNAs typically comprise a seed that consists of the first 2 to 7 nucleotides (i.e., counting from the 5' end of the miRNA) embedded within the seed region (nucleotides 1 to 8), which are responsible for Watson-Crick base pairing with their target mRNA (canonical sites). Not all nucleobases within the seed region are required to Watson-Crick base pair with a nucleobase of their target; some nucleotides within the seed may involve G:U wobble pairing or contain imperfect seed match (non-canonical sites). Hence the seed region may not be 100% complementary to its target

[0278] The miRNA termed ‘miR-124-3p’, is the mature active form of a miRNA that targets Fan1. miR-124-3p is produced from 3 genes encoded on different chromosomes. Different mature miRNAs may have identical seed sequences but differ in their 3’ sequences outside of the seed region.

[0279] Further, there also exist ‘isomiRs’ of miRNAs, which differ only by a few nucleotides relative to a reference sequence and are generated by various processes. It will be understood thatisomiRs of specific miRNAs referenced herein, including miR-124-3p, miR-181-5p, miR-145-5p and miR-197-3p are to be encompassed by the reference to the reference miRNA alone. As such, reference to miR-124-3p, miR-181-5p, miR-145-5p and miR-197-3p encompasses isomiRs of miR-124-3p, miR-181-5p, miR-145-5p and miR197-3p respectively.

[0280] In one embodiment, the Fan1 targeting agent of the invention competes with one or more types of microRNAs for binding to the 3’IITR of an RNA encoding FAN1. In other words, the agent competes with one or more set of miRNA with a particular sequence (including isomiRs thereof). In certain embodiments, the Fan1 targeting agent of the invention competes with one type of microRNA for binding to the 3’IITR of an RNA encoding FAN1. In certain embodiments, the Fan1 targeting agent of the invention competes with two types of microRNA for binding to the 3’IITR of an RNA encoding FAN1.

[0281] In one embodiment, the Fan1 targeting agent of the invention competes with two or more microRNA molecules for binding to the 3’IITR of an RNA encoding FAN1. In other words, the agent competes with two physical molecules of microRNA for binding to the 3’IITR of an RNA encoding FAN1. These molecules may have the same sequence (including isomiRs thereof) or may have different sequences. In certain embodiments, the Fan1 targeting agent of the invention competes with two molecules of microRNA for binding to the 3’IITR of an RNA encoding FANI.

[0282] It will be understood that use of the term “competes” does not necessarily suggest that the Fan1 targeting agent is actively competing with a microRNA at all times. In other words “competes” encompasses “is capable of competing with”.

[0283] In one embodiment, each of the contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by a microRNA that targets the 3’-UTR of Fan1.

[0284] In one embodiment, each of the two or more contiguous nucleotide sequences are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within a microRNA that targets the 3’-UTR of Fan1.In one embodiment, each of the two or more contiguous nucleotide sequences are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by the same type of microRNA that targets the 3’-UTR of Fan1.

[0285] In one embodiment, two or more of the two or more contiguous nucleotide sequences are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by the same type of microRNA that targets the 3’-UTR of Fan1.

[0286] In one embodiment, each of the two or more contiguous nucleotide sequences are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by a different type of microRNA that targets the 3’-UTR of Fan1.

[0287] In one embodiment, two or more of the two or more contiguous nucleotide sequences are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by a different type of microRNA that targets the 3’-UTR of Fan1.

[0288] In one embodiment, the microRNA is associated with modulating the onset of a triplet repeat disorder.

[0289] In one embodiment, the microRNA is associated with reducing the age at onset (AAO) of a triplet repeat disorder.

[0290] In one embodiment, the microRNA is associated with increasing the age at onset (AAO) of a triplet repeat disorder.

[0291] In one embodiment, the microRNA or one or more of the microRNAs is selected from the group consisting of: hsa-miR-197-3p, hsa-miR-145-5p, hsa-miR-181-5p, hsa-miR-299-3p, hsa-miR-3940-5p, hsa-miR-4265, hsa-miR-4507, hsa-miR-4657, hsa-miR-6748-5p, hsa-miR-6759-5p, hsa-miR-6793-5p, hsa-miR-6796-5p, hsa-miR-6839-3p, hsa-miR-629-5p, hsa-miR-1275, hsa-miR-193b-5p, hsa-miR-3675-5p, hsa-miR-4665-5p, hsa-miR-6751-5p, hsa-miR-6803-5p, hsa-miR-6835-5p, hsa-miR-6842-5p, hsa-miR-6890-5p, hsa-miR-7109-5p, hsa-miR-7110-5p, hsa-miR-198, hsa-miR-1911-3p, hsa-miR-6753-5p, hsa-miR-1256, hsa-miR-3910, hsa-miR-1910-3p, hsa-miR-2682-5p, hsa-miR-34a-5p, hsa-miR-34b-5p, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b-5p, hsa-miR-449c-5p, hsa-miR-548au-3p, hsa-miR-584-3p, hsa-miR-6511a-5p, hsa-miR-6808-5p, hsa-miR-6893-5p, hsa-miR-940, hsa-miR-3714, hsa-miR-125b-1-3p, hsa-miR-155-5p, hsa-miR-3621, hsa-miR-3610, hsa-miR-4665-3p, hsa-miR-4755-3p, hsa-miR-3622a-5p, hsa-miR-5582-5p, hsa-miR-124-3p, and hsa-miR-506-3p, or an isomiR thereof.

[0292] In another embodiment, the microRNA or one or more of the microRNAs is selected from the group consisting of the miRNAs defined in Table 1, i.e.,: hsa-miR-299-3p, hsa-miR-3940-5p, hsa-miR-4265, hsa-miR-4507, hsa-miR-4657, hsa-miR-6748-5p, hsa-miR-6759-5p, hsa-miR-6793-5p, hsa-miR-6796-5p, hsa-miR-6839-3p, hsa-miR-629-5p, hsa-miR-1275, hsa-miR-193b-5p, hsa-miR-3675-5p, hsa-miR-4665-5p, hsa-miR-6751-5p, hsa-miR-6803-5p, hsa-miR-6835-5p, hsa-miR-6842-5p, hsa-miR-6890-5p, hsa-miR-7109-5p, hsa-miR-7110-5p, hsa-miR-198, hsa-miR-1911-3p, hsa-miR-6753-5p, hsa-miR-1256, hsa-miR-3910, hsa-miR-1910-3p, hsa-miR-2682-5p, hsa-miR-34a-5p, hsa-miR-34b-5p, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b-5p, hsa-miR-449c-5p, hsa-miR-548au-3p, hsa-miR-584-3p, hsa-miR-6511a-5p, hsa-miR-6808-5p, hsa-miR-6893-5p, hsa-miR-940, hsa-miR-3714, hsa-miR-125b-1-3p, hsa-miR-155-5p, hsa-miR-3621, hsa-miR-3610, hsa-miR-4665-3p, hsa-miR-4755-3p, hsa-miR-3622a-5p, hsa-miR-5582-5p, hsa-miR-124-3p, hsa-miR-506-3p, hsa-miR-10527-5p, hsa-miR-1207-5p, hsa-miR-1262, hsa-miR-1273h-3p, hsa-miR-1287-3p, hsa-miR-1301-3p, hsa-miR-1303, hsa-miR-1304-5p, hsa-miR-1343-5p, hsa-miR-141-3p, hsa-miR-186-5p, hsa-miR-1914-3p, hsa-miR-200a-3p, hsa-miR-204-5p, hsa-miR-211-5p, hsa-miR-23a-5p, hsa-miR-23b-5p, hsa-miR-3120-3p, hsa-miR-3122, hsa-miR-3182, hsa-miR-3199, hsa-miR-335-3p, hsa-miR-3681-5p, hsa-miR-3913-5p, hsa-miR-3925-3p, hsa-miR-4284, hsa-miR-4469, hsa-miR-450b-5p, hsa-miR-4640-5p, hsa-miR-4649-3p, hsa-miR-4650-3p, hsa-miR-4667-3p, hsa-miR-4677-5p, hsa-miR-4693-3p, hsa-miR-4701-3p, hsa-miR-4726-5p, hsa-miR-4763-3p, hsa-miR-4768-5p, hsa-miR-4771, hsa-miR-4775, hsa-miR-4776-3p, hsa-miR-4797-3p, hsa-miR-485-5p, hsa-miR-5002-3p, hsa-miR-5008-5p, hsa-miR-5089-5p, hsa-miR-513b-5p, hsa-miR-5190, hsa-miR-5191, hsa-miR-5193, hsa-miR-5194, hsa-miR-543, hsa-miR-545-3p, hsa-miR-548a-3p, hsa-miR-548aa, hsa-miR-548an, hsa-miR-548ap-3p, hsa-miR-548ar-3p, hsa-miR-548az-3p, hsa-miR-548bc, hsa-miR-548e-3p, hsa-miR-548n, hsa-miR-548t-3p, hsa-miR-589-3p, hsa-miR-6730-5p, hsa-miR-6736-5p, hsa-miR-6738-5p, hsa-miR-6740-5p, hsa-miR-676-3p, hsa-miR-6770-5p, hsa-miR-6826-3p, hsa-miR-6831-5p, hsa-miR-6833-3p, hsa-miR-6845-3p, hsa-miR-6870-3p, hsa-miR-6875-3p, hsa-miR-6878-3p, hsa-miR-6884-3p, hsa-miR-7108-3p, hsa-miR-7974, hsa-miR-802, hsa-miR-939-5p, hsa-let-7f-2-3p, hsa-miR-11181-3p, hsa-miR-1185-1-3p, hsa-miR-1185-2-3p, hsa-miR-1197, hsa-miR-12129, hsa-miR-12136, hsa-miR-1228-3p, hsa-miR-124-3p, hsa-miR-1264, hsa-miR-1265, hsa-miR-1276, hsa-miR-1288-5p, hsa-miR-1290, hsa-miR-1299, hsa-miR-130a-5p, hsa-miR-135a-2-3p, hsa-miR-135b-3p, hsa-miR-138-1-3p, hsa-miR-145-5p, hsa-miR-15b-3p, hsa-miR-16-1-3p, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-187-3p, hsa-miR-194-5p, hsa-miR-196a-3p, hsa-miR-196b-3p, hsa-miR-197-3p, hsa-miR-19a-5p, hsa-miR-19b-1-5p, hsa-miR-216b-5p, hsa-miR-2276-3p, hsa-miR-2276-5p, hsa-miR-2278, hsa-miR-2355-3p, hsa-miR-27a-5p, hsa-miR-29a-5p, hsa-miR-3064-5p, hsa-miR-3085-3p, hsa-miR-3125, hsa-miR-3127-3p, hsa-miR-3135a, hsa-miR-3143, hsa-miR-3150a-3p, hsa-miR-3154, hsa-miR-3158-3p, hsa-miR-3159, hsa-miR-3160-5p, hsa-miR-3163, hsa-miR-3184-3p, hsa-miR-3189-5p, hsa-miR-3191-5p, hsa-miR-3202, hsa-miR-331-3p, hsa-miR-342-3p, hsa-miR-346, hsa-miR-3605-3p, hsa-miR-3663-5p, hsa-miR-3677-5p, hsa-miR-372-5p, hsa-miR-376b-5p, hsa-miR-378a-5p, hsa-miR-3916, hsa-miR-3929, hsa-miR-3938, hsa-miR-424-3p, hsa-miR-4254, hsa-miR-4282, hsa-miR-4323, hsa-miR-4428, hsa-miR-4443, hsa-miR-4451, hsa-miR-4476, hsa-miR-4478, hsa-miR-4502, hsa-miR-4503, hsa-miR-4515, hsa-miR-4679, hsa-miR-4694-5p, hsa-miR-4699-3p, hsa-miR-4729, hsa-miR-4738-3p, hsa-miR-4739, hsa-miR-4745-5p, hsa-miR-4755-5p, hsa-miR-4756-5p, hsa-miR-4766-5p, hsa-miR-4773, hsa-miR-4781-3p, hsa-miR-4803, hsa-miR-488-3p, hsa-miR-498-5p, hsa-miR-5001-3p, hsa-miR-5006-3p, hsa-miR-5008-3p, hsa-miR-505-3p, hsa-miR-506-3p, hsa-miR-506-5p, hsa-miR-5088-3p, hsa-miR-5089-3p, hsa-miR-5094, hsa-miR-5189-3p, hsa-miR-5195-3p, hsa-miR-539-5p, hsa-miR-548a-5p, hsa-miR-548ab, hsa-miR-548ad-5p, hsa-miR-548ae-5p, hsa-miR-548ag, hsa-miR-548ai, hsa-miR-548ak, hsa-miR-548am-5p, hsa-miR-548ap-5p, hsa-miR-548aq-5p, hsa-miR-548ar-5p, hsa-miR-548as-5p, hsa-miR-548au-5p, hsa-miR-548ay-5p, hsa-miR-548az-5p, hsa-miR-548b-5p, hsa-miR-548ba, hsa-miR-548bb-5p, hsa-miR-548c-5p, hsa-miR-548d-5p, hsa-miR-548g-3p, hsa-miR-548h-5p, hsa-miR-548i, hsa-miR-548j-5p, hsa-miR-548m, hsa-miR-548o-5p, hsa-miR-548p, hsa-miR-548t-5p, hsa-miR-548v, hsa-miR-548w, hsa-miR-548y, hsa-miR-5586-5p, hsa-miR-559, hsa-miR-5591-5p, hsa-miR-5693, hsa-miR-570-5p, hsa-miR-578, hsa-miR-596, hsa-miR-601, hsa-miR-6081, hsa-miR-643, hsa-miR-6501-3p, hsa-miR-6504-5p, hsa-miR-6511a-3p, hsa-miR-6511b-3p, hsa-miR-6513-5p, hsa-miR-660-3p, hsa-miR-661, hsa-miR-663b, hsa-miR-664a-3p, hsa-miR-6726-5p, hsa-miR-6734-5p, hsa-miR-6736-3p, hsa-miR-6737-3p, hsa-miR-6738-3p, hsa-miR-6739-3p, hsa-miR-6742-3p, hsa-miR-6746-3p, hsa-miR-6756-3p, hsa-miR-676-5p, hsa-miR-6761-5p, hsa-miR-6763-3p, hsa-miR-6763-5p, hsa-miR-6791-3p, hsa-miR-6796-3p, hsa-miR-6818-3p, hsa-miR-6825-5p, hsa-miR-6829-3p, hsa-miR-6833-5p, hsa-miR-6843-3p, hsa-miR-6848-3p, hsa-miR-6854-5p, hsa-miR-6859-5p, hsa-miR-6876-5p, hsa-miR-6894-5p, hsa-miR-6895-3p, hsa-miR-7114-5p, hsa-miR-7157-3p, hsa-miR-765, hsa-miR-766-5p, hsa-miR-7852-3p, hsa-miR-7977, hsa-miR-7978, hsa-miR-8485, hsa-miR-888-5p, hsa-miR-920, hsa-miR-943, hsa-miR-10398-5p, hsa-miR-105-5p, hsa-miR-10a-3p, hsa-miR-12115, hsa-miR-1236-3p, hsa-miR-1253, hsa-miR-125b-2-3p, hsa-miR-1286, hsa-miR-129-5p, hsa-miR-1293, hsa-miR-1302, hsa-miR-1324, hsa-miR-1343-3p, hsa-miR-1470, hsa-miR-147b-5p,hsa-miR-186-3p, hsa-miR-1912-5p, hsa-miR-196a-5p, hsa-miR-196b-5p, hsa-miR-1976, hsa-miR-205-5p, hsa-miR-2116-5p, hsa-miR-22-5p, hsa-miR-221-5p, hsa-miR-24-3p, hsa-miR-2467-5p, hsa-miR-2682-3p, hsa-miR-26b-3p, hsa-miR-30a-3p, hsa-miR-30d-3p, hsa-miR-30e-3p, hsa-miR-31-3p, hsa-miR-3133, hsa-miR-3145-3p, hsa-miR-3152-5p, hsa-miR-3155a, hsa-miR-3155b, hsa-miR-3166, hsa-miR-3171, hsa-miR-3175, hsa-miR-3177-3p, hsa-miR-3184-5p, hsa-miR-3188, hsa-miR-3190-3p, hsa-miR-324-5p, hsa-miR-326, hsa-miR-330-5p, hsa-miR-3529-5p, hsa-miR-3612, hsa-miR-362-5p, hsa-miR-3621, hsa-miR-363-5p, hsa-miR-3655, hsa-miR-365a-5p, hsa-miR-365b-5p, hsa-miR-3675-5p, hsa-miR-3680-3p, hsa-miR-3682-3p, hsa-miR-3682-5p, hsa-miR-3686, hsa-miR-3688-5p, hsa-miR-376a-3p, hsa-miR-376b-3p, hsa-miR-379-5p, hsa-miR-3925-5p, hsa-miR-3940-3p, hsa-miR-3942-3p, hsa-miR-423-5p, hsa-miR-4273, hsa-miR-4287, hsa-miR-4298, hsa-miR-4457, hsa-miR-4483, hsa-miR-4484, hsa-miR-450a-1-3p, hsa-miR-4632-3p, hsa-miR-4659a-3p, hsa-miR-4659a-5p, hsa-miR-4659b-3p, hsa-miR-4660, hsa-miR-4668-3p, hsa-miR-4685-3p, hsa-miR-4685-5p, hsa-miR-4687-3p, hsa-miR-4695-5p, hsa-miR-4707-5p, hsa-miR-4722-5p, hsa-miR-4724-5p, hsa-miR-4727-3p, hsa-miR-4733-5p, hsa-miR-4736, hsa-miR-4740-3p, hsa-miR-4742-3p, hsa-miR-4757-5p, hsa-miR-4762-3p, hsa-miR-4764-3p, hsa-miR-4769-3p, hsa-miR-4774-3p, hsa-miR-4779, hsa-miR-4799-5p, hsa-miR-484, hsa-miR-486-5p, hsa-miR-495-3p, hsa-miR-500b-5p, hsa-miR-501-5p, hsa-miR-507, hsa-miR-518a-5p, hsa-miR-526b-5p, hsa-miR-527, hsa-miR-542-5p, hsa-miR-548as-3p, hsa-miR-548at-3p, hsa-miR-548aw, hsa-miR-548ay-3p, hsa-miR-551b-5p, hsa-miR-557, hsa-miR-5582-3p, hsa-miR-5584-5p, hsa-miR-5587-3p, hsa-miR-5590-5p, hsa-miR-5687, hsa-miR-5688, hsa-miR-572, hsa-miR-576-5p, hsa-miR-590-3p, hsa-miR-6074, hsa-miR-6089, hsa-miR-6128, hsa-miR-623, hsa-miR-629-3p, hsa-miR-650, hsa-miR-6508-3p, hsa-miR-6511b-5p, hsa-miR-6515-3p, hsa-miR-6516-5p, hsa-miR-6721-5p, hsa-miR-6728-5p, hsa-miR-6729-3p, hsa-miR-6741-5p, hsa-miR-6745, hsa-miR-6750-5p, hsa-miR-6756-5p, hsa-miR-6764-3p, hsa-miR-6765-5p, hsa-miR-6766-5p, hsa-miR-6768-3p, hsa-miR-6774-5p, hsa-miR-6777-5p, hsa-miR-6781-3p, hsa-miR-6783-3p, hsa-miR-6792-5p, hsa-miR-6795-3p, hsa-miR-6807-5p, hsa-miR-6809-3p, hsa-miR-6811-5p, hsa-miR-6817-5p, hsa-miR-6820-5p, hsa-miR-6823-3p, hsa-miR-6824-3p, hsa-miR-6837-5p, hsa-miR-6844, hsa-miR-6873-3p, hsa-miR-6889-5p, hsa-miR-6890-5p, hsa-miR-6891-3p, hsa-miR-7-1-3p, hsa-miR-7-2-3p, hsa-miR-7113-3p, hsa-miR-7113-5p, hsa-miR-7151-5p, hsa-miR-7156-3p, hsa-miR-7156-5p, hsa-miR-7162-3p, hsa-miR-766-3p, hsa-miR-769-3p, hsa-miR-7853-5p, hsa-miR-8057, hsa-miR-8073, hsa-miR-874-5p, hsa-miR-885-5p, hsa-miR-887-5p, hsa-miR-95-3p, hsa-miR-9500, hsa-miR-9903, hsa-miR-9983-3p, hsa-let-7a-3p, hsa-let-7a-5p, hsa-let-7b-3p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-let-7e-5p, hsa-let-7f-1-3p, hsa-let-7f-5p, hsa-let-7g-5p, hsa-let-7i-5p, hsa-miR-1-3p, hsa-miR-10392-3p, hsa-miR-10526-3p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10b-3p, hsa-miR-1183, hsa-miR-1185-5p, hsa-miR-1199-3p, hsa-miR-1199-5p, hsa-miR-1200, hsa-miR-1208, hsa-miR-12124, hsa-miR-12132, hsa-miR-12135, hsa-miR-122-3p, hsa-miR-1226-5p, hsa-miR-122b-3p, hsa-miR-122b-5p, hsa-miR-1237-3p, hsa-miR-1245a, hsa-miR-1245b-5p, hsa-miR-1247-5p, hsa-miR-1248, hsa-miR-1251-3p, hsa-miR-1252-3p, hsa-miR-125b-1-3p, hsa-miR-1261, hsa-miR-1285-3p, hsa-miR-1288-3p, hsa-miR-1291, hsa-miR-1296-3p, hsa-miR-1298-5p, hsa-miR-1306-5p, hsa-miR-130b-5p, hsa-miR-132-3p, hsa-miR-1323, hsa-miR-134-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-136-3p, hsa-miR-136-5p, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-1468-3p, hsa-miR-149-3p, hsa-miR-149-5p, hsa-miR-153-5p, hsa-miR-1537-3p, hsa-miR-155-5p, hsa-miR-17-5p, hsa-miR-181a-2-3p, hsa-miR-181d-3p, hsa-miR-187-5p, hsa-miR-1909-3p, hsa-miR-191-5p, hsa-miR-194-3p, hsa-miR-200c-5p, hsa-miR-202-3p, hsa-miR-203a-3p, hsa-miR-2052, hsa-miR-206, hsa-miR-208b-5p, hsa-miR-20a-5p, hsa-miR-20b-3p, hsa-miR-20b-5p, hsa-miR-21-3p, hsa-miR-211-3p, hsa-miR-2110, hsa-miR-2115-3p, hsa-miR-212-3p, hsa-miR-216a-5p, hsa-miR-216b-3p, hsa-miR-217-3p, hsa-miR-218-2-3p, hsa-miR-218-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-222-5p, hsa-miR-2277-3p, hsa-miR-2392, hsa-miR-25-3p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-29b-2-5p, hsa-miR-302a-5p, hsa-miR-3064-3p, hsa-miR-3074-5p, hsa-miR-3115, hsa-miR-3116, hsa-miR-3130-3p, hsa-miR-3136-3p, hsa-miR-3136-5p, hsa-miR-3137, hsa-miR-3142, hsa-miR-3144-5p, hsa-miR-3148, hsa-miR-3149, hsa-miR-3150b-3p, hsa-miR-3152-3p, hsa-miR-3157-5p, hsa-miR-3160-3p, hsa-miR-3162-5p, hsa-miR-3167, hsa-miR-3173-3p, hsa-miR-3179, hsa-miR-3180-5p, hsa-miR-3187-5p, hsa-miR-3191-3p, hsa-miR-3194-5p, hsa-miR-32-5p, hsa-miR-3200-3p, hsa-miR-320a-3p, hsa-miR-320a-5p, hsa-miR-320b, hsa-miR-320c, hsa-miR-320d, hsa-miR-324-3p, hsa-miR-328-3p, hsa-miR-329-3p, hsa-miR-330-3p, hsa-miR-331-5p, hsa-miR-335-5p, hsa-miR-33a-3p, hsa-miR-340-3p, hsa-miR-345-5p, hsa-miR-34a-3p, hsa-miR-34b-3p, hsa-miR-3605-5p, hsa-miR-3609, hsa-miR-361-3p, hsa-miR-3610, hsa-miR-3613-3p, hsa-miR-3614-3p, hsa-miR-3616-5p, hsa-miR-3617-3p, hsa-miR-362-3p, hsa-miR-3620-3p, hsa-miR-3622a-5p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-365b-3p, hsa-miR-3662, hsa-miR-3663-3p, hsa-miR-3671, hsa-miR-3675-3p, hsa-miR-3679-3p, hsa-miR-3679-5p, hsa-miR-3688-3p, hsa-miR-3689a-5p, hsa-miR-3689b-5p, hsa-miR-3689e, hsa-miR-3689f, hsa-miR-369-3p, hsa-miR-3690, hsa-miR-3691-5p, hsa-miR-370-3p, hsa-miR-3714, hsa-miR-371a-5p, hsa-miR-371b-5p, hsa-miR-373-5p, hsa-miR-375-3p, hsa-miR-377-3p, hsa-miR-378g, hsa-miR-383-5p, hsa-miR-3910, hsa-miR-3919, hsa-miR-3920, hsa-miR-3928-3p, hsa-miR-3934-3p, hsa-miR-3940-5p, hsa-miR-3943, hsa-miR-409-3p, hsa-miR-421, hsa-miR-4270, hsa-miR-4288, hsa-miR-4290, hsa-miR-4292, hsa-miR-4429, hsa-miR-4446-3p, hsa-miR-4456, hsa-miR-4458, hsa-miR-4474-3p, hsa-miR-4475, hsa-miR-4477a, hsa-miR-4496, hsa-miR-4500, hsa-miR-4507, hsa-miR-4516, hsa-miR-4519, hsa-miR-4633-3p, hsa-miR-4639-5p, hsa-miR-4646-3p, hsa-miR-4652-3p, hsa-miR-4652-5p, hsa-miR-4653-3p, hsa-miR-4661-3p, hsa-miR-4665-3p, hsa-miR-4676-5p, hsa-miR-4677-3p, hsa-miR-4690-5p, hsa-miR-4691-3p, hsa-miR-4709-5p, hsa-miR-4711-3p, hsa-miR-4712-3p, hsa-miR-4713-5p, hsa-miR-4714-3p, hsa-miR-4715-3p, hsa-miR-4719, hsa-miR-4720-3p, hsa-miR-4728-3p, hsa-miR-4728-5p, hsa-miR-4731-3p, hsa-miR-4731-5p, hsa-miR-4732-5p, hsa-miR-4734, hsa-miR-4738-5p, hsa-miR-4740-5p, hsa-miR-4743-3p, hsa-miR-4744, hsa-miR-4747-3p, hsa-miR-4752, hsa-miR-4753-3p, hsa-miR-4755-3p, hsa-miR-4758-3p, hsa-miR-4763-5p, hsa-miR-4764-5p, hsa-miR-4772-3p, hsa-miR-4772-5p, hsa-miR-4782-5p, hsa-miR-4784, hsa-miR-4788, hsa-miR-4793-3p, hsa-miR-4793-5p, hsa-miR-4794, hsa-miR-4796-3p, hsa-miR-4797-5p, hsa-miR-4801, hsa-miR-4804-3p, hsa-miR-488-5p, hsa-miR-490-3p, hsa-miR-499b-5p, hsa-miR-5002-5p, hsa-miR-5088-5p, hsa-miR-513a-3p, hsa-miR-513c-3p, hsa-miR-515-5p, hsa-miR-516b-5p, hsa-miR-5189-5p, hsa-miR-5196-3p, hsa-miR-519d-3p, hsa-miR-520g-3p, hsa-miR-520h, hsa-miR-526b-3p, hsa-miR-541-5p, hsa-miR-544b, hsa-miR-548ac, hsa-miR-548ad-3p, hsa-miR-548ae-3p, hsa-miR-548ah-3p, hsa-miR-548ah-5p, hsa-miR-548aj-3p, hsa-miR-548aj-5p, hsa-miR-548am-3p, hsa-miR-548aq-3p, hsa-miR-548av-3p, hsa-miR-548bb-3p, hsa-miR-548d-3p, hsa-miR-548e-5p, hsa-miR-548f-5p, hsa-miR-548g-5p, hsa-miR-548h-3p, hsa-miR-548j-3p, hsa-miR-548k, hsa-miR-548l, hsa-miR-548o-3p, hsa-miR-548q, hsa-miR-548x-5p, hsa-miR-548z, hsa-miR-550a-3p, hsa-miR-558, hsa-miR-5582-5p, hsa-miR-5680, hsa-miR-5690, hsa-miR-5692a, hsa-miR-5692c, hsa-miR-5696, hsa-miR-5699-5p, hsa-miR-5702, hsa-miR-5703, hsa-miR-5706, hsa-miR-573, hsa-miR-579-3p, hsa-miR-580-3p, hsa-miR-583, hsa-miR-603, hsa-miR-6090, hsa-miR-612, hsa-miR-615-5p, hsa-miR-616-3p, hsa-miR-616-5p, hsa-miR-624-5p, hsa-miR-627-3p, hsa-miR-629-5p, hsa-miR-632, hsa-miR-642a-3p, hsa-miR-642a-5p, hsa-miR-642b-3p, hsa-miR-642b-5p, hsa-miR-647, hsa-miR-649, hsa-miR-6499-3p, hsa-miR-6505-5p, hsa-miR-6507-3p, hsa-miR-6507-5p, hsa-miR-651-3p, hsa-miR-6510-3p, hsa-miR-6510-5p, hsa-miR-6512-3p, hsa-miR-6515-5p, hsa-miR-6529-3p, hsa-miR-656-3p, hsa-miR-664a-5p, hsa-miR-664b-3p, hsa-miR-6715a-3p, hsa-miR-6720-5p, hsa-miR-6722-3p, hsa-miR-6724-5p, hsa-miR-6727-5p, hsa-miR-6735-3p, hsa-miR-6749-3p, hsa-miR-6751-3p, hsa-miR-6754-5p, hsa-miR-6757-3p, hsa-miR-6758-3p, hsa-miR-6758-5p, hsa-miR-6760-3p, hsa-miR-6760-5p, hsa-miR-6767-3p, hsa-miR-6769a-3p, hsa-miR-6771-3p, hsa-miR-6773-5p, hsa-miR-6774-3p, hsa-miR-6775-3p, hsa-miR-6778-3p, hsa-miR-6782-5p, hsa-miR-6783-5p, hsa-miR-6784-3p, hsa-miR-6785-5p, hsa-miR-6787-3p, hsa-miR-6791-5p, hsa-miR-6792-3p, hsa-miR-6798-5p, hsa-miR-6799-5p, hsa-miR-6800-3p, hsa-miR-6801-3p, hsa-miR-6810-3p, hsa-miR-6810-5p, hsa-miR-6813-3p, hsa-miR-6827-3p, hsa-miR-6827-5p, hsa-miR-6830-3p, hsa-miR-6830-5p, hsa-miR-6832-5p, hsa-miR-6834-5p, hsa-miR-6836-3p, hsa-miR-6836-5p, hsa-miR-6839-3p, hsa-miR-6842-3p, hsa-miR-6851-5p, hsa-miR-6852-5p, hsa-miR-6856-3p, hsa-miR-6856-5p, hsa-miR-6857-5p, hsa-miR-6858-3p, hsa-miR-6860, hsa-miR-6861-5p, hsa-miR-6862-3p, hsa-miR-6865-3p, hsa-miR-6868-3p, hsa-miR-6885-3p, hsa-miR-6889-3p, hsa-miR-6890-3p, hsa-miR-6891-5p, hsa-miR-6892-3p, hsa-miR-6893-3p, hsa-miR-7108-5p, hsa-miR-7109-3p, hsa-miR-7152-3p, hsa-miR-7152-5p,hsa-miR-7154-3p, hsa-miR-7155-3p, hsa-miR-718, hsa-miR-758-5p, hsa-miR-7704, hsa-miR-8062, hsa-miR-873-5p, hsa-miR-876-5p, hsa-miR-877-3p, hsa-miR-889-5p, hsa-miR-892a, hsa-miR-892c-5p, hsa-miR-9-3p, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-93-5p, hsa-miR-939-3p, hsa-miR-98-3p, hsa-miR-98-5p, hsa-miR-9985, hsa-miR-99a-3p, hsa-miR-99b-3p, or an isomiR thereof.

[0293] In another embodiment, the microRNA or one or more of the microRNAs is selected from the group consisting of hsa-miR-1301-3p, hsa-miR-1303, hsa-miR-186-5p, hsa-miR-204-5p, hsa-miR-335-3p, hsa-miR-485-5p, hsa-let-7f-2-3p, hsa-miR-12136, hsa-miR-124-3p, hsa-miR-145-5p, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-186-5p, hsa-miR-194-5p, hsa-miR-197-3p, hsa-miR-3184-3p, hsa-miR-331-3p, hsa-miR-342-3p, hsa-miR-488-3p, hsa-miR-7977, hsa-miR-12136, hsa-miR-125b-2-3p, hsa-miR-129-5p, hsa-miR-24-3p, hsa-miR-30a-3p, hsa-miR-30e-3p, hsa-miR-3184-5p, hsa-miR-330-5p, hsa-miR-335-3p, hsa-miR-379-5p, hsa-miR-423-5p, hsa-miR-484, hsa-miR-486-5p, hsa-miR-495-3p, hsa-miR-874-5p, hsa-miR-885-5p, hsa-miR-95-3p, hsa-let-7a-5p, hsa-let-7b-3p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-let-7e-5p, hsa-let-7f-5p, hsa-let-7g-5p, hsa-let-7i-5p hsa-miR-106b-5p, hsa-miR-125b-1-3p, hsa-miR-132-3p, hsa-miR-135a-5p, hsa-miR-136-3p hsa-miR-136-5p, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-149-5p, hsa-miR-149-5p, hsa-miR-17-5p, hsa-miR-181a-2-3p, hsa-miR-191-5p, hsa-miR-194-5p, hsa-miR-203a-3p, hsa-miR-20a-5p, hsa-miR-21-3p, hsa-miR-212-3p, hsa-miR-218-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-25-3p, hsa-miR-25-3p, hsa-miR-27a-3p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-27b-3p, hsa-miR-3074-5p, hsa-miR-3184-3p, hsa-miR-3200-3p, hsa-miR-320a-3p, hsa-miR-320b, hsa-miR-328-3p, hsa-miR-329-3p, hsa-miR-330-3p, hsa-miR-335-5p, hsa-miR-345-5p, hsa-miR-345-5p, hsa-miR-361-3p, hsa-miR-363-3p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-365a-3p, hsa-miR-365b-3p, hsa-miR-365b-3p, hsa-miR-369-3p, hsa-miR-370-3p, hsa-miR-375-3p, hsa-miR-379-5p, hsa-miR-383-5p, hsa-miR-409-3p, hsa-miR-421, hsa-miR-495-3p, hsa-miR-656-3p, hsa-miR-873-5p, hsa-miR-9-3p, hsa-miR-92a-3p, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-92b-3p, hsa-miR-93-5p, hsa-miR-98-3p, hsa-miR-98-5p.

[0294] In a preferred embodiment, the microRNA or one or more of the microRNAs is selected from the groups consisting of hsa-miR-186-5p, hsa-miR-335-3p, hsa-miR-1301-3p, hsa-miR-1303, hsa-miR-204-5p, hsa-miR-485-5p, hsa-let-7f-2-3p, hsa-miR-145-5p, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-186-5p, hsa-miR-197-3p, hsa-miR-3184-3p, hsa-miR-331-3p, hsa-miR-7977, hsa-miR-194-5p, hsa-miR-181d-5p, hsa-miR-342-3p, hsa-miR-12136, hsa-miR-181c-5p, hsa-miR-124-3p, hsa-miR-488-3p, hsa-miR-24-3p, hsa-miR-30e-3p, hsa-miR-3184-5p, hsa-miR-335-3p, hsa-miR-423-5p, hsa-miR-484, hsa-miR-95-3p, hsa-miR-486-5p, hsa-miR-330-5p, hsa-miR-30a-3p, hsa-miR-379-5p, hsa-miR-12136, hsa-miR-129-5p, hsa-miR-495-3p, hsa-miR-885-5p, hsa-miR-874-5p, hsa-miR-125b-2-3p.

[0295] In one embodiment, the microRNA is selected from the group consisting of: miR-124-3p, miR-197-3p, miR-145-5p, miR-181-5p or isomiRs thereof.

[0296] In one embodiment, one of the microRNAs is selected from the group consisting of: miR-124-3p, miR-197-3p, miR-145-5p, miR-181-5p or isomiRs thereof.

[0297] In one embodiment, the Fan1 targeting agent contains two contiguous nucleotide sequences that are independently complementary to a target sequence within the 3’ UTR of an RNA encoding Fan1 that is overlapping with a nucleotide sequence bound by a microRNA that targets the 3’-UTR of Fan1 and the two microRNAs are selected from the group consisting of: miR-197-3p_miR-145-5p, miR-197-3p_ miR-181-5p or miR-145-5p_ miR-181-5p, miR-124-3p_ miR-181-5p, miR-124-3p_ miR-145-5p, miR-124-3p_ miR-197-3p or isomiRs thereof.

[0298] In one embodiment, the microRNA is miR-124-3p or isomiRs thereof.

[0299] In one embodiment, one of the microRNAs is miR-124-3p or isomiRs thereof.

[0300] In one embodiment, the microRNA is miR-181-5p or isomiRs thereof.

[0301] In one embodiment, one of the microRNAs is miR-181-5p or isomiRs thereof.

[0302] In one embodiment, the microRNA is miR-145-5p or isomiRs thereof.

[0303] In one embodiment, one of the microRNAs is miR-145-5p or isomiRs thereof.

[0304] In one embodiment, the microRNA is miR-197-3p or isomiRs thereof.

[0305] In one embodiment, one of the microRNAs is miR-197-3p or isomiRs thereof.

[0306] In one embodiment, the microRNA comprises a sequence selected from the group consisting of: SEQ ID NOs: 19 to 70, or SEQ ID NO: 71 to 954.

[0307] In one embodiment, the microRNA consists of a sequence selected from the group consisting of: SEQ ID NOs: 19 to 70, or SEQ ID NO: 71 to 954.microRNAs are described in Table 1 below. Table 1 - Putative Fan1-tarqetinq MicroRNAs

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330]

[0331] Seed sequences displayed in Table 1 represent nucleotides 2 to 7 (as read 5’-3’) of the miRNA. It will be understood that the ‘seed target sequence’ corresponds to a sequence, e.g., a Fan1 sequence, that is bound by the miRNA and represents the reverse complement of the sequence identified as the ‘Seed sequence’. Thus, both seed and seed target sequences may be encompassed by the invention.

[0332] It will be understood that the target sequence is a contiguous nucleotide sequence.

[0333] Provided herein is a Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0334] In one embodiment, the Fan1 targeting agent of the invention competes with one or more of the microRNAs defined in Table 1, or an isomiR thereof, for binding to the 3’IITR of an RNA encoding FAN1.In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are each independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by any one or more of the microRNAs defined in Table 1, or an isomi R thereof.

[0335] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0336] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0337] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0338] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0339] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0340] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within one or more microRNAs defined in Table 1, or an isomiR thereof.

[0341] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NOs: 19 to 70, and / or SEQ ID NOs 71 to 954.In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 19 to 70, and / or SEQ ID NOs 71 to 954.

[0342] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 19 to 70, and / or SEQ ID NOs 71 to 954.

[0343] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 19 to 70, and / or SEQ ID NOs 71 to 954.

[0344] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 19 to 70, and / or SEQ ID NOs 71 to 954.

[0345] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 19 to 70, and / or SEQ ID NOs 71 to 954.

[0346] In one embodiment, the Fan1 targeting agent binds to one or more microRNAs defined in Table 1, or an isomiR thereof, thereby preventing binding to Fan1 mRNA.

[0347] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein the two or more contiguous nucleotide sequences are independently selected and are each complementary to an independently selected target sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0348] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 1 nucleotide within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0349] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR ofan RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0350] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0351] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0352] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0353] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0354] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.

[0355] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by one or more microRNAs defined in Table 1, or an isomiR thereof.miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p

[0356] The endogenous microRNAs miR-197-3p, miR-145-5p, miR-181-5p and miR-124-3p target Fan1. The sequences of miR-197-3p, miR-145-5p, miR-181-5p and miR-124-3p are set out in SEQ ID NOs: 183, 172, 175, 176, 177, 178 and 69.

[0357] In one embodiment, the Fan1 targeting agent of the invention competes with one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof, for binding to the 3’IITR of an RNA encoding FAN1.

[0358] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are each independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by any one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof,.

[0359] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0360] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0361] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0362] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0363] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0364] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.

[0365] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.

[0366] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.

[0367] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.

[0368] In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.In one embodiment, the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183, SEQ ID NO: 172, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178 and / or SEQ ID NO: 69.

[0369] In one embodiment, the Fan1 targeting agent binds to one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof, thereby preventing binding to Fan1 mRNA.

[0370] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein the two or more contiguous nucleotide sequences are independently selected and are each complementary to an independently selected target sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0371] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 1 nucleotide within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0372] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0373] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0374] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0375] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0376] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0377] In one embodiment, the two or more contiguous nucleotide sequences are independently complementary to an independently selected target nucleotide sequence within the 3’ UTR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by one or more of miR-197-3p, miR-145-5p, miR-181-5p, miR-124-3p, or an isomiR thereof.

[0378] miR-124-3p

[0379] The endogenous microRNA miR-124-3p targets Fan1. The sequence of miR-124-3p is set out in SEQ ID NO: 69.

[0380] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0381] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0382] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0383] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0384] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0385] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0386] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0387] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0388] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0389] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0390] In one embodiment, the Fan1 targeting agent competes with the microRNA miR-124-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0391] In one embodiment, the Fan1 targeting agent binds to the microRNA miR-124-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0392] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein at least one of the two or more contiguous nucleotide sequences is complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by the microRNA miR-124-3p.

[0393] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN 1 that is overlapping with 1 nucleotide within the nucleotide sequence bound by the microRNA miR-124-3p.

[0394] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0395] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0396] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNAencoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0397] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0398] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0399] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0400] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0401] By overlapping, it is meant that any given nucleotide bound by a specified miRNA is also bound by the Fan1 targeting agent. In other words “overlapping” includes situations wherein the target sequence includes nucleotides 5’ or 3’ of the nucleotide sequence bound by the microRNA along with at least one nucleotide bound by a specified miRNA.

[0402] miR124-3p and miR-181-5p

[0403] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.

[0404] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0405] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-181-5p and miR124-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0406] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-181-5p and miR-124-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0407] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-181 -5p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0408] miR-124-3p and miR-197-3p

[0409] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0410] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-197-3p and miR124-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0411] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-197-3p and miR-124-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0412] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-124-3p.

[0413] miR-124-3p and miR-145-5p

[0414] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-124-3p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 69.

[0415] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-145-5p and miR124-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0416] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-145-5p and miR-124-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0417] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0418] miR-181-5p

[0419] The endogenous microRNA miR-181-5p targets Fan1. The sequence of miR-181-5p is set out in SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 and SEQ ID NO: 178.

[0420] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.

[0421] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.

[0422] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.

[0423] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.

[0424] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA.

[0425] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178.

[0426] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178.

[0427] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178.

[0428] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178.

[0429] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 orSEQ ID NO: 178.

[0430] In one embodiment, the Fan1 targeting agent competes with the microRNA miR-181-5p for binding to the 3’IITR of an RNA encoding FAN1.

[0431] In one embodiment, the Fan1 targeting agent binds to the microRNA miR-181-5p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0432] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein at least one of the two or more contiguous nucleotide sequences is complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by the microRNA miR-181-5p.

[0433] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN 1 that is overlapping with 1 nucleotide within the nucleotide sequence bound by the microRNA miR-181-5p.

[0434] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0435] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNAencoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0436] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0437] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0438] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0439] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0440] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by the microRNA miR-181-5p.

[0441] miR-181-5p and miR-197-3p

[0442] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0443] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0444] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-181-5p and miR197-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0445] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-181-5p and miR-197-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0446] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-181 -5p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0447] miR181-5p and miR-145-5p

[0448] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-181-5p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177 or SEQ ID NO: 178 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0449] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-181-5p and miR-145-5p for binding to the 3’IITR of an RNA encoding FAN1.

[0450] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-181-5p and miR-145-5p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0451] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-181 -5p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0452] miR-145-5p

[0453] The endogenous microRNA miR-145-5p targets Fan1. The sequence of miR-145-5p is set out in SEQ ID NO: 172.

[0454] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.

[0455] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.

[0456] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.

[0457] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.

[0458] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA.

[0459] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0460] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0461] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0462] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0463] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172.

[0464] In one embodiment, the Fan1 targeting agent competes with the microRNA miR-145-5p for binding to the 3’IITR of an RNA encoding FAN1.

[0465] In one embodiment, the Fan1 targeting agent binds to the microRNA miR-145-5p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0466] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein at least one of the two or more contiguous nucleotide sequences is complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by the microRNA miR-145-5p.

[0467] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1that is overlapping with 1 nucleotide within the nucleotide sequence bound by the microRNA miR-145-5p.

[0468] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0469] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0470] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNAencoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0471] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0472] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0473] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0474] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p.

[0475] miR-145-5p and miR-197-3p

[0476] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-145-5p microRNA and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0477] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 172 and at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0478] In one embodiment, the Fan1 targeting agent competes with the microRNAs miR-145-5p and miR-197-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0479] In one embodiment, the Fan1 targeting agent binds to the microRNAs miR-145-5p and miR-197-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0480] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-145-5p and at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 1, 2, 3, 4, 5, 6 or 7 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0481] miR-197-3p

[0482] The endogenous microRNA miR-197-3p targets Fan1. The sequence of miR-197-3p is set out in SEQ ID NO:183.

[0483] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0484] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0485] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0486] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0487] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently 100% complementary to a contiguous nucleotide sequence within the miR-197-3p microRNA.

[0488] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary, such as at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or at least 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0489] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 80% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0490] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 85% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0491] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 90% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0492] In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are independently at least 95% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.In one embodiment, at least one of the two or more contiguous nucleotide sequences of the Fan1 targeting agent of the invention are 100% complementary to a contiguous nucleotide sequence within SEQ ID NO: 183.

[0493] In one embodiment, the Fan1 targeting agent competes with the microRNA miR-197-3p for binding to the 3’IITR of an RNA encoding FAN1.

[0494] In one embodiment, the Fan1 targeting agent binds to the microRNA miR-197-3p, preventing binding to the 3’IITR of an RNA encoding FAN1.

[0495] In one embodiment, the Fan1 targeting agent comprises two or more contiguous nucleotide sequences, wherein at least one of the two or more contiguous nucleotide sequences is complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with a nucleotide sequence bound by the microRNA miR-197-3p.

[0496] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1that is overlapping with 1 nucleotide within the nucleotide sequence bound by the microRNA miR-197-3p.

[0497] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 2 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0498] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 3 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0499] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 4 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 5 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0500] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 6 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0501] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with 7 nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0502] In one embodiment, at least one of the two or more contiguous nucleotide sequences are independently complementary to a target nucleotide sequence within the 3’IITR of an RNA encoding FAN1 that is overlapping with all of the nucleotides within the nucleotide sequence bound by the microRNA miR-197-3p.

[0503] Chemical modifications

[0504] The Fan1 targeting agents provided herein may comprise or consist of chemically modified substituents. That is, substituents that differ relative to the common naturally occurring DNA and RNA nucleotides.

[0505] Chemically modified Fan1 targeting agents comprise one or more modifications as compared with Fan1 targeting agents consisting of common naturally occurring (i.e., ‘unmodified’) DNA and RNA nucleotides. Said modified Fan1 targeting agents comprise one or more modified nucleosides and / or, independently, one or more modified internucleoside linkage.

[0506] The term “modification” or "chemical modification" refers to a structural change in, or on, the most common, natural ribonucleotides: adenosine, guanosine, cytidine, thymidine, or uridine ribonucleotides. In particular, the chemical modifications described herein may be changes in or on a nucleobase (i.e. a chemical base modification), or in or on a sugar (i.e. a chemical sugar modification). The chemical modifications may be introduced co-transcriptionally (e.g. by substitution of one or more nucleotides with a modified nucleotide during synthesis), orpost-transcriptionally (e.g. by the action of an enzyme), or via chemical (i.e., not transcriptionbased) oligonucleotide synthesis.

[0507] Chemical modifications typically constitute chemical modifications of the nucleobase comprising the nucleoside, chemical modifications of the sugar moiety comprising the oligonucleotide and / or modified internucleoside linkages joining nucleosides (which themselves may be modified or unmodified).

[0508] In one embodiment, the Fan1 targeting agent comprises DNA nucleotides, RNA nucleotides, modified DNA nucleotides, and / or modified RNA nucleotides. In one embodiment, Fan1 targeting agent comprises DNA and / or RNA analogues.

[0509] In one embodiment, the Fan1 targeting agent comprises DNA nucleosides, RNA nucleosides, modified DNA nucleosides, and / or modified RNA nucleosides.

[0510] It will be understood that a Fan1 targeting agent of the invention may refer to a RNA / DNA agent comprising only unmodified RNA / DNA nucleotides; a RNA / DNA agent comprising both modified and unmodified RNA / DNA nucleotides; and a RNA / DNA agent comprising all modified RNA / DNA nucleotides. Thus, reference to an RNA or DNA shall include reference to modified RNA / DNAs according to the invention.

[0511] In one embodiment, the Fan1 targeting agent comprises one or more chemical modifications of the nucleobase comprising the nucleosides therein.

[0512] In one embodiment, the Fan1 targeting agent comprises one or more chemical modifications of the sugar moiety comprising the nucleosides therein.

[0513] In one embodiment, the Fan1 targeting agent comprises one or more chemical modifications of internucleoside linkages joining nucleosides.

[0514] In one embodiment, the Fan1 targeting agent comprises one or more: modified nucleobases, modified sugar moieties, and / or modified internucleoside linkages.

[0515] In one embodiment, the Fan1 targeting agent comprises between 1 and 400 modified nucleosides.

[0516] In one embodiment, the Fan1 targeting agent comprises one or more modified nucleosides.In one embodiment, the Fan1 targeting agent comprises no modified nucleosides.

[0517] In one embodiment, the Fan1 targeting agent comprises one or more modified nucleosides such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399 or 400 modified nucleosides.

[0518] In one embodiment, the Fan1 targeting agent comprises modified nucleosides wherein at least 5%, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the nucleosides are modified nucleosides.

[0519] Chemical modifications are known in the art, for example as described in The RNA Modification Database provided by The RNA Institute (https: / / mods.rna.albany.edu / mods / ).Exemplary chemical modifications are described in detail elsewhere, including but not limited to, WO 2023 / 092057, WO 2023 / 064707, and WO 2023 / 023550, which are incorporated herein by reference.

[0520] Modified nucleobases

[0521] In one embodiment, the chemical modification is a chemical base modification, i.e., a modification of the nucleobase moiety. The chemical base modification may be selected from a modification of an adenine, cytosine and / or uracil nucleobase.

[0522] In one embodiment, the modified nucleobase is modified by alkylation, such as methylation, and / or isomerisation.

[0523] In some embodiments, the modified nucleobase refers to a nucleosides that is modified to lack a nucleobase. Hence, in some embodiments the modified nucleoside is an abasic nucleoside.

[0524] The modified nucleobases can be selected from the group consisting of: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and O-6 substituted purines.

[0525] The modified nucleobases can be selected from the group consisting of: 2-aminopropyladenine, 5 -hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyl adenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly 5-bromo, 5 -trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3 -deazaguanine, 3 -deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one and 9-(2 -aminoethoxy)-1, 3 -diazaphenoxazine-2 -one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deazaadenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.Additional nucleobases may be known to those skilled in the art and are contemplated within the scope of the invention.

[0526] In a further embodiment, the chemical base modification is selected from the group consisting of: Pseudouridine (^P), N1 -Methylpseudouridine (Nlm^P), 5-Methylcytidine (m5C) and N6-Methyladenosine (m6A). In a further embodiment, the chemical base modification is selected from the group consisting of: Pseudouridine, N1 -Methylpseudouridine and N6-Methyladenosine.

[0527] Modified sugar moieties

[0528] In one embodiment, the chemical modification is a chemical sugar modification, i.e., a modification of the sugar moiety.

[0529] Modified sugar moieties comprise a modified ribose ring structure as compared with the ribose sugar (i.e., deoxy and non-deoxy) as found in unmodified or naturally occurring DNA or RNA.

[0530] Sugars may be modified, for example, by replacement with a hexose ring (HNA), or a bicyclic ring, wherein said bicyclic ring may have a bridge between the C2 and C4 carbons on the ribose ring forming a locked nucleic acid (LNA).

[0531] Sugar modifications also include modifications made via altering the substituent groups on the ribose ring to groups other than hydrogen or the 2’-OH group naturally found in DNA and RNA nucleosides. Substituents may, for example be introduced at the 2’, 3’, 4’ or 5’ positions.

[0532] In some embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety.

[0533] In some embodiments, the modified sugar moiety is a bicyclic or tricyclic sugar moiety.

[0534] In further embodiments, the modified sugar moiety is a sugar surrogate (i.e., a non-sugar) or a non-ribose sugar, which may optionally comprise one or more substitutions as described for other types of modified sugar moieties.

[0535] In some embodiments, the modified sugar moiety is a non-bicyclic modified sugar moiety comprising a furanosyl ring with one or more substituent groups none of which bridges two atoms of the furanosyl ring to form a bicyclic structure. Such non bridging substituents may be at any position of the furanosyl, including but not limited to substituents at the 2’, 3’, 4’, and / or5’ positions. Examples of 2’-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2’-F, 2'-OCH3 (“OMe” or “O-methyl”), and 2'-O(CH2)2OCH3 (“MOE” or “O-methoxyethyl”), and 2’-O-N-alkyl acetamide, e.g., 2’-O-N-methyl acetamide (“NMA”), 2’-O-N-dimethyl acetamide, 2’-O-N-ethyl acetamide, or 2’-O-N-propyl acetamide.

[0536] It will be understood that modified sugar moieties may be further defined by the isomeric configuration in relation to a specific modification. Hence, isomeric variants of modified sugar moieties may also be used within the Fan1 targeting agents described herein.

[0537] In one embodiment, the modification is a chemical sugar modification is a 2’ modification.

[0538] A 2’ sugar modification results in a nucleoside in which a substituent other than H or -OH is present at the 2’ position (i.e., 2’ substituted). These 2’ modified sugars include 2’ linked biradicle capable of forming a bridge between the 2’ carbon and a second carbon in the ribose ring, thereby forming a LNA (2’ - 4’ biradicle bridged)

[0539] In some embodiments the 2’ sugar modification is independently selected from the group consisting of: 2’-O-alkyl-RNA, 2’-O-methyl-RNA, 2’-alkoxy-RNA, 2’-O-methoxyethyl-RNA (MOE), 2’-amino-DNA, 2’-Fluoro-RNA, and 2’-F-ANA nucleoside.

[0540] In a preferred embodiment the chemical sugar modification a 2'-O-Methyl (2-OMe) modification.

[0541] In a further embodiment, the chemical sugar modification is 2'-O-Methyladenosine (Am).

[0542] In a further embodiment, the chemical sugar modification is 2’-deoxy sugar.

[0543] In a further embodiment, the chemical sugar modification is 2’-Methoxyethyl sugar (2’-MOE).

[0544] In a further embodiment, the chemical sugar modification is 2’-Fluoride modification (2’-F).

[0545] In a further embodiment, the modified nucleoside is a bicyclic sugar moiety.

[0546] In one embodiment, the modified nucleoside is a locked nucleic acid (LNA).

[0547] In one embodiment, the modified nucleoside is a 2’-O-ethyl (cET) nucleotide.Modified internucleoside linkages

[0548] The Fan1 targeting agent of the invention may comprise one or more modified internucleoside linkages.

[0549] By modified internucleoside linkage it will be understood that the internucleoside linkage is a linkage other than a phosphodiester linkages, which functions analogously thereto to covalently couple two nucleosides.

[0550] Modified internucleoside linkages may confer on the Fan1 targeting agent advantageous properties such as increased resistance to nucleases. Such properties may be employed to improve, for example, the in vitro or in vivo half-life of the Fan1 targeting agent.

[0551] In one embodiment, the modified internucleoside linkage is an analogue of a phosphodiester linkage.

[0552] In one embodiment, the modified internucleoside linkage is a phosphonoacetate (PACE) linkage.

[0553] In one embodiment, the modified internucleoside linkage is a phosphoramidite linkage.

[0554] In one embodiment, the modified internucleoside linkage is a phosphorothioate (PS) linkage or a variant or derivative thereof.

[0555] In one embodiment, the modified internucleoside linkage is a diphosphorothioate linkage.

[0556] In one embodiment, the modified internucleoside linkage is an alkyl-, aryl- or heteroaryl-phosphorothioate linkage.

[0557] In one embodiment, the modified internucleoside linkage is a methyl-phosphorothioate linkage.

[0558] In one embodiment, the modified internucleoside linkage is a boranophosphate linkage.

[0559] In one embodiment, the modified internucleoside linkage is a phosphonate linkage ora variant or derivative thereof.In one embodiment, the modified internucleoside linkage is a alkyl-, aryl- or heteroaryl-phosphonate linkage.

[0560] In one embodiment, the modified internucleoside linkage is a methyl-phosphonate linkage.

[0561] In one embodiment, the modified internucleoside linkage is a phosphoryl guanidine linkage.

[0562] In one embodiment, each internucleoside linkage in the Fan1 targeting agent is independently selected from the group consisting of: a phosphodiester linkage (PO); a phosphonoacetate (PACE) linkage; a phosphoramidite linkage; a phosphorothioate linkage; a diphosphorothioate linkage; an alkyl-phosphorothioate linkage; an aryl-phosphorothioate linkage; a heteroaryl-phosphorothioate linkage; a boranophosphate linkage; a phosphonate linkage; an alkyl-phosphonate linkage; an aryl-phosphonate linkage; a heteroaryl-phosphonate linkage; a methyl-phosphonate linkage; and a phosphoryl guanidine linkage, and / or variants or derivatives thereof.

[0563] In one embodiment, the modified internucleoside linkage is independently selected from the group consisting of: a phosphodiester linkage; a phosphonoacetate (PACE) linkage; a phosphoramidite linkage; a phosphorothioate linkage; a diphosphorothioate linkage; an alkyl-phosphorothioate linkage; an aryl-phosphorothioate linkage; a heteroaryl-phosphorothioate linkage; a boranophosphate linkage; a phosphonate linkage; an alkyl-phosphonate linkage; an aryl-phosphonate linkage; a heteroaryl-phosphonate linkage; a methyl-phosphonate linkage; and a phosphoryl guanidine linkage, and / or variants or derivatives thereof.

[0564] In one embodiment, the Fan1 targeting agent comprises one or more modified internucleoside linkages.

[0565] In one embodiment, the Fan1 targeting agent comprises between 1 and 399 modified internucleoside linkages.

[0566] In one embodiment, the Fan1 targeting agent comprises no modified internucleoside linkages.

[0567] In another embodiment, the Fan1 targeting agent comprises one or more modified internucleoside linkages, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69,70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398 or 399 modified internucleoside linkages.

[0568] In one embodiment, the Fan1 targeting agent comprises modified internucleoside linkages wherein at least 5%, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the internucleoside linkages are modified internucleoside linkages.

[0569] It will be understood that any suitable internucleoside linkage known to the person skilled in the art may be selected for use in the Fan1 targeting agent molecule of the invention. Internuceoside linkages described herein are for example only and are not intended to be limiting.

[0570] It will also be understood that the choice of any given internucleoside linkage will be independent of the choice of any other internucleoside linkage, i.e., between any other pair of consecutive nucleosides.Nucleotide and nucleic acid analogues

[0571] Nucleotide and nucleic acid analogues are compounds that are structurally and / or functionally analogous to naturally occurring (or ‘unmodified’) RNA and DNA.

[0572] In one embodiment the Fan1 targeting agent comprises or consists of nucleotide analogues.

[0573] Nucleotide analogues may comprise nucleoside analogues wherein the sugar moiety is replaced with a non-sugar moiety, for example a peptide nucleic acids (PNA), or a morpholino nucleic acids, thereby providing structural analogy with an unmodified nucleoside but not comprising a modified sugar, perse.

[0574] In one embodiment the nucleotide analogue is independently selected from any one or more of a peptide nucleic acid (PNA) nucleotide, a morpholino nucleotide, a locked nucleic acid (LNA) nucleotide, a glycol nucleic acid (GNA) nucleotide, a threose nucleic acid (TNA) nucleotide, and / or a hexitol nucleic acid (HNA) nucleotide.

[0575] In one embodiment the nucleotide analogue is a morpholino nucleotide.

[0576] In one embodiment, the Fan1 targeting agent comprises one or more nucleotide analogues.

[0577] In one embodiment, the Fan1 targeting agent comprises between 1 and 400 nucleotide analogues.

[0578] In one embodiment, the Fan1 targeting agent comprises no nucleotide analogues, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265,266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399 or 400 nucleotide analogues.

[0579] In one embodiment, the Fan1 targeting agent comprises nucleotide analogues linkages wherein at least 5%, such as at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 100% of the nucleotides are nucleotide analogues.

[0580] It will be understood that a Fan1 targeting agent of the invention may be represented by either a basic sequence, or just a sequence which utilises standard IUB / IUPAC nucleic acid codes to represent the nucleobase sequence (e.g., A, T / U, G, C etc.) and / ora code in which chemical modifications of the constituent components are detailed.

[0581] If a Fan1 targeting agent of the invention is represented herein by a basic sequence, this permits any chemical modification of the constituent components, as detailed herein.

[0582] Conjugates and linkers

[0583] In one aspect, there is provided a conjugate comprising the Fan1 targeting agent of the invention and one or more moieties covalently bound to said Fan1 targeting agent.

[0584] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent are non-nucleotide based moieties.

[0585] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent are polypeptides or polypeptide analogues.

[0586] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent are polypeptides or proteins or a region (e.g., one or more domains), domain or fragment thereof.Suitable polypeptides and proteins may be selected from any known source and may, for example, include: viral proteins such as viral envelope / capsid proteins; toxins; and cellular receptors.

[0587] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is an antibody, an scFv, a nanobody, an antibody-based moiety, or a fragment of any of the foregoing.

[0588] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a ligand or receptor, or fragment thereof, capable of binding a corresponding receptor or ligand. In a preferred embodiment, the ligand and / or receptor are a cell-surface ligand / receptors.

[0589] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a carbohydrate moiety, such as an N-acetyl glucosamine moiety.

[0590] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a lipid moiety.

[0591] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a lipophilic moiety.

[0592] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a small molecule, such as a small heterocyclic molecule.

[0593] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is a small molecule, such as a small heterocyclic molecule.

[0594] Any combination or one or more of the foregoing one or more moieties covalently bound to said Fan1 targeting agent may be independently selected. Further, said one or more moieties covalently bound to said Fan1 targeting agent may be covalently bound to the Fan1 targeting agent at any suitable position within the Fan1 targeting agent.

[0595] The one or more moieties covalently bound to said Fan1 targeting agentmay confer favorable properties on the Fan1 targeting agent. The one or more moieties covalently bound to saidFan1 targeting agent may, for example: improve bioavailability, increase stability, improve cellular targeting, and / or improve cellular uptake.

[0596] In a particularly preferred embodiment, the one or more moieties covalently bound to said Fan1 targeting agent will facilitate or improve delivery across the blood brain barrier.

[0597] In one embodiment, the one or more moieties covalently bound to said Fan1 targeting agent is an oligonucleotide or analogue thereof.

[0598] In one embodiment, the Fan1 targeting agent comprises a linker between the Fan1 targeting agent and the one or more moieties covalently bound to said Fan1 targeting agent.

[0599] A linker may be any moiety that serves to link, such as covalently link, two or more distinct moieties (e.g., Fan1 targeting agent and one or more moieties covalently bound to said Fan1 targeting agent).

[0600] Advantageously, linkers may be cleavable, such as by enzymes, in order to facilitate temporal and / or spatial control of moieties attached to the Fan1 targeting agent. For example, the one or more moieties covalently bound to said Fan1 targeting agent may be joined to a Fan1 targeting agent via a cleavable linker, which, upon contact with a cellular protease may be cleaved to liberate the Fan1 targeting agent from the one or more moieties covalently bound to said Fan1 targeting agent.

[0601] In one embodiment, the linker is an oligonucleotide or analogue thereof.

[0602] DNA molecules and vectors

[0603] According to a further aspect of the invention, there is provided a DNA molecule encoding a Fan1 targeting agent of the invention.

[0604] According to a further aspect of the invention, there is provided an expression vector comprising said DNA molecule.

[0605] Exemplary expression vectors are known in the art and may include, for example, plasmid vectors, viral vectors (for example adenovirus, adeno-associated virus, retrovirus or lentivirus vectors), phage vectors, cosmid vectors and the like. The choice of expression vector may be dependent upon the type of host cell to be used and the purpose of use. In particular, andwithout limitation, the following plasmids have been used for expression of Fan1 targeting agents:

[0606] Mammalian expression plasmids:

[0607] - pCDNA3.1 (-)

[0608] pDUAL-eGFPΔ (modified from peGFP-C2)

[0609] Viral vectors:

[0610] pAAV (an Adeno-Associated Virus vector)

[0611] rcLV -TetOne-Puro (a 3rdgeneration Lentivirus vector)

[0612] pLPCX-link (a 3rdgeneration Retrovirus vector)

[0613] In one embodiment the mammalian expression plasmid is pCDNA3.1 (-).

[0614] In another embodiment the mammalian expression plasmid is pDUAL-eGFPΔ.

[0615] Plasmids of the invention may comprise any one of more features selected from the list comprising: a CMV promoter, a H1 promoter, and / or a BGH poly(A) terminator.

[0616] In one embodiment the viral vector is pAAV.

[0617] In one embodiment the viral vector is rcLV -TetOne-Puro.

[0618] In one embodiment the viral vector is pLPCX-link.

[0619] Vectors of the invention may comprise any one of more features selected from the list comprising: a CAG promoter, a CMV enhancer, SV40 late poly(A) terminator, a LTR-TREt (Tre-Tight) promoter, and / or a BGH poly(A) terminator.

[0620] It should be noted that any promoter may be used in the vector. Since the activity of the Fan1 targeting agents of the invention is independent of the promoter it is envisaged that these will work just as well as those exemplified above.

[0621] Compositions and methods

[0622] The present invention also relates to compositions comprising the Fan1 targeting agent, the DNA molecule or the expression vector according to the invention.The composition may comprise components which enable delivery of said Fan1 targeting agent by viral vectors (AAV, lentivirus and the like) and non-viral vectors (nanoparticles, lipid particles and the like). Alternatively, the Fan1 targeting agent of the invention may be administered as naked or unpackaged DNA and or RNA.

[0623] The composition may comprise components that are known in the art to aid the stability of nucleic acid molecules, e.g., salts (such as those providing Mg2+ions).

[0624] The Fan1 targeting agent may be administered as part of a composition, for example a composition comprising a suitable carrier. In certain embodiments, the carrier is selected based upon its ability to facilitate the transfection of a target cell with one or more Fan1 targeting agents.

[0625] Therefore, according to a further aspect of the invention, there is provided a composition comprising the Fan1 targeting agent, the DNA molecule, or the expression vector as described herein.

[0626] In one embodiment, there is provided a pharmaceutical composition comprising at least one Fan1 targeting agent, at least one DNA molecule, or at least one expression vector according to the present invention.

[0627] Suitably, a pharmaceutical composition may comprise at least one Fan1 targeting agent, at least one DNA molecule, or at least one expression vector according to the present invention with a suitable pharmaceutical excipient, diluent, carrier, and / or salt.

[0628] The suitable pharmaceutical excipient, diluent, carrier, and / or salt may depend on the intended route of administration and standard pharmaceutical practice.

[0629] A suitable carrier may include any of the standard pharmaceutical carriers, vehicles, diluents or excipients known in the art and which are generally intended for use in facilitating the delivery of nucleic acids, such as RNA. Liposomes, exosomes, lipidic particles or nanoparticles are examples of suitable carriers that may be used for the delivery of RNA. In a preferred embodiment, the carrier or vehicle delivers its contents to the target cell such that the Fan1 targeting agent is delivered to the appropriate subcellular compartment, such as the cytoplasm.In one aspect, provided herein is a pharmaceutically acceptable salt of the Fan1 targeting agent of the invention, or the conjugate of the invention.

[0630] Such salts are known to those skilled in the art and are contemplated within the scope.

[0631] Methods, methods of treatment and medical uses

[0632] Fan1 targeting agents of the invention, which are capable of increasing the expression of Fan1 vial post-transcriptional inhibition of miRNA-mediated repression of Fan1 can be used for therapeutic and non-therapeutic purposes.

[0633] ASO adverse effects can result from unintended interactions with cellular proteins and off-target hybridization, as well as immune activation from unintended toll-like receptor (TLR) stimulation, triggering inflammatory responses. Optimising the length of the oligonucleotide moieties, internucleoside linkages and selection of linker may be advantageous for reducing adverse effects and improving the safety profile / reducing toxicity of the Fan1 targeting agent of the present invention. For instance some combination of, sugar modifications (e.g. 2’-O-methyl and 2’-O-methoxyethyl), reducing length of the oligonucleotide moieties (arm length), replacing phosphorothioate (PS) internucleoside linkages with phosphodiester (PO) internucleoside linkages or replacing TrEG linkers with another linker may reduce toxicity of the Fan1 targeting agent, for instance when administered in vivo.

[0634] In one aspect, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and a microRNA targeting Fan1 are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0635] In one embodiment, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-124-3p are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0636] In one embodiment, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-197-3p are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate,the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0637] In one embodiment, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-145-5p are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0638] In one embodiment, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-181-5p are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0639] In one embodiment, there is provided an in vitro or in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and any combination of the microRNAs miR-124-3p, miR-197-3p, miR-145-5p and miR-181-5p are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0640] In one aspect, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and a microRNA targeting Fan1 are present, the method comprising the steps of administering to the cell a therapeutically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0641] In one embodiment, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-124-3p are present, the method comprising the steps of administering to the cell a therapeutically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0642] In one embodiment, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-197-3p are present, the method comprising the steps of administering to the cell a therapeutically effective amount ofthe Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0643] In one embodiment, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-145-5p are present, the method comprising the steps of administering to the cell a therapeutically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0644] In one embodiment, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and the microRNA miR-181-5p are present, the method comprising the steps of administering to the cell a therapeutically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0645] In one embodiment, there is provided an in vivo method for modulating Fan1 protein expression in a target cell in which Fan1 and any combination of the microRNAs miR-124-3p, miR-197-3p, miR-145-5p and miR-181-5p are present, the method comprising the steps of administering to the cell a therapeutically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0646] In any of these methods “modulating” may be increasing or decreasing. In a preferred embodiment “modulating” may be increasing.

[0647] In a further aspect, there is provided a method of treating, preventing, or delaying the onset of a disease associated with FAN1 protein in a subject, the method comprising administering to the subject a therapeutically or prophylactically effective amount of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, the composition, or the pharmaceutical composition of the invention.

[0648] In one embodiment, the disease associated with FAN1 is a disease associated with a deficiency of FAN1.

[0649] In another embodiment, the disease associated with FAN1 is a disease that can be ameliorated by increasing the amount of FAN1 is a system (e.g., cell).In a further aspect, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in medicine or therapy.

[0650] In one embodiment, the use is prophylactic or curative.

[0651] In one embodiment, the use is prophylactic.

[0652] In one embodiment, the use is curative.

[0653] The methods and uses herein are applicable to the treatment, prevention, or delay of onset of a disease associated with the expansion of disease-associated polynucleotide tracts.

[0654] In one embodiment, the disease is a triplet repeat disorder.

[0655] In one embodiment, the disease is a disease associated with or caused by CAG triplet repeat expansion, CGG triplet repeat expansion, CTG triplet repeat expansion, GAA triplet repeat expansion, GCC triplet repeat expansion, or GCG triplet repeat expansion.

[0656] In one embodiment, the disease is a CAG, CGG, CTG, GAA, GCC, or GCG triplet repeat disorder.

[0657] In one embodiment, the disease is a CGG repeat disorder.

[0658] In one embodiment, the disease is a polyglutamine (polyQ) disease.

[0659] In a further embodiment, the disease is selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7), Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0660] In a preferred embodiment, the disease is Huntington’s disease (HD).

[0661] In one embodiment, the disease is a CGG repeat disorder.In one embodiment, the CGG repeat disorder is a fragile X-related disorder (FXD).

[0662] In one embodiment, the disease is a a CTG repeat disorder.

[0663] In one embodiment, the CTG repeat disorder is myotonic dystrophy type 1.

[0664] In one embodiment, the disease is a GAA repeat disorder.

[0665] In one embodiment, the GAA repeat disorder is Friedreich ataxia.

[0666] In one embodiment, the disease is a GCC repeat disorder.

[0667] In one embodiment, the GCC repeat disorder is FRAXE mental retardation.

[0668] In one embodiment, the disease is a GCG repeat disorder.

[0669] In one embodiment, the GCG repeat disorder is oculopharyngeal muscular dystrophy.

[0670] In an aspect, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a triplet repeat disorder.

[0671] In one embodiment, the triplet repeat disorder is a CAG, CGG, CTG, GAA, GCC, or GCG triplet repeat disorder.

[0672] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a CAG repeat disorder.

[0673] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a polyglutamine (polyQ) disease.

[0674] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a disease selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar AtaxiaType2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7), Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0675] In a preferred embodiment, the disease is Huntington’s disease (HD).

[0676] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a CGG repeat disorder.

[0677] In one embodiment, the CGG repeat disorder is a fragile X-related disorder (FXD).

[0678] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a CTG repeat disorder.

[0679] In one embodiment, the CTG repeat disorder is myotonic dystrophy type 1.

[0680] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a GAA repeat disorder.

[0681] In one embodiment, the GAA repeat disorder is Friedreich ataxia.

[0682] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a GCC repeat disorder.

[0683] In one embodiment, the GCC repeat disorder is FRAXE mental retardation.

[0684] In one embodiment, there is provided the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for use in the treatment, prevention, or delay of onset of a GCG repeat disorder.

[0685] In one embodiment, the GCG repeat disorder is oculopharyngeal muscular dystrophy.In an aspect, there is provided use of the Fan1 targeting agent, the conjugate, the pharmaceutically acceptable salt, or the pharmaceutical composition of the invention for the preparation of a medicament for the treatment, prevention, or delay of a triplet repeat disorder.

[0686] In one embodiment, the medicament is for the treatment, prevention, or delay of a CAG triplet repeat disorder.

[0687] In one embodiment, the medicament is for the treatment, prevention, or delay of a polyglutamine disease (polyQ).

[0688] In one embodiment, the medicament is for the treatment, prevention, or delay of a disease selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7), Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0689] In one embodiment, the medicament is for the treatment, prevention, or delay of Huntington’s disease (HD).

[0690] In one embodiment, the medicament is for the treatment, prevention, or delay of a CGG repeat disorder.

[0691] In one embodiment, the CGG repeat disorder is a fragile X-related disorder (FXD).

[0692] In one embodiment, the medicament is for the treatment, prevention, or delay of a CTG repeat disorder.

[0693] In one embodiment, the CTG repeat disorder is myotonic dystrophy type 1.

[0694] In one embodiment, the medicament is for the treatment, prevention, or delay of a GAA repeat disorder.

[0695] In one embodiment, the GAA repeat disorder is Friedreich ataxia.

[0696] In one embodiment, the medicament is for the treatment, prevention, or delay of a GCC repeat disorder.In one embodiment, the GCC repeat disorder is FRAXE mental retardation.

[0697] In one embodiment, the medicament is for the treatment, prevention, or delay of a GCG repeat disorder.

[0698] In one embodiment, the GCG repeat disorder is oculopharyngeal muscular dystrophy.

[0699] In all of the foregoing methods and uses the action of the Fan1 targeting agent may be considered disease modifying.

[0700] Further, in each of the foregoing aspects, a DNA or vector encoding the Fan1 targeting agent of the invention may also be utilised, either in combination with any other component or in isolation.

[0701] Methods of the invention can be performed in vitro, ex vivo or in vivo.

[0702] The methods described herein may comprise transfecting into a cell the Fan1 targeting agent, DNA molecule, expression vector, composition or pharmaceutical composition as defined herein. The Fan1 targeting agent, DNA molecule, expression vector, composition or pharmaceutical composition may be administered to target cells using methods known in the art and include, for example, microinjection, lipofection, electroporation, using calcium phosphate, self-infection by the vector or viral transduction.

[0703] The Fan1 targeting agents, DNA molecules, compositions and / or pharmaceutical compositions can be used as medicaments, preferably for triplet repeat expansion diseases / disorders, for example polyglutamine (polyQ) diseases.

[0704] It will be understood that, since these disorders are hereditary, prevention refers to the prevention of triplet expansion and any pathological consequences associated therewith. That is, rather than prevention of the disease outright.

[0705] Further prevention may also encompass modulation of the age at onset of disease (AAO).

[0706] It will be understood that the Fan1 targeting agent of the invention ultimately finds use in increasing the level of Fan1 protein. Said increase in Fan1 is preferably within a cell, such as the cell of a subject.In preferable embodiments, the subject is a human subject.

[0707] In yet further preferable embodiments, the subject is a human subject with a hereditary triplet repeat disorder.

[0708] In one embodiment, the disease or disorder is a neurological disease or disorder.

[0709] In one embodiment, the disease or disorder is Huntington’s disease (HD).

[0710] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 1 (SCA1).

[0711] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 2 (SCA2).

[0712] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 3 (SCA3). Spinocerebellar Ataxia Type 3 is also known as Machado-Joseph disease (MJD).

[0713] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 6 (SCA6).

[0714] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 7 (SCA7).

[0715] In one embodiment, the disease or disorder is Spinocerebellar Ataxia Type 17 (SCA17).

[0716] In one embodiment, the disease or disorder is dentatorubral pallidoluysian atrophy (DRPLA).

[0717] In one embodiment, the disease or disorder is and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0718] Numbered embodiments

[0719] The present invention will now be disclosed in the following numbered embodiments:

[0720] 1. A Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarityto a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two target sequences are within five nucleotides of each other.

[0721] 2. A Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein no two distinct target sequences are within five nucleotides of each other.

[0722] 3. A Fan1 targeting agent, wherein the Fan1 targeting agent comprises two oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein the target sequences are not within five nucleotides of each other.

[0723] 4. A Fan1 targeting agent, wherein the Fan1 targeting agent comprises two oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN1, wherein distinct target sequences are not within five nucleotides of each other.

[0724] 5. The Fan1 targeting agent of any of the preceding numbered embodiments wherein the RNA encoding FAN1 is an mRNA or a pre-mRNA.

[0725] 6. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein Fan1 is selected from any one or more of:

[0726] a) FAN 1-221, FAN 1-228, FAN 1-217, FAN 1-216, FAN 1-215, FAN 1-207, FAN 1-203, FAN 1-202, and / or FAN 1-201; and / or

[0727] b) SEQ ID NOs: 1 to 18.

[0728] 7. The Fan1 targeting agent of any of numbered embodiments 1, 2, 5, and 6 wherein the Fan1 targeting agent comprises 2, 3, 4, 5, 6, 7, 8, 9 or 10 oligonucleotide moieties.8. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein the Fan1 targeting agent comprises 2 oligonucleotide moieties.

[0729] 9. The Fan1 targeting agent of any of the preceding numbered embodiments wherein two or more of the oligonucleotide moieties are separated by an independently selected linker.

[0730] 10. The Fan1 targeting agent of any of the preceding numbered embodiments wherein each of the oligonucleotide moieties are separated by an independently selected linker.

[0731] 11. The Fan1 targeting agent of numbered embodiments 9 and / or 10 wherein one or more of the linkers is a triethyleneglycol (TrEG) linker.

[0732] 12. The Fan1 targeting agent of any of numbered embodiments 9, 10 and 11 wherein one or more of the linkers is an oligonucleotide linker.

[0733] 13. The Fan1 targeting agent of any of numbered embodiments 9, 10, 11 and 12, wherein each linker is independently a cleavable linker, preferably a bio-cleavable linker, or a non-cleavable linker.

[0734] 14. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein two or more of the contiguous nucleotide sequences are complementary to a different target sequence within the 3’UTR of the RNA encoding FANI.

[0735] 15. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein each of the contiguous nucleotide sequences is complementary to a different target sequence within the 3’UTR of the RNA encoding FAN1.

[0736] 16. The Fan1 targeting agent of any of numbered embodiments 1 to 15, wherein at least one oligonucleotide moiety competes with a microRNA for binding to the 3’UTR of the RNA encoding FANI.

[0737] 17. The Fan1 targeting agent of numbered embodiment 16, wherein two or more oligonucleotide moieties compete with a microRNA for binding to the 3’UTR of the RNA encoding FANI.

[0738] 18. The Fan1 targeting agent of numbered embodiment 17, wherein each oligonucleotide moiety competes with a microRNA for binding to the 3’UTR of the RNA encoding FAN1.19. The Fan1 targeting agent of any of numbered embodiments 1 to 14 or 16 to 18 wherein two or more of the contiguous nucleotide sequence are complementary to the same target sequence within the 3’IITR of the RNA encoding FAN1.

[0739] 20. The Fan1 targeting agent of numbered embodiment 19, wherein each contiguous nucleotide sequence is complementary to the same target sequence within the 3’IITR of the RNA encoding FANI.

[0740] 21. The Fan1 targeting agent of numbered embodiments 1 to 18, wherein two or more of the oligonucleotide moieties compete with a different microRNA for binding to the 3’IITR of the RNA encoding FANI.

[0741] 22. The Fan1 targeting agent of numbered embodiment 21, wherein each oligonucleotide moiety competes with a different microRNA for binding to the 3’IITR of the RNA encoding FANI.

[0742] 23. The Fan1 targeting agent of numbered embodiments 1 to 14 or 16 to 21, wherein two or more of the oligonucleotide moieties competes with the same microRNA for binding to the 3’IITR of the RNA encoding FANI.

[0743] 24. The Fan1 targeting agent of numbered embodiment 23, wherein each oligonucleotide moiety competes with the same microRNA for binding to the 3’IITR of the RNA encoding FANI.

[0744] 25. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein each target sequence within the 3’IITR of the RNA encoding FAN1 overlaps with a nucleotide sequence bound by a microRNA.

[0745] 26. The Fan1 targeting agent of numbered embodiment 1 to 19, 21 to 23 or 25, wherein two or more target sequences within the 3’IITR of the RNA encoding FAN1 overlap with a nucleotide sequence bound by a different microRNA.

[0746] 27. The Fan1 targeting agent of numbered embodiment 26, wherein each target sequence within the 3’IITR of the RNA encoding FAN1 overlaps with a nucleotide sequence bound by a different microRNA.28. The Fan1 targeting agent of numbered embodiment 1 to 14, 16 to 21 or 23 to 26, wherein two or more target sequences within the 3’IITR of the RNA encoding FAN1 overlap with a nucleotide sequence bound by the same microRNA.

[0747] 29. The Fan1 targeting agent of numbered embodiment 28, wherein each target sequence within the 3’IITR of the RNA encoding FAN1 overlaps with a nucleotide sequence bound by the same microRNA.

[0748] 30. The Fan1 targeting agent of any of numbered embodiments 16 to 29, wherein the microRNA is associated with modulating the onset of a triple repeat disorder.

[0749] 31. The Fan1 targeting agent of numbered embodiment 30 wherein the microRNA:

[0750] (a) is selected from hsa-miR-299-3p, hsa-miR-3940-5p, hsa-miR-4265, hsa-miR-4507, hsa-miR-4657, hsa-miR-6748-5p, hsa-miR-6759-5p, hsa-miR-6793-5p, hsa-miR-6796-5p, hsa-miR-6839-3p, hsa-miR-629-5p, hsa-miR-1275, hsa-miR-193b-5p, hsa-miR-3675-5p, hsa-miR-4665-5p, hsa-miR-6751-5p, hsa-miR-6803-5p, hsa-miR-6835-5p, hsa-miR-6842-5p, hsa-miR-6890-5p, hsa-miR-7109-5p, hsa-miR-7110-5p, hsa-miR-198, hsa-miR-1911-3p, hsa-miR-6753-5p, hsa-miR-1256, hsa-miR-3910, hsa-miR-1910-3p, hsa-miR-2682-5p, hsa-miR-34a-5p, hsa-miR-34b-5p, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b-5p, hsa-miR-449c-5p, hsa-miR-548au-3p, hsa-miR-584-3p, hsa-miR-6511a-5p, hsa-miR-6808-5p, hsa-miR-6893-5p, hsa-miR-940, hsa-miR-3714, hsa-miR-125b-1-3p, hsa-miR-155-5p, hsa-miR-3621, hsa-miR-3610, hsa-miR-4665-3p, hsa-miR-4755-3p, hsa-miR-3622a-5p, hsa-miR-5582-5p, hsa-miR-124-3p, hsa-miR-506-3p, hsa-miR-10527-5p, hsa-miR-1207-5p, hsa-miR-1262, hsa-miR-1273h-3p, hsa-miR-1287-3p, hsa-miR-1301-3p, hsa-miR-1303, hsa-miR-1304-5p, hsa-miR-1343-5p, hsa-miR-141-3p, hsa-miR-186-5p, hsa-miR-1914-3p, hsa-miR-200a-3p, hsa-miR-204-5p, hsa-miR-211-5p, hsa-miR-23a-5p, hsa-miR-23b-5p, hsa-miR-3120-3p, hsa-miR-3122, hsa-miR-3182, hsa-miR-3199, hsa-miR-335-3p, hsa-miR-3681-5p, hsa-miR-3913-5p, hsa-miR-3925-3p, hsa-miR-4284, hsa-miR-4469, hsa-miR-450b-5p, hsa-miR-4640-5p, hsa-miR-4649-3p, hsa-miR-4650-3p, hsa-miR-4667-3p, hsa-miR-4677-5p, hsa-miR-4693-3p, hsa-miR-4701-3p, hsa-miR-4726-5p, hsa-miR-4763-3p, hsa-miR-4768-5p, hsa-miR-4771, hsa-miR-4775, hsa-miR-4776-3p, hsa-miR-4797-3p, hsa-miR-485-5p, hsa-miR-5002-3p, hsa-miR-5008-5p, hsa-miR-5089-5p, hsa-miR-513b-5p, hsa-miR-5190, hsa-miR-5191, hsa-miR-5193, hsa-miR-5194, hsa-miR-543, hsa-miR-545-3p, hsa-miR-548a-3p, hsa-miR-548aa, hsa-miR-548an, hsa-miR-548ap-3p, hsa-miR-548ar-3p, hsa-miR-548az-3p, hsa-miR-548bc, hsa-miR-548e-3p, hsa-miR-548n, hsa-miR-548t-3p, hsa-miR-589-3p, hsa-miR-6730-5p, hsa-miR-6736-5p, hsa-miR-6738-5p, hsa-miR-6740-5p, hsa-miR-676-3p, hsa-miR-6770-5p, hsa-miR-6826-3p, hsa-miR-6831-5p, hsa-miR-6833-3p, hsa-miR-6845-3p, hsa-miR-6870-3p, hsa-miR-6875-3p, hsa-miR-6878-3p, hsa-miR-6884-3p, hsa-miR-7108-3p, hsa-miR-7974, hsa-miR-802, hsa-miR-939-5p, hsa-let-7f-2-3p, hsa-miR-11181-3p, hsa-miR-1185-1-3p, hsa-miR-1185-2-3p, hsa-miR-1197, hsa-miR-12129, hsa-miR-12136, hsa-miR-1228-3p, hsa-miR-124-3p, hsa-miR-1264, hsa-miR-1265, hsa-miR-1276, hsa-miR-1288-5p, hsa-miR-1290, hsa-miR-1299, hsa-miR-130a-5p, hsa-miR-135a-2-3p, hsa-miR-135b-3p, hsa-miR-138-1-3p, hsa-miR-145-5p, hsa-miR-15b-3p, hsa-miR-16-1-3p, hsa-miR-181a-5p, hsa-miR-181 b-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-187-3p, hsa-miR-194-5p, hsa-miR-196a-3p, hsa-miR-196b-3p, hsa-miR-197-3p, hsa-miR-19a-5p, hsa-miR-19b-1-5p, hsa-miR-216b-5p, hsa-miR-2276-3p, hsa-miR-2276-5p, hsa-miR-2278, hsa-miR-2355-3p, hsa-miR-27a-5p, hsa-miR-29a-5p, hsa-miR-3064-5p, hsa-miR-3085-3p, hsa-miR-3125, hsa-miR-3127-3p, hsa-miR-3135a, hsa-miR-3143, hsa-miR-3150a-3p, hsa-miR-3154, hsa-miR-3158-3p, hsa-miR-3159, hsa-miR-3160-5p, hsa-miR-3163, hsa-miR-3184-3p, hsa-miR-3189-5p, hsa-miR-3191-5p, hsa-miR-3202, hsa-miR-331-3p, hsa-miR-342-3p, hsa-miR-346, hsa-miR-3605-3p, hsa-miR-3663-5p, hsa-miR-3677-5p, hsa-miR-372-5p, hsa-miR-376b-5p, hsa-miR-378a-5p, hsa-miR-3916, hsa-miR-3929, hsa-miR-3938, hsa-miR-424-3p, hsa-miR-4254, hsa-miR-4282, hsa-miR-4323, hsa-miR-4428, hsa-miR-4443, hsa-miR-4451, hsa-miR-4476, hsa-miR-4478, hsa-miR-4502, hsa-miR-4503, hsa-miR-4515, hsa-miR-4679, hsa-miR-4694-5p, hsa-miR-4699-3p, hsa-miR-4729, hsa-miR-4738-3p, hsa-miR-4739, hsa-miR-4745-5p, hsa-miR-4755-5p, hsa-miR-4756-5p, hsa-miR-4766-5p, hsa-miR-4773, hsa-miR-4781-3p, hsa-miR-4803, hsa-miR-488-3p, hsa-miR-498-5p, hsa-miR-5001-3p, hsa-miR-5006-3p, hsa-miR-5008-3p, hsa-miR-505-3p, hsa-miR-506-3p, hsa-miR-506-5p, hsa-miR-5088-3p, hsa-miR-5089-3p, hsa-miR-5094, hsa-miR-5189-3p, hsa-miR-5195-3p, hsa-miR-539-5p, hsa-miR-548a-5p, hsa-miR-548ab, hsa-miR-548ad-5p, hsa-miR-548ae-5p, hsa-miR-548ag, hsa-miR-548ai, hsa-miR-548ak, hsa-miR-548am-5p, hsa-miR-548ap-5p, hsa-miR-548aq-5p, hsa-miR-548ar-5p, hsa-miR-548as-5p, hsa-miR-548au-5p, hsa-miR-548ay-5p, hsa-miR-548az-5p, hsa-miR-548b-5p, hsa-miR-548ba, hsa-miR-548bb-5p, hsa-miR-548c-5p, hsa-miR-548d-5p, hsa-miR-548g-3p, hsa-miR-548h-5p, hsa-miR-548i, hsa-miR-548j-5p, hsa-miR-548m, hsa-miR-548o-5p, hsa-miR-548p, hsa-miR-548t-5p, hsa-miR-548v, hsa-miR-548w, hsa-miR-548y, hsa-miR-5586-5p, hsa-miR-559, hsa-miR-5591-5p, hsa-miR-5693, hsa-miR-570-5p, hsa-miR-578, hsa-miR-596, hsa-miR-601, hsa-miR-6081, hsa-miR-643, hsa-miR-6501-3p, hsa-miR-6504-5p, hsa-miR-6511a-3p, hsa-miR-6511b-3p, hsa-miR-6513-5p, hsa-miR-660-3p, hsa-miR-661, hsa-miR-663b, hsa-miR-664a-3p, hsa-miR-6726-5p, hsa-miR-6734-5p, hsa-miR-6736-3p, hsa-miR-6737-3p, hsa-miR-6738-3p, hsa-miR-6739-3p, hsa-miR-6742-3p, hsa-miR-6746-3p, hsa-miR-6756-3p, hsa-miR-676-5p, hsa-miR-6761-5p, hsa-miR-6763-3p, hsa-miR-6763-5p, hsa-miR-6791-3p, hsa-miR-6796-3p, hsa-miR-6818-3p, hsa-miR-6825-5p, hsa-miR-6829-3p, hsa-miR-6833-5p, hsa-miR-6843-3p, hsa-miR-6848-3p, hsa-miR-6854-5p, hsa-miR-6859-5p, hsa-miR-6876-5p, hsa-miR-6894-5p, hsa-miR-6895-3p, hsa-miR-7114-5p, hsa-miR-7157-3p,hsa-miR-765, hsa-miR-766-5p, hsa-miR-7852-3p, hsa-miR-7977, hsa-miR-7978, hsa-miR-8485, hsa-miR-888-5p, hsa-miR-920, hsa-miR-943, hsa-miR-10398-5p, hsa-miR-105-5p, hsa-miR-10a-3p, hsa-miR-12115, hsa-miR-1236-3p, hsa-miR-1253, hsa-miR-125b-2-3p, hsa-miR-1286, hsa-miR-129-5p, hsa-miR-1293, hsa-miR-1302, hsa-miR-1324, hsa-miR-1343-3p, hsa-miR-1470, hsa-miR-147b-5p, hsa-miR-186-3p, hsa-miR-1912-5p, hsa-miR-196a-5p, hsa-miR-196b-5p, hsa-miR-1976, hsa-miR-205-5p, hsa-miR-2116-5p, hsa-miR-22-5p, hsa-miR-221-5p, hsa-miR-24-3p, hsa-miR-2467-5p, hsa-miR-2682-3p, hsa-miR-26b-3p, hsa-miR-30a-3p, hsa-miR-30d-3p, hsa-miR-30e-3p, hsa-miR-31-3p, hsa-miR-3133, hsa-miR-3145-3p, hsa-miR-3152-5p, hsa-miR-3155a, hsa-miR-3155b, hsa-miR-3166, hsa-miR-3171, hsa-miR-3175, hsa-miR-3177-3p, hsa-miR-3184-5p, hsa-miR-3188, hsa-miR-3190-3p, hsa-miR-324-5p, hsa-miR-326, hsa-miR-330-5p, hsa-miR-3529-5p, hsa-miR-3612, hsa-miR-362-5p, hsa-miR-3621, hsa-miR-363-5p, hsa-miR-3655, hsa-miR-365a-5p, hsa-miR-365b-5p, hsa-miR-3675-5p, hsa-miR-3680-3p, hsa-miR-3682-3p, hsa-miR-3682-5p, hsa-miR-3686, hsa-miR-3688-5p, hsa-miR-376a-3p, hsa-miR-376b-3p, hsa-miR-379-5p, hsa-miR-3925-5p, hsa-miR-3940-3p, hsa-miR-3942-3p, hsa-miR-423-5p, hsa-miR-4273, hsa-miR-4287, hsa-miR-4298, hsa-miR-4457, hsa-miR-4483, hsa-miR-4484, hsa-miR-450a-1-3p, hsa-miR-4632-3p, hsa-miR-4659a-3p, hsa-miR-4659a-5p, hsa-miR-4659b-3p, hsa-miR-4660, hsa-miR-4668-3p, hsa-miR-4685-3p, hsa-miR-4685-5p, hsa-miR-4687-3p, hsa-miR-4695-5p, hsa-miR-4707-5p, hsa-miR-4722-5p, hsa-miR-4724-5p, hsa-miR-4727-3p, hsa-miR-4733-5p, hsa-miR-4736, hsa-miR-4740-3p, hsa-miR-4742-3p, hsa-miR-4757-5p, hsa-miR-4762-3p, hsa-miR-4764-3p, hsa-miR-4769-3p, hsa-miR-4774-3p, hsa-miR-4779, hsa-miR-4799-5p, hsa-miR-484, hsa-miR-486-5p, hsa-miR-495-3p, hsa-miR-500b-5p, hsa-miR-501-5p, hsa-miR-507, hsa-miR-518a-5p, hsa-miR-526b-5p, hsa-miR-527, hsa-miR-542-5p, hsa-miR-548as-3p, hsa-miR-548at-3p, hsa-miR-548aw, hsa-miR-548ay-3p, hsa-miR-551b-5p, hsa-miR-557, hsa-miR-5582-3p, hsa-miR-5584-5p, hsa-miR-5587-3p, hsa-miR-5590-5p, hsa-miR-5687, hsa-miR-5688, hsa-miR-572, hsa-miR-576-5p, hsa-miR-590-3p, hsa-miR-6074, hsa-miR-6089, hsa-miR-6128, hsa-miR-623, hsa-miR-629-3p, hsa-miR-650, hsa-miR-6508-3p, hsa-miR-6511b-5p, hsa-miR-6515-3p, hsa-miR-6516-5p, hsa-miR-6721-5p, hsa-miR-6728-5p, hsa-miR-6729-3p, hsa-miR-6741-5p, hsa-miR-6745, hsa-miR-6750-5p, hsa-miR-6756-5p, hsa-miR-6764-3p, hsa-miR-6765-5p, hsa-miR-6766-5p, hsa-miR-6768-3p, hsa-miR-6774-5p, hsa-miR-6777-5p, hsa-miR-6781-3p, hsa-miR-6783-3p, hsa-miR-6792-5p, hsa-miR-6795-3p, hsa-miR-6807-5p, hsa-miR-6809-3p, hsa-miR-6811-5p, hsa-miR-6817-5p, hsa-miR-6820-5p, hsa-miR-6823-3p, hsa-miR-6824-3p, hsa-miR-6837-5p, hsa-miR-6844, hsa-miR-6873-3p, hsa-miR-6889-5p, hsa-miR-6890-5p, hsa-miR-6891-3p, hsa-miR-7-1-3p, hsa-miR-7-2-3p, hsa-miR-7113-3p, hsa-miR-7113-5p, hsa-miR-7151-5p, hsa-miR-7156-3p, hsa-miR-7156-5p, hsa-miR-7162-3p, hsa-miR-766-3p, hsa-miR-769-3p, hsa-miR-7853-5p, hsa-miR-8057, hsa-miR-8073, hsa-miR-874-5p, hsa-miR-885-5p, hsa-miR-887-5p, hsa-miR-95-3p, hsa-miR-9500, hsa-miR-9903, hsa-miR-9983-3p, hsa-let-7a-3p, hsa-let-7a-5p, hsa-let-7b-3p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-let-7e-5p, hsa-let-7f-1-3p, hsa-let-7f-5p, hsa-let-7g-5p, hsa-let-7i-5p, hsa-miR-1-3p, hsa-miR-10392-3p, hsa-miR-10526-3p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10b-3p, hsa-miR-1183, hsa-miR-1185-5p, hsa-miR-1199-3p, hsa-miR-1199-5p, hsa-miR-1200, hsa-miR-1208, hsa-miR-12124, hsa-miR-12132, hsa-miR-12135, hsa-miR-122-3p, hsa-miR-1226-5p, hsa-miR-122b-3p, hsa-miR-122b-5p, hsa-miR-1237-3p, hsa-miR-1245a, hsa-miR-1245b-5p, hsa-miR-1247-5p, hsa-miR-1248, hsa-miR-1251-3p, hsa-miR-1252-3p, hsa-miR-125b-1-3p, hsa-miR-1261, hsa-miR-1285-3p, hsa-miR-1288-3p, hsa-miR-1291, hsa-miR-1296-3p, hsa-miR-1298-5p, hsa-miR-1306-5p, hsa-miR-130b-5p, hsa-miR-132-3p, hsa-miR-1323, hsa-miR-134-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-136-3p, hsa-miR-136-5p, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-1468-3p, hsa-miR-149-3p, hsa-miR-149-5p, hsa-miR-153-5p, hsa-miR-1537-3p, hsa-miR-155-5p, hsa-miR-17-5p, hsa-miR-181a-2-3p, hsa-miR-181d-3p, hsa-miR-187-5p, hsa-miR-1909-3p, hsa-miR-191-5p, hsa-miR-194-3p, hsa-miR-200c-5p, hsa-miR-202-3p, hsa-miR-203a-3p, hsa-miR-2052, hsa-miR-206, hsa-miR-208b-5p, hsa-miR-20a-5p, hsa-miR-20b-3p, hsa-miR-20b-5p, hsa-miR-21-3p, hsa-miR-211-3p, hsa-miR-2110, hsa-miR-2115-3p, hsa-miR-212-3p, hsa-miR-216a-5p, hsa-miR-216b-3p, hsa-miR-217-3p, hsa-miR-218-2-3p, hsa-miR-218-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-222-5p, hsa-miR-2277-3p, hsa-miR-2392, hsa-miR-25-3p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-29b-2-5p, hsa-miR-302a-5p, hsa-miR-3064-3p, hsa-miR-3074-5p, hsa-miR-3115, hsa-miR-3116, hsa-miR-3130-3p, hsa-miR-3136-3p, hsa-miR-3136-5p, hsa-miR-3137, hsa-miR-3142, hsa-miR-3144-5p, hsa-miR-3148, hsa-miR-3149, hsa-miR-3150b-3p, hsa-miR-3152-3p, hsa-miR-3157-5p, hsa-miR-3160-3p, hsa-miR-3162-5p, hsa-miR-3167, hsa-miR-3173-3p, hsa-miR-3179, hsa-miR-3180-5p, hsa-miR-3187-5p, hsa-miR-3191-3p, hsa-miR-3194-5p, hsa-miR-32-5p, hsa-miR-3200-3p, hsa-miR-320a-3p, hsa-miR-320a-5p, hsa-miR-320b, hsa-miR-320c, hsa-miR-320d, hsa-miR-324-3p, hsa-miR-328-3p, hsa-miR-329-3p, hsa-miR-330-3p, hsa-miR-331-5p, hsa-miR-335-5p, hsa-miR-33a-3p, hsa-miR-340-3p, hsa-miR-345-5p, hsa-miR-34a-3p, hsa-miR-34b-3p, hsa-miR-3605-5p, hsa-miR-3609, hsa-miR-361-3p, hsa-miR-3610, hsa-miR-3613-3p, hsa-miR-3614-3p, hsa-miR-3616-5p, hsa-miR-3617-3p, hsa-miR-362-3p, hsa-miR-3620-3p, hsa-miR-3622a-5p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-365b-3p, hsa-miR-3662, hsa-miR-3663-3p, hsa-miR-3671, hsa-miR-3675-3p, hsa-miR-3679-3p, hsa-miR-3679-5p, hsa-miR-3688-3p, hsa-miR-3689a-5p, hsa-miR-3689b-5p, hsa-miR-3689e, hsa-miR-3689f, hsa-miR-369-3p, hsa-miR-3690, hsa-miR-3691-5p, hsa-miR-370-3p, hsa-miR-3714, hsa-miR-371a-5p, hsa-miR-371b-5p, hsa-miR-373-5p, hsa-miR-375-3p, hsa-miR-377-3p, hsa-miR-378g, hsa-miR-383-5p, hsa-miR-3910, hsa-miR-3919, hsa-miR-3920, hsa-miR-3928-3p, hsa-miR-3934-3p, hsa-miR-3940-5p, hsa-miR-3943, hsa-miR-409-3p, hsa-miR-421, hsa-miR-4270, hsa-miR-4288, hsa-miR-4290, hsa-miR-4292, hsa-miR-4429, hsa-miR-4446-3p, hsa-miR-4456, hsa-miR-4458, hsa-miR-4474-3p, hsa-miR-4475, hsa-miR-4477a, hsa-miR-4496, hsa-miR-4500, hsa-miR-4507, hsa-miR-4516, hsa-miR-4519, hsa-miR-4633-3p, hsa-miR-4639-5p, hsa-miR-4646-3p, hsa-miR-4652-3p, hsa-miR-4652-5p, hsa-miR-4653-3p, hsa-miR-4661-3p, hsa-miR-4665-3p, hsa-miR-4676-5p, hsa-miR-4677-3p, hsa-miR-4690-5p, hsa-miR-4691-3p, hsa-miR-4709-5p, hsa-miR-4711-3p, hsa-miR-4712-3p, hsa-miR-4713-5p, hsa-miR-4714-3p, hsa-miR-4715-3p, hsa-miR-4719, hsa-miR-4720-3p, hsa-miR-4728-3p, hsa-miR-4728-5p, hsa-miR-4731-3p, hsa-miR-4731-5p, hsa-miR-4732-5p, hsa-miR-4734, hsa-miR-4738-5p, hsa-miR-4740-5p, hsa-miR-4743-3p, hsa-miR-4744, hsa-miR-4747-3p, hsa-miR-4752, hsa-miR-4753-3p, hsa-miR-4755-3p, hsa-miR-4758-3p, hsa-miR-4763-5p, hsa-miR-4764-5p, hsa-miR-4772-3p, hsa-miR-4772-5p, hsa-miR-4782-5p, hsa-miR-4784, hsa-miR-4788, hsa-miR-4793-3p, hsa-miR-4793-5p, hsa-miR-4794, hsa-miR-4796-3p, hsa-miR-4797-5p, hsa-miR-4801, hsa-miR-4804-3p, hsa-miR-488-5p, hsa-miR-490-3p, hsa-miR-499b-5p, hsa-miR-5002-5p, hsa-miR-5088-5p, hsa-miR-513a-3p, hsa-miR-513c-3p, hsa-miR-515-5p, hsa-miR-516b-5p, hsa-miR-5189-5p, hsa-miR-5196-3p, hsa-miR-519d-3p, hsa-miR-520g-3p, hsa-miR-520h, hsa-miR-526b-3p, hsa-miR-541-5p, hsa-miR-544b, hsa-miR-548ac, hsa-miR-548ad-3p, hsa-miR-548ae-3p, hsa-miR-548ah-3p, hsa-miR-548ah-5p, hsa-miR-548aj-3p, hsa-miR-548aj-5p, hsa-miR-548am-3p, hsa-miR-548aq-3p, hsa-miR-548av-3p, hsa-miR-548bb-3p, hsa-miR-548d-3p, hsa-miR-548e-5p, hsa-miR-548f-5p, hsa-miR-548g-5p, hsa-miR-548h-3p, hsa-miR-548j-3p, hsa-miR-548k, hsa-miR-548l, hsa-miR-548o-3p, hsa-miR-548q, hsa-miR-548x-5p, hsa-miR-548z, hsa-miR-550a-3p, hsa-miR-558, hsa-miR-5582-5p, hsa-miR-5680, hsa-miR-5690, hsa-miR-5692a, hsa-miR-5692c, hsa-miR-5696, hsa-miR-5699-5p, hsa-miR-5702, hsa-miR-5703, hsa-miR-5706, hsa-miR-573, hsa-miR-579-3p, hsa-miR-580-3p, hsa-miR-583, hsa-miR-603, hsa-miR-6090, hsa-miR-612, hsa-miR-615-5p, hsa-miR-616-3p, hsa-miR-616-5p, hsa-miR-624-5p, hsa-miR-627-3p, hsa-miR-629-5p, hsa-miR-632, hsa-miR-642a-3p, hsa-miR-642a-5p, hsa-miR-642b-3p, hsa-miR-642b-5p, hsa-miR-647, hsa-miR-649, hsa-miR-6499-3p, hsa-miR-6505-5p, hsa-miR-6507-3p, hsa-miR-6507-5p, hsa-miR-651-3p, hsa-miR-6510-3p, hsa-miR-6510-5p, hsa-miR-6512-3p, hsa-miR-6515-5p, hsa-miR-6529-3p, hsa-miR-656-3p, hsa-miR-664a-5p, hsa-miR-664b-3p, hsa-miR-6715a-3p, hsa-miR-6720-5p, hsa-miR-6722-3p, hsa-miR-6724-5p, hsa-miR-6727-5p, hsa-miR-6735-3p, hsa-miR-6749-3p, hsa-miR-6751-3p, hsa-miR-6754-5p, hsa-miR-6757-3p, hsa-miR-6758-3p, hsa-miR-6758-5p, hsa-miR-6760-3p, hsa-miR-6760-5p, hsa-miR-6767-3p, hsa-miR-6769a-3p, hsa-miR-6771-3p, hsa-miR-6773-5p, hsa-miR-6774-3p, hsa-miR-6775-3p, hsa-miR-6778-3p, hsa-miR-6782-5p, hsa-miR-6783-5p, hsa-miR-6784-3p, hsa-miR-6785-5p, hsa-miR-6787-3p, hsa-miR-6791-5p, hsa-miR-6792-3p, hsa-miR-6798-5p, hsa-miR-6799-5p, hsa-miR-6800-3p, hsa-miR-6801-3p, hsa-miR-6810-3p, hsa-miR-6810-5p, hsa-miR-6813-3p, hsa-miR-6827-3p, hsa-miR-6827-5p, hsa-miR-6830-3p, hsa-miR-6830-5p, hsa-miR-6832-5p, hsa-miR-6834-5p, hsa-miR-6836-3p, hsa-miR-6836-5p, hsa-miR-6839-3p, hsa-miR-6842-3p, hsa-miR-6851-5p,hsa-miR-6852-5p, hsa-miR-6856-3p, hsa-miR-6856-5p, hsa-miR-6857-5p, hsa-miR-6858-3p, hsa-miR-6860, hsa-miR-6861-5p, hsa-miR-6862-3p, hsa-miR-6865-3p, hsa-miR-6868-3p, hsa-miR-6885-3p, hsa-miR-6889-3p, hsa-miR-6890-3p, hsa-miR-6891-5p, hsa-miR-6892-3p, hsa-miR-6893-3p, hsa-miR-7108-5p, hsa-miR-7109-3p, hsa-miR-7152-3p, hsa-miR-7152-5p, hsa-miR-7154-3p, hsa-miR-7155-3p, hsa-miR-718, hsa-miR-758-5p, hsa-miR-7704, hsa-miR-8062, hsa-miR-873-5p, hsa-miR-876-5p, hsa-miR-877-3p, hsa-miR-889-5p, hsa-miR-892a, hsa-miR-892c-5p, hsa-miR-9-3p, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-93-5p, hsa-miR-939-3p, hsa-miR-98-3p, hsa-miR-98-5p, hsa-miR-9985, hsa-miR-99a-3p, hsa-miR-99b-3p, or an isomiR thereof; and / or

[0751] (b) comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 19 to 954.

[0752] 32. The Fan1 targeting agent of numbered embodiment 31, wherein the 3’IITR of the RNA encoding FAN1 is as set forth in any one of the sequences selected from the group consisting of SEQ ID NOs 1 to 9 and SEQ ID NOs 10 to 18.

[0753] 33. The Fan1 targeting agent of numbered embodiment 31 or 32, wherein one or more of the contiguous nucleotide sequences comprises or consists of a sequence independently selected from the group consisting of SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782, or comprises or consists of a sequence with at least 90% sequence identity to a sequence independently selected from the group consisting of SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424;1450; 1595 to 1688; and 1689 to 1782.

[0754] 34. The Fan1 targeting agent of numbered embodiment 33, wherein one or more of the oligonucleotide moieties comprises or consists of a sequence independently selected from the group consisting of SEQ ID NO 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782, or comprises or consists of a sequence with at least 90% sequence identity to a sequence independently selected from the group consisting of SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.35. The Fan1 targeting agent of numbered embodiment 34, wherein the Fan1 targeting agent comprises or consists of:

[0755] a) a sequence selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594, or comprises or consists of a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281, 1344 to 1355;1425 to 1499; 1451 to 1522; and 1523 to 1594;

[0756] b) SEQ ID NO: 1158;

[0757] c) SEQ ID NO: 1217;

[0758] d) SEQ ID NO: 1160;

[0759] e) SEQ ID NO: 1219;

[0760] f) SEQ ID NO: 1476; and / or

[0761] g) SEQ ID NO: 1548.

[0762] 36. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein the agent:

[0763] a) increases the translation of the Fan1 ORF; and / or

[0764] b) increases the production of FAN1 protein.

[0765] 37. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein the Fan1 targeting agent comprises one or more modified nucleoside.

[0766] 38. The Fan1 targeting agent of numbered embodiment 37, wherein the Fan1 targeting agent consists of modified nucleosides.

[0767] 39. The Fan1 targeting agent of numbered embodiments 37 or 38, wherein the modified nucleosides independently comprise a modified sugar moiety or a modified nucleobase.

[0768] 40. The Fan1 targeting agent of numbered embodiment 39, wherein the one or more modified nucleosides independently comprise a modified sugar moiety independently selected from any one or more of: 2’-deoxy, 2’-MOE, 2’-OMe, and 2’-F.

[0769] 41. The Fan1 targeting agent of any of numbered embodiments 37 to 40, wherein the one or more modified nucleosides comprise a bicyclic sugar moiety.42. The Fan1 targeting agent of any of numbered embodiments 37 to 41, wherein the one or more modified nucleosides comprise a bicyclic sugar moiety selected from LNA and cET.

[0770] 43. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein the agent comprises one or more modified internucleoside linkages.

[0771] 44. The Fan1 targeting agent of any of the preceding numbered embodiments, wherein the Fan1 targeting agent comprises one or more nucleotide analogues.

[0772] 45. A conjugate comprising the Fan1 targeting agent of any of the preceding numbered embodiments and one or more moieties covalently bound to said agent.

[0773] 46. A pharmaceutically acceptable salt of the Fan1 targeting agent of any of numbered embodiments 1 to 44, or the conjugate of numbered embodiment 45.

[0774] 47. A composition comprising the Fan1 targeting agent of any of numbered embodiments 1 to 44, the conjugate of numbered embodiment 45, or the pharmaceutically acceptable salt of numbered embodiment 46, and a diluent, solvent, carrier, salt and / or adjuvant.

[0775] 48. A pharmaceutical composition comprising the Fan1 targeting agent of any of numbered embodiments 1 to 44, the conjugate of numbered embodiment 45, or the pharmaceutically acceptable salt of numbered embodiment 46, and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

[0776] 49. An in vivo or in vitro method for modulating FAN1 protein expression in a target cell in which Fan1 and a microRNA targeting Fan1 are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent of any of numbered embodiments 1 to 44, the conjugate of numbered embodiment 45, the pharmaceutically acceptable salt of numbered embodiment 46, the composition of numbered embodiment 47, or the pharmaceutical composition of numbered embodiment 48.

[0777] 50. A method of treating, preventing, or delaying the onset of a disease associated with FAN1 protein in a subject, comprising administering to the subject a therapeutically or prophylactically effective amount of the Fan1 targeting agent of any of numbered embodiments 1 to 44, the conjugate of numbered embodiment 45, the pharmaceutically acceptable salt of numbered embodiment 46, or the pharmaceutical composition of numbered embodiment 48.51. The Fan1 targeting agent of any of numbered embodiment 1 to 44, the conjugate of numbered embodiment 45, the pharmaceutically acceptable salt of numbered embodiment 46, or the pharmaceutical composition of numbered embodiment 48 for use in treating, preventing, or delaying the onset of a disease.

[0778] 52. Use of the Fan1 targeting agent of any of numbered embodiments 1 to 44, the conjugate of numbered embodiment 45, the pharmaceutically acceptable salt of numbered embodiment 46, or the pharmaceutical composition of numbered embodiment 48 for the preparation of a medicament for the treatment, prevention, or delay of a disease.

[0779] 53. The method according to numbered embodiment 50, the Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, or pharmaceutical composition for use according to numbered embodiment 51, or use of the Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, or pharmaceutical composition according to numbered embodiment 52, wherein the disease is a triplet repeat disorder.

[0780] 54. The method, Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, or the pharmaceutical composition for use or use according to numbered embodiment 53, wherein the disease is a disease associated with or caused by CAG triplet repeat expansion, CGG triplet repeat expansion, CTG triplet repeat expansion, GAA triplet repeat expansion, GCC triplet repeat expansion, or GCG triplet repeat expansion.

[0781] 55. The method, Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, pharmaceutical composition for use or use according to numbered embodiment 54, wherein the disease is selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7), Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA).

[0782] 56. The method, Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, pharmaceutical composition, or use according to numbered embodiment 55, wherein the disease is Huntington’s disease (HD).57. A method of stoichiometrically delivering two or more oligonucleotide moieties to a cell wherein the method comprises administering the Fan1 targeting agent of any of numbered embodiment 1 to 44, the conjugate of numbered embodiment 45, the pharmaceutically acceptable salt of numbered embodiment 46, the composition of numbered embodiment 47, or the pharmaceutical composition of numbered embodiment 48.

[0783] Herein instances of the plural form of words should be taken to cover also the singular form of the word and vice versa, unless the context clearly dictates otherwise.

[0784] The invention will now be illustrated with reference to the following non-limiting examples.

[0785] EXAMPLES

[0786] Example 1 - Bispecific miRNA steric blocking ASOs induce higher FAN1 upregulation compared to a monospecific miRNA steric blocking ASO.

[0787] To investigate whether more potent FAN1 upregulation could be achieved by blocking multiple miRNA target sites, an initial library of bispecific ASOs was designed.

[0788] ASOs were designed carrying two binding arms, each of which had full complementarity to a region of Fan1 3’-UTR where a miRNA was predicted to bind. Sequences were selected to ensure overlap specifically over the region expected to pair with the miRNA seed. Arms were designed with 12, 14, 18 or 20 nt in length and connected via a triethylene glycol (TrEG) linker (Figure 1).

[0789] Each sequence was produced with two different sets of chemical modifications:

[0790] • Phosphorothioate backbone (PS), 2’-O-methoxyethyl (MOE): referred to as “PS-MOE” • Phosphorothioate backbone (PS), 2’-O-methoxyethyl (MOE), two most 5’ and 3’ nucleotides of the molecule as locked nucleic acid (LNA): referred to as “PS-MOE- LNA”

[0791] To facilitate screening, a CRISPR-engineered HCT116 cell line was created to express a C-terminal HiBiT-tagged version of FAN1, which can be quantified in a luminescence assay.

[0792] Cell culture and transfection

[0793] ASOs were manufactured by Genscript, resuspended in TE buffer and dispatched onto 96-well white-walled plates using an Assist Plus Pipetting Robot (INTEGRA Biosciences Ltd). Plates were kept at -20°C until the moment of use.HCT116 FAN1-HiBiT cells were engineered by Synthego. Cells were cultured in DMEM GlutaMAX media (Gibco), supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin).

[0794] A transfection mix was prepared with HiPerFect (Qiagen) and dispatched onto the wells containing ASOs. Plates were shaken and incubated 10 min at room temperature. Following incubation, 25,000 cells per well were seeded in each transfection plate and incubated at 37°C, 95% humidity, 5% CO2 for 24h. Volumes were adjusted to achieve 25 nM final ASO concentration.

[0795] Luminescence assay

[0796] At 24h following transfection, HiBiT luminescence, as a proxy of FAN1 expression, was measured using the Nano-Gio® HiBiT Lytic Detection System (Promega) according to the manufacturer’s instructions.

[0797] Controls and analyses

[0798] For analysis, following background removal, the fold change of HiBiT luminescence was calculated between samples transfected with bispecific ASOs or mock-transfected.

[0799] Non-targeting and FAN 1 -targeting gapmers (which result in FAN1 transcript degradation) were used as transfection and HiBiT controls. As a positive control for FAN1 upregulation, a monospecific miR-197-3p steric blocking ASO was used.

[0800] When normalised against their respective control value, the data reveal that bispecific ASOs simultaneously targeting miR-197-3p and miR-145-5p or miR-197-3p and miR-181-5p induce higher upregulation than a monospecific miR-197-3p steric blocking ASO alone. Highest upregulation was observed with LNA-modified bispecific ASOs carrying 14 nt arms, which were selected for further validation experiments (Figure 1 B).

[0801] Table 2: List of ASOs used in Example 1

[0802]

[0803]

[0804] Example 2 - Bispecific miRNA steric blocking ASOs induce increased FAN1 upregulation.

[0805] To test whether bispecific ASOs induce increased upregulation, their activity was compared to that of individual monospecific miRNA steric blocking ASOs. Cell culture, transfection and luminescence assays were performed as previously described.

[0806] In the first experiment, monospecific miRNA steric blocking ASOs against miR-197-3p, miR-145-5p and miR-181-5p sites on Fan1 3’-UTR were transfected individually at 25 nM. In parallel, bispecific ASOs designed to target miR-197-3p_miR-145-5p, miR-197-3p_ miR-181-5p or miR-145-5p_ miR-181-5p were transfected at equal molarity (25 nM).

[0807] When normalised against their respective control value, the data reveal that bispecific ASOs induce increased upregulation compared to the activity of monospecific miRNA steric blocking ASOs (Figure 3A).

[0808] In the second experiment, monospecific miRNA steric blocking ASOs against miR-145-5p and miR-181-5p sites on Fan1 3’-UTR were transfected individually at25 nM. In parallel, bispecificASOs designed to target miR-145-5p_ miR-181-5p or miR-145-5p_miR-145-5p were transfected at equal molarity (25 nM).

[0809] When normalised against their respective control value, the data reveal that bispecific ASOs induce increased upregulation compared to the activity of monospecific miRNA steric blocking ASOs (Figure 3B). The data also reveal that bispecific ASOs with oligonucleotide moieties directed to the same (identical) target sequence induce similar upregulation compared to bispecific ASOs with oligonucleotide moieties directed to different target sequences.

[0810] Table 3: List of ASOs used in Example 2

[0811]

[0812] Example 3 - Bispecific miRNA steric blocking ASOs induce dose-dependent Fan1 upregulation at RNA and protein level.

[0813] To determine whether bispecific ASOs induce dose-dependent FAN1 upregulation and whether such effect occurs at the RNA or protein level, cells were treated with ASOs targeting miR-197-3p_miR-145-5p, miR-197-3p_ miR-181-5p or miR-145-5p_ miR-181-5p in doses ranging from 1.56 to 100 nM. In parallel, cells were treated with a non-targeting control ASO at the same concentrations. Samples were collected 24h post transfection for HiBiT luminescence measurement and qRT-PCR analyses. Cell culture and transfection were performed as previously described.

[0814] qRT-PCR

[0815] qRT-PCR was performed in three independent wells per condition using a Cells-to-CT™ 1-Step TaqMan® Kit (Ambion) according to the manufacturer’s instructions. Primers and probes were synthesised by IDT.

[0816] Analysis was performed using the comparative Ct method using B2M as a normaliser. Fold change between mock- and bispecific or non-targeting ASO-treated samples was calculated.Table 4: Primerand probe sequences

[0817]

[0818] When normalised against their respective control value (mock), the data reveal that bispecific ASOs induce dose-dependent FAN1 upregulation, which is not seen when cells are treated with a non-targeting control ASO at the same concentrations. Highest upregulation (up to 1.8-fold) was observed at concentrations ranging from 12.5 to 50 nM, with calculated EC50 values ranging from 2.3 to 3 nM, demonstrating the high potency of bispecific ASOs (Figure 4).

[0819] qRT-PCR analysis suggests that FAN1 upregulation following bispecific ASO treatment occurs partially at the RNA level, as Fan1 transcript levels also increase in a dose-dependent manner across treatments (Figure 4).

[0820] Table 5: List of ASOs used in Example 3

[0821]

[0822] Example 4 - Optimised bispecific miRNA steric blocking ASOs retain increased upregulation activity.

[0823] To test whether bispecific ASOs could be optimised whilst still retaining potent upregulation activity, a few modifications were made to miR-197-3p_miR-145-5p, miR-145-5p_miR-181-5p and miR-181-5p_miR-197-3p ASOs:

[0824] • Arm length reduction from 14 nt to 12 nt

[0825] • Replacement of some phosphorothioate (PS) by phosphodiester (PO) backbones • Removal of the TrEG linker

[0826] Cell culture, transfection and luminescence assays were performed as previously described.When normalised against their respective control value, the data reveal that bispecific ASOs retain superior upregulation compared to a monospecific miR-197-3p or miR-145-5p steric blocking ASO despite i. addition of PO backbones or ii. omission of TrEG linker in combination with shortened arms (Figure 5A-C).

[0827] Table 6: List of ASOs used in Example 4

[0828]

[0829] Example 5 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation in HD patient-derived striatal neurons

[0830] To verify whether FAN1 upregulation activity of bispecific ASOs could be observed in a HD relevant cell model, gymnosis was performed in patient-derived striatal neurons carrying a mutant Htt allele with >109 CAG repeats. In addition to previously tested sequences, a bispecific ASO designed to simultaneously target miR-181-5p and miR-124-3p sites in Fan1 UTR was also included, as the latter is expected to be expressed specifically in neurons.Striatal neuron culture and gymnosis

[0831] Striatal neurons (BrainXell, BX-0700) were cultured on plates coated with PDL (Thermo, A3890401) and SureBond (Axol, ax0053). Cell thawing and maintenance was performed following the manufacturer’s protocol. Forty thousand cells were plated per well in 96-well plates.

[0832] On day 7, neurons were first treated via gymnosis with a non-targeting control ASO or miRNA steric blocking ASOs. ASOs were manufactured by Integrated DNA Technologies (IDT) and resuspended in TE buffer. Briefly, a 50% medium change was performed every week with prewarmed medium supplemented with ASOs to achieve a final concentration of 5 pM. Neurons were dosed five times before sample collection at day 42.

[0833] Western blotting analysis

[0834] Medium was removed, each well was washed with PBS and lysed in 20 pl Laemmli SDS buffer (Thermo Scientific) diluted to 1x with RIPA (ThermoFisher). Samples were boiled at 95°C for 5 min and 13 pl of lysate was loaded per well. Samples were run on NuPAGE 4-12% Bis Tris Midi Gels (ThermoFisher) at 150V for 80 min.

[0835] Separated proteins were transferred to nitrocellulose membranes using BOLT Transfer Buffer (ThermoFisher) at 350 mA for 1h. Membranes were blocked in 5% BSA (Sigma Aldrich) and probed with primary antibodies for 1 h at room temperature (for Tubulin-β3) or overnight at 4°C (for FAN1), followed by 1h incubation with fluorescent secondary antibodies at room temperature (see Table X below). Proteins were imaged using an Odyssey Imager (Li-Cor) and bands were quantified using the Empiria Studio 2.2 software. Analysis was performed using Tubulin-β3 as a normaliser. Fold change between untreated and non-targeting ASO control, regular miRNA steric blocking ASO or bispecific miRNA steric blocking ASO samples was calculated.

[0836] Table 7: antibodies used for western blotting

[0837]

[0838] When normalised against their respective control value, the data reveal that the level of FAN1 is increased in neurons treated with bispecific ASOs targeting different combinations of miRNA sites relative to those untreated or receiving the control ASO. Observed upregulation followingtreatment with bispecific ASOs is more pronounced when compared to that observed with monospecific miRNA steric blocking ASOs (Figure 6).

[0839] The activity of this ASO modality is expected to be highly correlated with the expression level of the miRNA of interest - a highly cell-specific parameter. This is illustrated by the fact that the most potent bispecific ASO targets the combination of miR-181-5p and miR-124-3p sites - two miRNAs known to be particularly highly expressed in the human brain (Boudreau, Ryan L. et al. Neuron, Jan 2014; 81(2):294 - 305, doi:10.1016 / j.neuron.2013.10.062).

[0840] These data suggest the ability of a bispecific ASO to bind to Fan1 3’-UTR and compete with two miRNAs relieving miRNA-mediated repression and thereby upregulating FAN1 protein levels to a higher extent than that observed with monospecific miRNA steric blocking ASOs.

[0841] Table 8: ASOs used in Example 5

[0842]

[0843] Example 6 - Bispecific miRNA steric blocking ASO-mediated FAN1 upregulation in HD patient-derived medium spiny neurons decreases the rate of CAG repeat expansion FAN1 upregulation is known to decrease the rate of Htt CAG repeat expansion (Goold et al, 2019).

[0844] An experiment is devised to investigate whether bispecific miRNA steric blocking ASO treatment in striatal neurons affects CAG expansion rate as a result of FAN1 upregulation. The objective of said experiment is to determine CAG tract mean somatic length gain in striatal neurons.

[0845] gDNA is extracted from neurons treated with bispecific miRNA steric blocking or non-targeting ASOs after 10 weeks of gymnosis. gDNA is used for PCR amplification of the Htt locus. PCR products are sent for Nanopore long-read sequencing, and the resulting data is used to calculate the CAG tract mean somatic length gain. Neurons treated with non-targeting or FAN1 gapmer are also included as a control.The data reveals that slower expansion of the CAG tract is seen with FAN1 upregulation as a result of treatment with bispecific miRNA steric blocking ASO treatment. Whereas, in the control neurons treated with FAN1 gapmer, faster expansion of the CAG tract was observed as a result of FAN1 downregulation. This illustrates the relevance of miRNA regulation blockage using bispecific ASOs is a valid strategy for FAN1 upregulation in Huntington’s disease therapiesTable 9: ASOs described herein

[0846]

[0847]

[0848]

[0849]

[0850]

[0851]

[0852]

[0853]

[0854]

[0855]

[0856]

[0857] io LT)

[0858]

[0859]

[0860]

[0861]

[0862]

[0863]

[0864] Table 10: Fan1 targeting agents described herein

[0865]

[0866]

[0867]

[0868]

[0869]

[0870]

[0871]

[0872]

[0873]

[0874]

[0875]

[0876]

[0877]

[0878]

[0879]

[0880]

[0881]

[0882]

[0883] Table 11: Control ASOs described herein

[0884]

[0885]

[0886] Wherein in all of the tables herein - unless otherwise stated - "m" denotes a 2'-O-methyl modified nucleoside; "*" denotes a phosphorothioate bond between adjacent nucleotides; "+" denotes an LNA nucleotide; and 752MOEr_ / , / i2MOEr_ / , / 32MOEr” denote 5’, internal and 3’_2'-O-methoxyethyl nucleosides, respectively.

[0887] In the composition sequence, “i2MOErG” or “mG” denotes a single guanine nucleotide linker; no linker is simply denoted by a continuation of the sequence into the next arm; “iSp9” denotes a TrEG linker.

[0888] Wherein may or may not represent a linker as will be understood by consulting the corresponding composition sequence.Example 7 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation over 5 weeks of dosing in HD patient-derived medium spiny neurons

[0889] To verify whether FAN1 upregulation activity of bispecific ASOs is also observed in a HD relevant cell model at a lower dose than previously tested, gymnosis was performed in patient iPSC-derived striatal neurons carrying a mutant HTT allele with >109 CAG repeats.

[0890] Striatal neuron culture and gymnosis

[0891] / 7TT-CAG109 iPSC-derived striatal neurons (BrainXell, BX-0700) were cultured on plates coated with PDL (Thermo, A3890401) and SureBond (Axol, ax0053). Cell thawing and maintenance was performed following the manufacturer’s protocol. Forty thousand cells were plated per well in 96-well plates.

[0892] On day 7, neurons were first treated via gymnosis with a non-targeting control gapmer, FAN1 gapmer or bispecific miRNA steric blocking ASOs of the present invention. ASOs were manufactured by ATDBio and resuspended in nuclease-free water. Briefly, a 50% medium change was performed every week with pre-warmed medium supplemented with ASOs to achieve a final concentration of 2.5 pM. Neurons were dosed five times before sample collection at day 42.

[0893] Table 12: ASOs used in Example 7

[0894]

[0895] Compounds 10 and 12 are FAN1 targeting agents according to the present invention.

[0896] Western blotting analysis

[0897] Medium was removed, each well was washed with PBS and every two wells per condition were pooled and lysed in 30 pl RIPA buffer (Thermo Scientific) supplemented with a complete™, Mini, EDTA-free Protease Inhibitor Cocktail (Roche). Lysates were kept on ice with regular vortexing for 15 min. Protein concentration was determined by Pierce BCA Protein assay kit according to the manufacturer’s instructions. Samples were boiled at 95°C for 5 min and 10 pg of protein was loaded per well. Samples were run on NuPAGE 4-12% Bis Tris Midi Gels (ThermoFisher) at 150V for 90 min.Separated proteins were transferred to nitrocellulose membranes using BOLT Transfer Buffer (ThermoFisher) at 350 mA for 1h. Membranes were stained with Revert 700 Total Protein Stain (TPS) according to the manufacturer’s instructions. Membranes were scanned in a using an Odyssey Imager (Li-Cor), followed by destaining. Membranes were blocked in 5% BSA (Sigma Aldrich) and probed with primary antibodies overnight at 4°C, followed by 1h incubation with fluorescent secondary antibodies at room temperature (see Table 13 below). Protein bands were imaged using an Odyssey Imager (Li-Cor) and quantified on the Empiria Studio 2.2 software, using FAN1 gapmer samples as antibody specificity controls. Analysis was performed using TPS as a loading normaliser. Fold change between non-targeting ASO control and bispecific miRNA steric blocking ASO samples was calculated.

[0898] Table 13: antibodies used for western blotting

[0899]

[0900] When normalised against their respective control value, the data reveal that the level of FAN1 is increased in neurons treated with lower concentration of bispecific ASOs relative to those receiving the control ASO (Figure 7).

[0901] Example 8 - Bispecific miRNA steric blocking ASO-induced FAN1 upregulation follows a dose response in HD patient-derived medium spiny neurons

[0902] To verify whether FAN1 upregulation activity of bispecific ASOs follows a dose-response in a HD relevant cell model, gymnosis was performed in patient iPSC-derived striatal neurons carrying a mutant HTT allele with >109 CAG repeats. In this experiment, two iterations of bispecific ASOs targeting the same miRNAs were tested.

[0903] Table 14: ASOs used in Example 8

[0904]

[0905] Striatal neuron culture and gymnosis

[0906] / 7TT-CAG109 iPSC-derived striatal neurons were cultured as per Example 7. On day 7, neurons were first treated via gymnosis with a non-targeting control gapmer, FAN1 gapmer orbispecific miRNA steric blocking ASOs. ASOs were manufactured by ATDBio and resuspended in nuclease-free water. Briefly, a 50% medium change was performed every week with pre-warmed medium supplemented with ASOs to achieve a final concentration of 0.3, 1 or 2.5 pM. Neurons were dosed five times before sample collection at day 42.

[0907] FAN1 ELISA

[0908] Medium was removed, each well was washed with PBS and lysed. Lysates were spun down and the supernatant collected. Protein concentration was determined with a Micro BCA Protein Assay Kit (Thermo Scientific). White-walled 96-well polystyrene plates were coated with detection antibody overnight at 4°C. Plates were washed three times and blocked for 90 min at room temperature. Recombinant protein standards and samples were diluted in blocking buffer and incubated overnight at 4°C. After three washes, detection antibody was added and incubated for 1h at room temperature. After three washes, streptavidin-HRP was added and incubated for 30 min at room temperature. After five washes, ELISA chemiluminescent substrate was added, plates were shaken for 1 min and luminescence signal was scanned in a CLARIOstar plate reader (BMG). FAN1 concentration was quantified relative to a recombinant protein standard curve using the 4PL model.

[0909] Table 15: Antibodies used for ELISA

[0910]

[0911] When quantified relative to a recombinant protein standard curve and normalised against their respective control value, the data reveal that the level of FAN1 is increased in neurons treated with increasing concentrations of bispecific ASOs relative to those receiving the control ASO. Whilst compound 12 shows higher potency at 1 pM, both test ASOs induce similar levels of upregulation at 2.5 pM (Figure 8).

[0912] Example 9 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation and reduce H7T-CAG tract expansion in HD patient-derived medium spiny neurons

[0913] To demonstrate the downstream effects of FAN1 upregulation on / 7TT-CAG tract expansion, / 7TT-CAG109 iPSC-derived striatal neurons were treated with control ASO and a bispecific ASO to induce FAN1 upregulation over 15 weeks. As a control, neurons were treated with FAN1 gapmer to induce FAN1 downregulation and, consequently, accelerate / 7TT-CAG expansion. We have previously determined that the extended CAG tracts in the mutant HTTallele of this cell line expands at a measurable rate. This cell line therefore provides a clinically relevant model in which to assess the rate of CAG expansion under different treatments.

[0914] Striatal neuron culture and qymnosis

[0915] / 7TT-CAG109 iPSC-derived striatal neurons were cultured as per Example 7. On day 7, neurons were first treated via gymnosis with a non-targeting control gapmer, FAN1 gapmer or bispecific miRNA steric blocking ASOs. ASOs were manufactured by ATDBio and resuspended in nuclease-free water. Briefly, a 50% medium change was performed every week with pre-warmed medium supplemented with ASOs to achieve a final concentration of 5 pM. Neurons were dosed five times before sample collection at day 42 for protein upregulation analyses by western blotting. For / 7TT-CAG expansion assay, neurons were kept in culture following a weekly dosing schedule for up to 100 days.

[0916] Table 16: ASOs used in Example 9

[0917]

[0918] Western blotting analysis

[0919] Western blotting was performed as per Example 7; quantified outputs from western blotting are show in Figure 9(A).

[0920] / 7TT-CAG expansion assay

[0921] For / 7TT-CAG expansion assay, samples were collected following 5, 8, 11 and 15 weeks of dosing. For gDNA extraction, striatal neurons are washed in PBS, and lysed and processed with the Zymo Quick-DNA 96 kit (Zymo Research) according to the manufacturer’s instructions and DNA concentration was measured by Qubit. Normalised gDNA samples were used for amplification of the HTT locus using La Taq DNA polymerase (Takara) as described below.

[0922] Table 17: / 7TT-CAG PCR reaction

[0923]

[0924] Table 18: PCR primers

[0925]

[0926] Table 19: PCR conditions

[0927]

[0928] Amplification of wild-type and mutant alleles was confirmed by agarose gel electrophoresis. PCR reactions were shipped to Full Circle (UK), where purification and Nanopore amplicon sequencing was performed. QC-filtered reads were mapped to a pseudo-genome consisting of HTT exon 1 with CAGn and the number of CAG trinucleotides was calculated for each read. Mean somatic length gain (MSLG) was calculated as described in Matlik et al, 2024 (doi.org / 10.1038 / s41588-024-01653-6).

[0929] When compared to control ASO-treated samples, compound 10-treated samples show 50% more FAN1 after 5 weeks of dosing (Figure 9A). FAN1 gapmer-treated samples show increased expansion in CAG tract length=. Samples treated with compound 10, which were associated with FAN1 upregulation, show a reduction in CAG tract length expansion (Figure 9B) and therefore provide proof of concept that FAN1 targeting agents of the present invention are able to upregulate FAN1 protein levels and consequently reduce CAG repeat expansion.

[0930] Example 10 - Bispecific miRNA steric blocking ASOs induce FAN1 upregulation and reduce H7T-CAG tract expansion in patient iPSC-derived cerebral organoids

[0931] To demonstrate the downstream effects of FAN1 upregulation on / 7TT-CAG tract expansion in an alternative system, / 7TT-CAG127 iPSCs were used to generate mature / 7TT-CAG-expanding cerebral organoids in culture. Organoids have been previously characterised and shown to express markers of cortical deep layer and striatum beyond 10 weeks in culture. In addition, / 7TT-CAG expansion has been shown to occur at a rate of -0.17 CAG / week in this system, making it a clinically and physiologically relevant model in which to assess the rate of CAG expansion under different treatments.Cerebral organoid culture and ASO treatment

[0932] Cerebral organoids were differentiated using STEMdiff Cerebral Organoid Kit (Stemcell Technologies) according to the manufacturer’s protocol. Treatments started from day 28, with ASO-supplemented media changes three times per week at a final concentration of 5 pM, for up to 140 days. Organoids were treated with a control ASO, bispecific ASO or FAN1 gapmer. Samples were collected at days 28, 84 and 140 and stored at -80°C until the moment of use.

[0933] Table 20: ASOs used in Example 10

[0934]

[0935] Organoid sample processing

[0936] Organoid samples were processed with the AHPrep DNA / RNA / Protein Mini Kit (Qiagen) according to the manufacturer’s instructions. DNA concentration was measured by Qubit; RNA concentration and purity was measured by Nanodrop; protein concentration was measured by Pierce BOA Protein assay (ThermoFisher).

[0937] Western blotting analysis

[0938] Western blotting was performed as per Example 7; quantified outputs from western blotting are show in Figure 10(B).

[0939] gRT-PCR analysis

[0940] Reverse transcription was performed on 250 ng of RNA using the iScript cDNA Synthesis Kit (Bio-Rad) using random primers, according to the manufacturer’s instructions. cDNA was diluted 1:5 in nuclease-free water and TaqMan qRT-PCR (Applied Biosystems) reactions were performed according to the manufacturer’s instructions:

[0941] Table 21: gRT-PCR reactions

[0942]

[0943] FAN 1-201 mRNA relative expression levels were quantified using TBP as the reference gene and calculated according to the 2-AACtmethod. Fold change relative to control ASO was calculated.

[0944] HTT-CAG expansion assay

[0945] Normalised gDNA samples were used for amplification of the HTT locus using La Taq DNA polymerase (Takara) as described in Example 9.

[0946] When compared to control ASO-treated samples, FAN1 gapmer-treated organoids show very low levels of FAN1 mRNA and protein, as expected. Compound 12-treated organoids show 50% and 100% more FAN1 mRNA and protein at 140 days, respectively (Figure 10A-B). Accordingly, FAN1 gapmer-treated samples show increased expansion in CAG tract length, whilst samples treated with compound 12 show reduction in CAG tract length expansion over 140 days in culture (Figure 10C). These data corroborate the findings of Example 9 - using an alternative and complementary biologically relevant system - that FAN1 targeting agents of the present invention are able to upregulate both FAN1 mRNA and protein levels and consequently reduce CAG repeat expansion.

[0947] Example 11 - Bispecific miRNA steric blocking ASOs outcompete synthetic miRNA binding to FAN1 3’-UTR

[0948] To demonstrate that / . bispecific ASOs can compete with miRNAs for binding to FAN1 3’-UTR, and / / . that the same bispecific ASO can compete against two different miRNAs for binding to two different regions of FAN13’-UTR (i.e., the regions targeted by the respective miRNAs), a Forster Resonance Energy Transfer (FRET)-based assay was performed to assess the interactions between a target mRNA, a FAN1 targeting agent according to the invention, and a miRNA in vitro (Figure 11A).

[0949] FRET assay

[0950] Sequences were produced by ATDBio (UK) as follows (Table 22):

[0951] • A 40 nt long fragment of FAN1 3’-UTR encompassing the target site for miR-197-3p was synthesised conjugated with 5’-Cy3;

[0952] • A 40 nt long fragment of FAN13’-UTR encompassing the target site for miR-145-5p was synthesised conjugated with 5’-Cy3;

[0953] • The mature sequence of miR-197-3p was synthesised conjugated with 3’-Cy5;

[0954] • The mature sequence of miR-145-5p was synthesised conjugated with 3’-Cy5;Table 22: Conjugated synthetic RNA sequences

[0955]

[0956] The FRET assay was performed with the following bispecific ASOs:

[0957] Table 23: ASOs used in Example 11

[0958]

[0959] Oligonucleotides were resuspended in nuclease-free water and protected from light. UTR fragments were briefly heated at 70°C for 2 min and cooled down to room temperature. Reactions were prepared in 96-well black plates with matching pairs of sequences (UTR fragment and miRNA) at 1 pM concentration in 1x Saline-Sodium Citrate (SSC) buffer 0.005% Tween. A titration of non-targeting control or bispecific miRNA steric blocking ASO was added in concentrations ranging from 0 - 8 pM in duplicates. Reactions were gently mixed and plates were incubated at 37°C for 30 min protected from light. Plates were read using a CLARIOstar (BMG Labtech) plate reader with excitation at 509 nm and emission at 563 nm (donor), followed by excitation at 509 nm and emission at 660 nm (acceptor). For each well, the fluorescence emission ratio (660 nm 1563 nm) was calculated and normalised relative to the minimum and maximum FRET ratios obtained in this experiment.

[0960] When compared to a chemistry-matched non-targeting bispecific ASO, a bispecific miRNA steric blocking ASO reduced the FRET signal in a dose-dependent manner. In line with its bispecific nature, the same ASO can compete with miR-145-5p (Figure 11 B) and miR-197-3p (Figure 11C) for binding to two distinct UTR fragments.

[0961] Finally, when tested in equimolar concentration with each UTR fragment and its respective miRNA, a bispecific ASO can displace -75% of the interaction in both cases. These results confirm the mode of action of bispecific miRNA steric blocking ASOs, demonstrating its ability to compete against two miRNAs for binding to two distinct 3’-UTR sites.

Claims

CLAIMS1. A Fan1 targeting agent, wherein the Fan1 targeting agent comprises two or more oligonucleotide moieties, and each oligonucleotide moiety independently comprises an oligonucleotide sequence of 10 to 40 nucleotides in length that comprises a contiguous nucleotide sequence of five or more nucleotides in length having at least 80% complementarity to a target sequence within the 3’IITR of an RNA encoding FAN 1, wherein no two target sequences are within five nucleotides of each other.

2. The Fan1 targeting agent of claim 1, wherein two or more of the oligonucleotide moieties are separated by an independently selected linker, optionally wherein each of the oligonucleotide moieties are separated by an independently selected linker.

3. The Fan1 targeting agent of any of the preceding claims, wherein at least one oligonucleotide moiety competes with a microRNA for binding to the 3’IITR of the RNA encoding FAN1, optionally wherein each oligonucleotide moiety competes with a microRNA for binding to the 3’IITR of the RNA encoding FAN1.

4. The Fan1 targeting agent of any of the preceding claims, wherein each target sequence within the 3’IITR of the RNA encoding FAN1 overlaps with a nucleotide sequence bound by a microRNA, optionally wherein the microRNA is associated with modulating the onset of a triple repeat disorder.

5. The Fan1 targeting agent of claim 4 wherein the microRNA:(a) is selected from hsa-miR-299-3p, hsa-miR-3940-5p, hsa-miR-4265, hsa-miR-4507, hsa-miR-4657, hsa-miR-6748-5p, hsa-miR-6759-5p, hsa-miR-6793-5p, hsa-miR-6796-5p, hsa-miR-6839-3p, hsa-miR-629-5p, hsa-miR-1275, hsa-miR-193b-5p, hsa-miR-3675-5p, hsa-miR-4665-5p, hsa-miR-6751-5p, hsa-miR-6803-5p, hsa-miR-6835-5p, hsa-miR-6842-5p, hsa-miR-6890-5p, hsa-miR-7109-5p, hsa-miR-7110-5p, hsa-miR-198, hsa-miR-1911-3p, hsa-miR-6753-5p, hsa-miR-1256, hsa-miR-3910, hsa-miR-1910-3p, hsa-miR-2682-5p, hsa-miR-34a-5p, hsa-miR-34b-5p, hsa-miR-34c-5p, hsa-miR-449a, hsa-miR-449b-5p, hsa-miR-449c-5p, hsa-miR-548au-3p, hsa-miR-584-3p, hsa-miR-6511a-5p, hsa-miR-6808-5p, hsa-miR-6893-5p, hsa-miR-940, hsa-miR-3714, hsa-miR-125b-1-3p, hsa-miR-155-5p, hsa-miR-3621, hsa-miR-3610, hsa-miR-4665-3p, hsa-miR-4755-3p, hsa-miR-3622a-5p, hsa-miR-5582-5p, hsa-miR-124-3p, hsa-miR-506-3p, hsa-miR-10527-5p, hsa-miR-1207-5p, hsa-miR-1262, hsa-miR-1273h-3p, hsa-miR-1287-3p, hsa-miR-1301-3p, hsa-miR-1303, hsa-miR-1304-5p, hsa-miR-1343-5p, hsa-miR-141-3p, hsa-miR-186-5p, hsa-miR-1914-3p, hsa-miR-200a-3p, hsa-miR-204-5p, hsa-miR-211-5p, hsa-miR-23a-5p, hsa-miR-23b-5p, hsa-miR-3120-3p, hsa-miR-3122, hsa-miR-3182, hsa-miR-3199, hsa-miR-335-3p, hsa-miR-3681-5p, hsa-miR-3913-5p, hsa-miR-3925-3p, hsa-miR-4284, hsa-miR-4469, hsa-miR-450b-5p, hsa-miR-4640-5p, hsa-miR-4649-3p, hsa-miR-4650-3p, hsa-miR-4667-3p, hsa-miR-4677-5p, hsa-miR-4693-3p, hsa-miR-4701-3p, hsa-miR-4726-5p, hsa-miR-4763-3p, hsa-miR-4768-5p, hsa-miR-4771, hsa-miR-4775, hsa-miR-4776-3p, hsa-miR-4797-3p, hsa-miR-485-5p, hsa-miR-5002-3p, hsa-miR-5008-5p, hsa-miR-5089-5p, hsa-miR-513b-5p, hsa-miR-5190, hsa-miR-5191, hsa-miR-5193, hsa-miR-5194, hsa-miR-543, hsa-miR-545-3p, hsa-miR-548a-3p, hsa-miR-548aa, hsa-miR-548an, hsa-miR-548ap-3p, hsa-miR-548ar-3p, hsa-miR-548az-3p, hsa-miR-548bc, hsa-miR-548e-3p, hsa-miR-548n, hsa-miR-548t-3p, hsa-miR-589-3p, hsa-miR-6730-5p, hsa-miR-6736-5p, hsa-miR-6738-5p, hsa-miR-6740-5p, hsa-miR-676-3p, hsa-miR-6770-5p, hsa-miR-6826-3p, hsa-miR-6831-5p, hsa-miR-6833-3p, hsa-miR-6845-3p, hsa-miR-6870-3p, hsa-miR-6875-3p, hsa-miR-6878-3p, hsa-miR-6884-3p, hsa-miR-7108-3p, hsa-miR-7974, hsa-miR-802, hsa-miR-939-5p, hsa-let-7f-2-3p, hsa-miR-11181-3p, hsa-miR-1185-1-3p, hsa-miR-1185-2-3p, hsa-miR-1197, hsa-miR-12129, hsa-miR-12136, hsa-miR-1228-3p, hsa-miR-124-3p, hsa-miR-1264, hsa-miR-1265, hsa-miR-1276, hsa-miR-1288-5p, hsa-miR-1290, hsa-miR-1299, hsa-miR-130a-5p, hsa-miR-135a-2-3p, hsa-miR-135b-3p, hsa-miR-138-1-3p, hsa-miR-145-5p, hsa-miR-15b-3p, hsa-miR-16-1-3p, hsa-miR-181a-5p, hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-181d-5p, hsa-miR-187-3p, hsa-miR-194-5p, hsa-miR-196a-3p, hsa-miR-196b-3p, hsa-miR-197-3p, hsa-miR-19a-5p, hsa-miR-19b-1-5p, hsa-miR-216b-5p, hsa-miR-2276-3p, hsa-miR-2276-5p, hsa-miR-2278, hsa-miR-2355-3p, hsa-miR-27a-5p, hsa-miR-29a-5p, hsa-miR-3064-5p, hsa-miR-3085-3p, hsa-miR-3125, hsa-miR-3127-3p, hsa-miR-3135a, hsa-miR-3143, hsa-miR-3150a-3p, hsa-miR-3154, hsa-miR-3158-3p, hsa-miR-3159, hsa-miR-3160-5p, hsa-miR-3163, hsa-miR-3184-3p, hsa-miR-3189-5p, hsa-miR-3191-5p, hsa-miR-3202, hsa-miR-331-3p, hsa-miR-342-3p, hsa-miR-346, hsa-miR-3605-3p, hsa-miR-3663-5p, hsa-miR-3677-5p, hsa-miR-372-5p, hsa-miR-376b-5p, hsa-miR-378a-5p, hsa-miR-3916, hsa-miR-3929, hsa-miR-3938, hsa-miR-424-3p, hsa-miR-4254, hsa-miR-4282, hsa-miR-4323, hsa-miR-4428, hsa-miR-4443, hsa-miR-4451, hsa-miR-4476, hsa-miR-4478, hsa-miR-4502, hsa-miR-4503, hsa-miR-4515, hsa-miR-4679, hsa-miR-4694-5p, hsa-miR-4699-3p, hsa-miR-4729, hsa-miR-4738-3p, hsa-miR-4739, hsa-miR-4745-5p, hsa-miR-4755-5p, hsa-miR-4756-5p, hsa-miR-4766-5p, hsa-miR-4773, hsa-miR-4781-3p, hsa-miR-4803, hsa-miR-488-3p, hsa-miR-498-5p, hsa-miR-5001-3p, hsa-miR-5006-3p, hsa-miR-5008-3p, hsa-miR-505-3p, hsa-miR-506-3p, hsa-miR-506-5p, hsa-miR-5088-3p, hsa-miR-5089-3p, hsa-miR-5094, hsa-miR-5189-3p, hsa-miR-5195-3p, hsa-miR-539-5p, hsa-miR-548a-5p, hsa-miR-548ab, hsa-miR-548ad-5p, hsa-miR-548ae-5p, hsa-miR-548ag, hsa-miR-548ai, hsa-miR-548ak, hsa-miR-548am-5p, hsa-miR-548ap-5p, hsa-miR-548aq-5p, hsa-miR-548ar-5p, hsa-miR-548as-5p, hsa-miR-548au-5p, hsa-miR-548ay-5p, hsa-miR-548az-5p, hsa-miR-548b-5p, hsa-miR-548ba, hsa-miR-548bb-5p, hsa-miR-548c-5p, hsa-miR-548d-5p, hsa-miR-548g-3p, hsa-miR-548h-5p, hsa-miR-548i, hsa-miR-548j-5p, hsa-miR-548m, hsa-miR-548o-5p, hsa-miR-548p, hsa-miR-548t-5p, hsa-miR-548v, hsa-miR-548w, hsa-miR-548y, hsa-miR-5586-5p, hsa-miR-559, hsa-miR-5591-5p, hsa-miR-5693, hsa-miR-570-5p, hsa-miR-578, hsa-miR-596, hsa-miR-601, hsa-miR-6081, hsa-miR-643, hsa-miR-6501-3p, hsa-miR-6504-5p, hsa-miR-6511a-3p, hsa-miR-6511b-3p, hsa-miR-6513-5p, hsa-miR-660-3p, hsa-miR-661, hsa-miR-663b, hsa-miR-664a-3p, hsa-miR-6726-5p, hsa-miR-6734-5p, hsa-miR-6736-3p, hsa-miR-6737-3p, hsa-miR-6738-3p, hsa-miR-6739-3p, hsa-miR-6742-3p, hsa-miR-6746-3p, hsa-miR-6756-3p, hsa-miR-676-5p, hsa-miR-6761-5p, hsa-miR-6763-3p, hsa-miR-6763-5p, hsa-miR-6791-3p, hsa-miR-6796-3p, hsa-miR-6818-3p, hsa-miR-6825-5p, hsa-miR-6829-3p, hsa-miR-6833-5p, hsa-miR-6843-3p, hsa-miR-6848-3p, hsa-miR-6854-5p, hsa-miR-6859-5p, hsa-miR-6876-5p, hsa-miR-6894-5p, hsa-miR-6895-3p, hsa-miR-7114-5p, hsa-miR-7157-3p, hsa-miR-765, hsa-miR-766-5p, hsa-miR-7852-3p, hsa-miR-7977, hsa-miR-7978, hsa-miR-8485, hsa-miR-888-5p, hsa-miR-920, hsa-miR-943, hsa-miR-10398-5p, hsa-miR-105-5p, hsa-miR-10a-3p, hsa-miR-12115, hsa-miR-1236-3p, hsa-miR-1253, hsa-miR-125b-2-3p, hsa-miR-1286, hsa-miR-129-5p, hsa-miR-1293, hsa-miR-1302, hsa-miR-1324, hsa-miR-1343-3p, hsa-miR-1470, hsa-miR-147b-5p, hsa-miR-186-3p, hsa-miR-1912-5p, hsa-miR-196a-5p, hsa-miR-196b-5p, hsa-miR-1976, hsa-miR-205-5p, hsa-miR-2116-5p, hsa-miR-22-5p, hsa-miR-221-5p, hsa-miR-24-3p, hsa-miR-2467-5p, hsa-miR-2682-3p, hsa-miR-26b-3p, hsa-miR-30a-3p, hsa-miR-30d-3p, hsa-miR-30e-3p, hsa-miR-31-3p, hsa-miR-3133, hsa-miR-3145-3p, hsa-miR-3152-5p, hsa-miR-3155a, hsa-miR-3155b, hsa-miR-3166, hsa-miR-3171, hsa-miR-3175, hsa-miR-3177-3p, hsa-miR-3184-5p, hsa-miR-3188, hsa-miR-3190-3p, hsa-miR-324-5p, hsa-miR-326, hsa-miR-330-5p, hsa-miR-3529-5p, hsa-miR-3612, hsa-miR-362-5p, hsa-miR-3621, hsa-miR-363-5p, hsa-miR-3655, hsa-miR-365a-5p, hsa-miR-365b-5p, hsa-miR-3675-5p, hsa-miR-3680-3p, hsa-miR-3682-3p, hsa-miR-3682-5p, hsa-miR-3686, hsa-miR-3688-5p, hsa-miR-376a-3p, hsa-miR-376b-3p, hsa-miR-379-5p, hsa-miR-3925-5p, hsa-miR-3940-3p, hsa-miR-3942-3p, hsa-miR-423-5p, hsa-miR-4273, hsa-miR-4287, hsa-miR-4298, hsa-miR-4457, hsa-miR-4483, hsa-miR-4484, hsa-miR-450a-1-3p, hsa-miR-4632-3p, hsa-miR-4659a-3p, hsa-miR-4659a-5p, hsa-miR-4659b-3p, hsa-miR-4660, hsa-miR-4668-3p, hsa-miR-4685-3p, hsa-miR-4685-5p, hsa-miR-4687-3p, hsa-miR-4695-5p, hsa-miR-4707-5p, hsa-miR-4722-5p, hsa-miR-4724-5p, hsa-miR-4727-3p, hsa-miR-4733-5p, hsa-miR-4736, hsa-miR-4740-3p, hsa-miR-4742-3p, hsa-miR-4757-5p, hsa-miR-4762-3p, hsa-miR-4764-3p, hsa-miR-4769-3p, hsa-miR-4774-3p, hsa-miR-4779, hsa-miR-4799-5p, hsa-miR-484, hsa-miR-486-5p, hsa-miR-495-3p, hsa-miR-500b-5p, hsa-miR-501-5p, hsa-miR-507, hsa-miR-518a-5p, hsa-miR-526b-5p, hsa-miR-527, hsa-miR-542-5p, hsa-miR-548as-3p, hsa-miR-548at-3p, hsa-miR-548aw, hsa-miR-548ay-3p, hsa-miR-551b-5p, hsa-miR-557, hsa-miR-5582-3p, hsa-miR-5584-5p, hsa-miR-5587-3p, hsa-miR-5590-5p, hsa-miR-5687, hsa-miR-5688, hsa-miR-572, hsa-miR-576-5p, hsa-miR-590-3p, hsa-miR-6074, hsa-miR-6089, hsa-miR-6128, hsa-miR-623, hsa-miR-629-3p, hsa-miR-650, hsa-miR-6508-3p, hsa-miR-6511b-5p, hsa-miR-6515-3p, hsa-miR-6516-5p, hsa-miR-6721-5p, hsa-miR-6728-5p, hsa-miR-6729-3p, hsa-miR-6741-5p, hsa-miR-6745, hsa-miR-6750-5p, hsa-miR-6756-5p, hsa-miR-6764-3p, hsa-miR-6765-5p, hsa-miR-6766-5p, hsa-miR-6768-3p, hsa-miR-6774-5p, hsa-miR-6777-5p, hsa-miR-6781-3p, hsa-miR-6783-3p, hsa-miR-6792-5p, hsa-miR-6795-3p, hsa-miR-6807-5p, hsa-miR-6809-3p, hsa-miR-6811-5p, hsa-miR-6817-5p, hsa-miR-6820-5p, hsa-miR-6823-3p, hsa-miR-6824-3p, hsa-miR-6837-5p, hsa-miR-6844, hsa-miR-6873-3p, hsa-miR-6889-5p, hsa-miR-6890-5p, hsa-miR-6891-3p, hsa-miR-7-1-3p, hsa-miR-7-2-3p, hsa-miR-7113-3p, hsa-miR-7113-5p, hsa-miR-7151-5p, hsa-miR-7156-3p, hsa-miR-7156-5p, hsa-miR-7162-3p, hsa-miR-766-3p, hsa-miR-769-3p, hsa-miR-7853-5p, hsa-miR-8057, hsa-miR-8073, hsa-miR-874-5p, hsa-miR-885-5p, hsa-miR-887-5p, hsa-miR-95-3p, hsa-miR-9500, hsa-miR-9903, hsa-miR-9983-3p, hsa-let-7a-3p, hsa-let-7a-5p, hsa-let-7b-3p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-5p, hsa-let-7e-5p, hsa-let-7f-1-3p, hsa-let-7f-5p, hsa-let-7g-5p, hsa-let-7i-5p, hsa-miR-1-3p, hsa-miR-10392-3p, hsa-miR-10526-3p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-miR-10b-3p, hsa-miR-1183, hsa-miR-1185-5p, hsa-miR-1199-3p, hsa-miR-1199-5p, hsa-miR-1200, hsa-miR-1208, hsa-miR-12124, hsa-miR-12132, hsa-miR-12135, hsa-miR-122-3p, hsa-miR-1226-5p, hsa-miR-122b-3p, hsa-miR-122b-5p, hsa-miR-1237-3p, hsa-miR-1245a, hsa-miR-1245b-5p, hsa-miR-1247-5p, hsa-miR-1248, hsa-miR-1251-3p, hsa-miR-1252-3p, hsa-miR-125b-1-3p, hsa-miR-1261, hsa-miR-1285-3p, hsa-miR-1288-3p, hsa-miR-1291, hsa-miR-1296-3p, hsa-miR-1298-5p, hsa-miR-1306-5p, hsa-miR-130b-5p, hsa-miR-132-3p, hsa-miR-1323, hsa-miR-134-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, hsa-miR-136-3p, hsa-miR-136-5p, hsa-miR-139-5p, hsa-miR-140-3p, hsa-miR-1468-3p, hsa-miR-149-3p, hsa-miR-149-5p, hsa-miR-153-5p, hsa-miR-1537-3p, hsa-miR-155-5p, hsa-miR-17-5p, hsa-miR-181a-2-3p, hsa-miR-181d-3p, hsa-miR-187-5p, hsa-miR-1909-3p, hsa-miR-191-5p, hsa-miR-194-3p, hsa-miR-200c-5p, hsa-miR-202-3p, hsa-miR-203a-3p, hsa-miR-2052, hsa-miR-206, hsa-miR-208b-5p, hsa-miR-20a-5p, hsa-miR-20b-3p, hsa-miR-20b-5p, hsa-miR-21-3p, hsa-miR-211-3p, hsa-miR-2110, hsa-miR-2115-3p, hsa-miR-212-3p, hsa-miR-216a-5p, hsa-miR-216b-3p, hsa-miR-217-3p, hsa-miR-218-2-3p, hsa-miR-218-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-222-5p, hsa-miR-2277-3p, hsa-miR-2392, hsa-miR-25-3p, hsa-miR-27a-3p, hsa-miR-27b-3p, hsa-miR-29b-2-5p, hsa-miR-302a-5p, hsa-miR-3064-3p, hsa-miR-3074-5p, hsa-miR-3115, hsa-miR-3116, hsa-miR-3130-3p, hsa-miR-3136-3p, hsa-miR-3136-5p, hsa-miR-3137, hsa-miR-3142, hsa-miR-3144-5p, hsa-miR-3148, hsa-miR-3149, hsa-miR-3150b-3p, hsa-miR-3152-3p, hsa-miR-3157-5p, hsa-miR-3160-3p, hsa-miR-3162-5p, hsa-miR-3167, hsa-miR-3173-3p, hsa-miR-3179, hsa-miR-3180-5p, hsa-miR-3187-5p, hsa-miR-3191-3p, hsa-miR-3194-5p, hsa-miR-32-5p, hsa-miR-3200-3p, hsa-miR-320a-3p, hsa-miR-320a-5p, hsa-miR-320b, hsa-miR-320c, hsa-miR-320d, hsa-miR-324-3p, hsa-miR-328-3p, hsa-miR-329-3p, hsa-miR-330-3p, hsa-miR-331-5p, hsa-miR-335-5p, hsa-miR-33a-3p, hsa-miR-340-3p, hsa-miR-345-5p, hsa-miR-34a-3p, hsa-miR-34b-3p, hsa-miR-3605-5p, hsa-miR-3609, hsa-miR-361-3p, hsa-miR-3610, hsa-miR-3613-3p, hsa-miR-3614-3p, hsa-miR-3616-5p, hsa-miR-3617-3p, hsa-miR-362-3p, hsa-miR-3620-3p, hsa-miR-3622a-5p, hsa-miR-363-3p, hsa-miR-365a-3p, hsa-miR-365b-3p, hsa-miR-3662, hsa-miR-3663-3p, hsa-miR-3671, hsa-miR-3675-3p, hsa-miR-3679-3p, hsa-miR-3679-5p, hsa-miR-3688-3p, hsa-miR-3689a-5p, hsa-miR-3689b-5p, hsa-miR-3689e, hsa-miR-3689f, hsa-miR-369-3p, hsa-miR-3690, hsa-miR-3691-5p, hsa-miR-370-3p, hsa-miR-3714, hsa-miR-371a-5p, hsa-miR-371b-5p, hsa-miR-373-5p, hsa-miR-375-3p, hsa-miR-377-3p, hsa-miR-378g, hsa-miR-383-5p, hsa-miR-3910, hsa-miR-3919, hsa-miR-3920, hsa-miR-3928-3p, hsa-miR-3934-3p, hsa-miR-3940-5p, hsa-miR-3943, hsa-miR-409-3p, hsa-miR-421, hsa-miR-4270, hsa-miR-4288, hsa-miR-4290, hsa-miR-4292, hsa-miR-4429, hsa-miR-4446-3p, hsa-miR-4456, hsa-miR-4458, hsa-miR-4474-3p, hsa-miR-4475, hsa-miR-4477a, hsa-miR-4496, hsa-miR-4500, hsa-miR-4507, hsa-miR-4516, hsa-miR-4519, hsa-miR-4633-3p, hsa-miR-4639-5p, hsa-miR-4646-3p, hsa-miR-4652-3p, hsa-miR-4652-5p, hsa-miR-4653-3p, hsa-miR-4661-3p, hsa-miR-4665-3p, hsa-miR-4676-5p, hsa-miR-4677-3p, hsa-miR-4690-5p, hsa-miR-4691-3p, hsa-miR-4709-5p, hsa-miR-4711-3p, hsa-miR-4712-3p, hsa-miR-4713-5p, hsa-miR-4714-3p, hsa-miR-4715-3p, hsa-miR-4719, hsa-miR-4720-3p, hsa-miR-4728-3p, hsa-miR-4728-5p, hsa-miR-4731-3p, hsa-miR-4731-5p, hsa-miR-4732-5p, hsa-miR-4734, hsa-miR-4738-5p, hsa-miR-4740-5p, hsa-miR-4743-3p, hsa-miR-4744, hsa-miR-4747-3p, hsa-miR-4752, hsa-miR-4753-3p, hsa-miR-4755-3p, hsa-miR-4758-3p, hsa-miR-4763-5p, hsa-miR-4764-5p, hsa-miR-4772-3p, hsa-miR-4772-5p, hsa-miR-4782-5p, hsa-miR-4784, hsa-miR-4788, hsa-miR-4793-3p, hsa-miR-4793-5p, hsa-miR-4794, hsa-miR-4796-3p, hsa-miR-4797-5p, hsa-miR-4801, hsa-miR-4804-3p, hsa-miR-488-5p, hsa-miR-490-3p, hsa-miR-499b-5p, hsa-miR-5002-5p, hsa-miR-5088-5p, hsa-miR-513a-3p, hsa-miR-513c-3p, hsa-miR-515-5p, hsa-miR-516b-5p, hsa-miR-5189-5p, hsa-miR-5196-3p, hsa-miR-519d-3p, hsa-miR-520g-3p, hsa-miR-520h, hsa-miR-526b-3p, hsa-miR-541-5p, hsa-miR-544b, hsa-miR-548ac, hsa-miR-548ad-3p, hsa-miR-548ae-3p, hsa-miR-548ah-3p, hsa-miR-548ah-5p, hsa-miR-548aj-3p, hsa-miR-548aj-5p, hsa-miR-548am-3p, hsa-miR-548aq-3p, hsa-miR-548av-3p, hsa-miR-548bb-3p, hsa-miR-548d-3p, hsa-miR-548e-5p, hsa-miR-548f-5p, hsa-miR-548g-5p, hsa-miR-548h-3p, hsa-miR-548j-3p, hsa-miR-548k, hsa-miR-548l, hsa-miR-548o-3p, hsa-miR-548q, hsa-miR-548x-5p, hsa-miR-548z, hsa-miR-550a-3p, hsa-miR-558, hsa-miR-5582-5p, hsa-miR-5680, hsa-miR-5690, hsa-miR-5692a, hsa-miR-5692c, hsa-miR-5696, hsa-miR-5699-5p, hsa-miR-5702, hsa-miR-5703, hsa-miR-5706, hsa-miR-573, hsa-miR-579-3p, hsa-miR-580-3p, hsa-miR-583, hsa-miR-603, hsa-miR-6090, hsa-miR-612, hsa-miR-615-5p, hsa-miR-616-3p, hsa-miR-616-5p, hsa-miR-624-5p, hsa-miR-627-3p, hsa-miR-629-5p, hsa-miR-632, hsa-miR-642a-3p, hsa-miR-642a-5p, hsa-miR-642b-3p, hsa-miR-642b-5p, hsa-miR-647, hsa-miR-649, hsa-miR-6499-3p, hsa-miR-6505-5p, hsa-miR-6507-3p, hsa-miR-6507-5p, hsa-miR-651-3p, hsa-miR-6510-3p, hsa-miR-6510-5p, hsa-miR-6512-3p, hsa-miR-6515-5p, hsa-miR-6529-3p, hsa-miR-656-3p, hsa-miR-664a-5p, hsa-miR-664b-3p, hsa-miR-6715a-3p, hsa-miR-6720-5p, hsa-miR-6722-3p, hsa-miR-6724-5p, hsa-miR-6727-5p, hsa-miR-6735-3p, hsa-miR-6749-3p, hsa-miR-6751-3p, hsa-miR-6754-5p, hsa-miR-6757-3p, hsa-miR-6758-3p, hsa-miR-6758-5p, hsa-miR-6760-3p, hsa-miR-6760-5p, hsa-miR-6767-3p, hsa-miR-6769a-3p, hsa-miR-6771-3p, hsa-miR-6773-5p, hsa-miR-6774-3p, hsa-miR-6775-3p, hsa-miR-6778-3p, hsa-miR-6782-5p, hsa-miR-6783-5p, hsa-miR-6784-3p, hsa-miR-6785-5p, hsa-miR-6787-3p, hsa-miR-6791-5p, hsa-miR-6792-3p, hsa-miR-6798-5p, hsa-miR-6799-5p, hsa-miR-6800-3p, hsa-miR-6801-3p, hsa-miR-6810-3p, hsa-miR-6810-5p, hsa-miR-6813-3p, hsa-miR-6827-3p, hsa-miR-6827-5p, hsa-miR-6830-3p, hsa-miR-6830-5p, hsa-miR-6832-5p, hsa-miR-6834-5p, hsa-miR-6836-3p, hsa-miR-6836-5p, hsa-miR-6839-3p, hsa-miR-6842-3p, hsa-miR-6851-5p, hsa-miR-6852-5p, hsa-miR-6856-3p, hsa-miR-6856-5p, hsa-miR-6857-5p, hsa-miR-6858-3p, hsa-miR-6860, hsa-miR-6861-5p, hsa-miR-6862-3p, hsa-miR-6865-3p, hsa-miR-6868-3p, hsa-miR-6885-3p, hsa-miR-6889-3p, hsa-miR-6890-3p, hsa-miR-6891-5p, hsa-miR-6892-3p, hsa-miR-6893-3p, hsa-miR-7108-5p, hsa-miR-7109-3p, hsa-miR-7152-3p, hsa-miR-7152-5p, hsa-miR-7154-3p, hsa-miR-7155-3p, hsa-miR-718, hsa-miR-758-5p, hsa-miR-7704, hsa-miR-8062, hsa-miR-873-5p, hsa-miR-876-5p, hsa-miR-877-3p, hsa-miR-889-5p, hsa-miR-892a, hsa-miR-892c-5p, hsa-miR-9-3p, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-miR-93-5p, hsa-miR-939-3p, hsa-miR-98-3p, hsa-miR-98-5p, hsa-miR-9985, hsa-miR-99a-3p, hsa-miR-99b-3p, or an isomiR thereof; and / or(b) comprises or consists of a sequence selected from the group consisting of: SEQ ID NOs: 19 to 954.

6. The Fan1 targeting agent of any of the preceding claims, wherein the 3’IITR of the RNA encoding FAN1 is as set forth in any one of the sequences selected from the group consisting of SEQ ID NOs 1 to 9 and 10 to 18.

7. The Fan1 targeting agent of any of the preceding claims, wherein one or more of the contiguous nucleotide sequences comprises or consists of a sequence independently selected from the group consisting of SEQ ID NO 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782, or comprises or consists of asequence with at least 90% sequence identity to a sequence independently selected from the group consisting of SEQ ID NOs 961 to 985; 986 to 1010; 1011 to 1076; 1077 to 1142; 1144; 1145 to 1150; 1152 to 1154; 1282 to 1294; 1295 to 1307, 1308 to 1343, 1363 to 1424; 1450; 1595 to 1688; and 1689 to 1782.

8. The Fan1 targeting agent of claim 7, wherein the Fan1 targeting agent comprises or consists of a sequence selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281; 1344 to 1355; 1425 to 1499; 1451 to 1522; and 1523 to 1594, or comprises or consists of a sequence with at least 90% sequence identity to a sequence selected from the group consisting of SEQ ID NOs: 1155 to 1166; 1356; 1208 to 1232; 1233 to 1240; 1167 to 1207; 1241 to 1281, 1344 to 1355;1425 to 1499; 1451 to 1522; and 1523 to 1594.

9. The Fan1 targeting agent of any of the preceding claims, wherein the Fan1 targeting agent comprises one or more modified nucleoside, optionally wherein the one or more modified nucleoside independently comprises:a) a modified sugar moiety or a modified nucleobase,b) a modified sugar moiety independently selected from any one or more of: 2’- deoxy, 2’-MOE, 2’-OMe, and 2’-F, and / orc) a bicyclic sugar moiety, optionally wherein the bicyclic sugar moiety is selected from LNA and cET.

10. The Fan1 targeting agent of any of the preceding claims, wherein the Fan1 targeting agent comprises:a) one or more modified internucleoside linkages; and / orb) one or more nucleotide analogues.

11. A conjugate comprising the Fan1 targeting agent of any of the preceding claims and one or more moieties covalently bound to said agent.

12. A pharmaceutically acceptable salt of the Fan1 targeting agent of any of claims 1 to 10, or the conjugate of claim 11.

13. A composition comprising the Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, or the pharmaceutically acceptable salt of claim 12, and a diluent, solvent, carrier, salt and / or adjuvant.

14. A pharmaceutical composition comprising the Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, or the pharmaceutically acceptable salt of claim 12, and a pharmaceutically acceptable diluent, solvent, carrier, salt and / or adjuvant.

15. An in vivo or in vitro method for modulating FAN1 protein expression in a target cell in which Fan1 and a microRNA targeting Fan1 are present, the method comprising the steps of exposing the cell to the Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, the pharmaceutically acceptable salt of claim 12, the composition of claim 13, or the pharmaceutical composition of claim 14.

16. A method of treating, preventing, or delaying the onset of a disease associated with FAN1 protein in a subject, comprising administering to the subject a therapeutically or prophylactically effective amount of the Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, the pharmaceutically acceptable salt of claim 12, or the pharmaceutical composition of claim 14.

17. The Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, the pharmaceutically acceptable salt of claim 12, or the pharmaceutical composition of claim 14 for use in treating, preventing, or delaying the onset of a disease.

18. Use of the Fan1 targeting agent of any of claims 1 to 10, the conjugate of claim 11, the pharmaceutically acceptable salt of claim 12, or the pharmaceutical composition of claim 14 for the preparation of a medicament for the treatment, prevention, or delay of a disease.

19. The method according to claim 16 the Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, or pharmaceutical composition for use according to claim 17, or use of the Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, or pharmaceutical composition according to claim 18, wherein the disease is a triplet repeat disorder, optionally wherein the disease is a disease associated with or caused by CAG triplet repeat expansion, CGG triplet repeat expansion, CTG triplet repeat expansion, GAA triplet repeat expansion, GCC triplet repeat expansion, or GCG triplet repeat expansion.

20. The method, Fan1 targeting agent, conjugate, pharmaceutically acceptable salt, pharmaceutical composition for use or use according to claim 19, wherein the disease is selected from the group consisting of: Huntington’s disease (HD), Spinocerebellar Ataxia Type 1 (SCA1), Spinocerebellar Ataxia Type 2 (SCA2), Spinocerebellar Ataxia Type 3 (SCA3), Spinocerebellar Ataxia Type 6 (SCA6), Spinocerebellar Ataxia Type 7 (SCA7),Spinocerebellar Ataxia Type 17 (SCA17), dentatorubral pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy, X-linked 1 (SMAX1 / SBMA), preferably wherein the disease is Huntington’s disease (HD).